Lentivirale transgene Technologie zur Erforschung der Rolle von Th17 Zellen im autoimmunen Diabetes und zur Generierung einer Beta-Zell-Reportermaus by Joseph, Julie
  
 
Studying the role of Th17 cells in autoimmune diabetes and 
generation of a beta cell reporter mouse by lentiviral transgenesis 
 
Lentivirale transgene Technologie zur Erforschung der Rolle 
von Th17 Zellen im autoimmunen Diabetes und zur Generierung 
einer Beta-Zell-Reportermaus 
 
 
Doctoral thesis for a doctoral degree at the Graduate School of Life Sciences 
Julius- Maximilians- Universität Würzburg 
Section Biomedicine 
 
Submitted by 
Julie Joseph 
 
From 
Kerala, India 
Würzburg 2011 
1
  
 
Submitted on: …………………………………………………………..…….. 
Office stamp 
Members of the Promotionskomitee: 
Chairperson: Prof. Dr. med. Manfred Gessler 
Primary Supervisor: Dr. Stephan Kissler 
Supervisor (Second): Prof. Dr. rer. nat Thomas Hünig 
Supervisor (Third): PD Dr. Heike Hermanns 
Date of Public Defence: …………………………………………….………… 
Date of Receipt of Certificates: ………………………………………………. 
 
 
 
 
 
 
2
 CONTENT OUTLINE 
 
 
 
Summary          9 
 
Acknowledgements         11 
 
Abbreviations         12 
 
 
 
1.INTRODUCTION         18  
 
 1.1 Immune system        19  
 1.2 Autoimmune diseases       21 
 1.3 Type 1 diabetes        24 
 1.4 Background and the relevance of current work    26 
 1.5 The NOD mouse model       28 
 1.6 Models of induced diabetes in research     30 
 1.7 RNAi as a tool for elucidation of gene function    32 
 1.8 Viral vectors and generation of transgenic animals   36 
 1.9 Combining lentiviral transgenesis and RNAi    38 
 
 Analyzing the role of IL-17A in type 1 diabetes 
 
1.10 T cells         41 
 1.11 T helper lineage        44 
 1.12 Th1/ Th2 paradigm       44 
 1.13 Discovery of IL-23 and Th17 cells     46 
 1.14 Characteristics of Th17 cells      48 
3
  1.15 IL-17 and its functions       49 
 1.16 Th17/ IL-17A in autoimmune diseases     51 
 1.17 Th17/ IL-17A in type 1 diabetes     52 
 1.18 Aim         53 
 
 Generation of β- cell reporter mouse models and modulation of β- cell mass 
 
1.19 Pancreas and beta cells       55 
1.20 in vitro models for beta cell studies     58 
1.21 Relevance of a RIP- luciferase NOD mouse model   60 
1.22 Bioluminescence imaging      61 
1.23 Menin as a modulator of beta cell growth    62 
1.24 Aim         65 
 
2. MATERIALS         67 
 
 2.1 Chemicals         68 
 2.2 Reagents         69 
  2.2.1 Antibodies and hormones     69 
  2.2.2 Bacterial strains and transfection reagents   70 
  2.2.3 Cell culture reagents      70 
  2.2.4 Enzymes and PCR reagents     71 
  2.2.5 General reagents      71 
 2.3 Antibodies         72 
  2.3.1 Western blot       72 
  2.3.2 Cell culture and FACS      73 
 2.4 Cytokines         74 
 2.5 cDNA and cell lines       74 
 2.6 Kits         74 
 2.7 PCR primers and probes       76 
 2.8 shRNA sequences        77 
4
  2.9 Linker         80 
 2.10 Buffers         80 
 
3. METHODS         84 
 
 3.1 Bacterial culture techniques      85 
  3.1.1 Transformation of bacteria     85 
  3.1.2 Miniprep preparation      85 
  3.1.2 Maxiprep preparation      85 
 3.2 Molecular biology techniques      86 
  3.2.1 Cloning        86 
  3.2.2 Verification of insert- vector ligation    86 
  3.2.3 Luciferase assay       87 
  3.2.4 Tail DNA synthesis      88 
  3.2.5 RNA extraction       88 
  3.2.6 cDNA synthesis       90 
  3.2.7 PCR        90 
  3.2.8 Western blot       92 
  3.2.9 Southern blot       92 
  3.2.10 ELISA        93 
 3.3 RNAi & LT techniques       94 
  3.3.1 Lentivirus production      94 
  3.3.2 Virus titration       95 
  3.3.3 Viral infection of cells      95 
  3.3.4 Generation of transgenic mice     96 
 3.4 Immunology techniques       96 
  3.4.1 Purification of CD4+CD62L+ T cells    96 
  3.4.2 T helper differentiation in vitro     97 
  3.4.3 aCD3/CD28 bead stimulation     98 
  3.4.4 MOG peptide stimulation     98 
  3.4.5 Cell depletion and NOD- SCID transfer   98 
5
 3.4.6 Islet isolation and in vitro culture     99 
  3.4.7 FACS analyses       99 
 3.5 Bioimaging techniques       100 
  3.5.1 Preparation of D- luciferin/ anesthetic mix   100 
  3.5.2 Imaging of cultured cells     100 
  3.5.3 Imaging of whole mouse     101 
 3.6 Cell culture techniques       101 
  3.6.1 Preparation of media      101 
  3.6.2 Cell culture and passaging     102 
  3.6.3 Puromycin selection      103 
 3.7 General assay techniques       104 
  3.7.1 PI/ AnnexinV staining for apoptosis    104 
  3.7.2 PI staining for cell cycle analyses    104 
  3.7.3 eFluor670 staining      105 
  3.7.4 Cyclophosphamide injection     105 
  3.7.5 High dose streptozotocin injection    105 
 
4. RESULTS          107 
 
 Analyzing the role of IL-17A in type a diabetes 
 
4.1 Generation and validation of shRNA constructs   109 
 4.1.1 Generation of IL-17A shRNA construct  109 
 4.1.2 Verification of silencing efficiency & specificity 111 
4.2 Generation and lineage of IL-17A KD transgenic mice  113 
 4.2.1 Generation of lentivirus and IL-17A KD line  113 
 4.2.2 GFP expression levels and lineage studies  115 
 4.2.3 High and Low transgenic lines    116 
 4.2.4 Southern blot analysis     117 
4.3 Phenotypic characterization of lymphocyte compartments 119 
 4.3.1 Characterization of T cell subsets   119 
6
  4.3.2 Characterization of T cell activation status  120 
 4.3.3 Characterization of regulatory T cell compartment 121 
4.4 Verification of RNAi and reduced IL-17A levels  123 
 4.4.1 in vitro differentiated cells    125 
 4.4.2 ex vivo pancreatic islets & pancreatic LN  125 
4.5 Characterization of in vitro differentiated Th17 cells   127 
4.6 Characterization of in vitro differentiated Th1 cells  129 
4.7 Cytokine expression profiles in KD pancreatic islets  130 
4.8 Analysis of diabetes in IL-17A KD mice    132 
 4.8.1 Spontaneous diabetes     133 
 4.8.2 Cyclophosphamide induced diabetes   133 
 4.8.3 Adoptive transfer of diabetogenic splenocytes  134  
4.9 Verification of systemic gene silencing in vivo   136 
 4.9.1 Incidence and disease severity after EAE induction 137 
 4.9.2 Cytokine analyses upon recall response  137 
 
 Generation of β- cell reporter mouse models and modulation of β- cell mass 
 
  Generation of RIP-luciferase mouse models    140 
  
4.10 Generation of pRLM construct     141 
4.11 Verification of specificity of pRLM construct in vitro  142 
4.12 Generation and genotyping of pRLM mice   145 
4.13 Bioimaging of non- diabetic and diabetic pRLM mice  146 
4.14 Specificity of luciferase expression    148 
4.15 Phenotype of pRLM mice     149 
4.16 Streptozotocin induced diabetes     150 
4.17 Cyclophosphamide induced diabetes    152 
4.18 Generation and genotyping of NOD-SCID pRLM mice 153 
 
 
7
                  Modulation of β- cell mass       155 
 
  4.19 Generation and validation of menin constructs   156 
   4.19.1 shRNA- pLBM construct generation   157 
   4.19.2 Subcloning      157 
   4.19.3 Luciferase assay     158 
   4.19.4 Menin psi-check generation    159 
  4.20 in vitro analyses using INS-1E and NIT-1 cells   160 
   4.20.1 Viral infection of cells     160 
   4.20.2 Analysis of menin KD     161 
   4.20.3 Analysis of phenotype of menin KD cells  163 
    4.20.3.1 Analysis of proliferation   163 
    4.20.3.2 Analysis of apoptosis   166 
  4.21 Generation of virus for embryo injection   168 
 
5.DISCUSSION         169 
 
 IL-17A silencing does not protect NOD mice from autoimmune diabetes 
 
 Generation of β- cell reporter mouse models and modulation of β- cell mass 
 
6. BIBLIOGRAPHY         186 
 
 
 
CURRICULUM VITAE        213 
 
LIST OF PUBLICATIONS        216 
 
AFFIDAVIT 
 
8
  
Summary/ Zusammenfassung 
 
English: Type 1 diabetes affects around 0.5% of the population in developed countries 
and the incidence rates have been rising over the years. The destruction of beta cells is 
irreversible and the current therapy available to patients only manages the symptoms and 
does not prevent the associated pathological manifestations. The patients need lifelong 
therapy and intensive research is being carried out to identify ways to eliminate 
autoimmune responses directed against pancreatic beta cells and to replace or regenerate 
beta cells. The work presented herein aimed at analyzing the role of the Th17 T cell 
subset, characterized by secretion of the pro- inflammatory cytokine IL-17A, in 
autoimmune diabetes and also at generating a beta cell reporter mouse line in the NOD 
background, the most widely- used mouse model for type 1 diabetes. We generated IL-
17A knockdown (KD) NOD mice, using RNAi in combination with lentiviral 
transgenesis. We analyzed diabetes frequency in IL-17A deficient mice and found that 
the loss of IL-17A did not protect the transgenic mice from diabetes. Based on these 
observations, we believe that Th17 cells do not play a critical role in type 1 diabetes 
through the IL-17A pathway, though they might still be involved in the disease process 
through alternate pathways.  We also generated NOD and NOD-SCID mice with a 
transgene that drives the beta cell specific expression of a luciferase reporter gene. We 
used a lentiviral construct, which combined a luciferase sequence and a short- hairpin 
RNA (shRNA) expression cassette, allowing gene- knockdown under the beta cell 
specific rat insulin promoter (RIP). These mice will be of use in studying beta cell 
phenotypes resulting from the knockdown of target genes, using non- invasive 
bioimaging. We believe that the generation of these reporter mouse lines for diabetes 
studies will prove valuable in future investigations. Furthermore, the demonstration that 
the loss of IL-17A does not alter susceptibility to type 1 diabetes should help clarify the 
controversial involvement of Th17 cells in this disease.  
 
Deutsch: In Industrieländern erkranken etwa 0,5 % der Bevölkerung an Typ-1-Diabetes 
und die Krankheitsrate ist in den letzten Jahren angestiegen. Die dabei stattfindende 
9
  
Zerstörung der insulinproduzierenden Beta-Zellen ist irreversibel und die derzeitig 
verfügbaren Therapien behandeln lediglich Symptome, verhindern die pathologischen 
Auswirkungen aber nicht. Patienten benötigen daher eine lebenslange Therapie und es 
wird intensiv daran gearbeitet, Wege zu identifizieren, die die autoimmune Antwort 
gegen pankreatische Beta-Zellen unterbinden, oder aber Beta-Zellen ersetzen, 
beziehungsweise regenerieren lassen.  
 
Die vorliegende Arbeit hat zum Ziel, die Rolle der Th17 T-Zellen, welche durch die 
Sekretion des proinflammatorischen Zytokins IL-17A gekennzeichnet sind, in Typ-1-
Diabetes zu analysieren. Zusätzlich wurden Reportermauslinien im NOD Hintergrund, 
dem am weitesten verbreiteten Mausmodell für Typ-1-Diabetes, generiert.  
 
Durch RNAi, in Kombination mit lentiviraler transgener Technologie, wurden IL-17A 
Knockdown (KD) NOD Mäuse generiert. Die Diabeteshäufigkeit in IL-17A defizienten 
Mäusen wurde mit dem Ergebnis untersucht, dass der Verlust von IL-17A die transgenen 
Mäuse nicht vor Diabetes schützt. Von dieser Beobachtung ausgehend wurde gefolgert, 
dass Th17 Zellen zumindest über den IL-17A Signalweg keine entscheidende Rolle bei 
Typ-1-Diabetes spielen, diese allerdings durch alternative Signalwege durchaus im 
Krankheitsprozess beteiligt sein könnten. 
 
Außerdem wurden NOD und NOD-SCID Mäuse mit einem Transgen, das die Beta-Zell 
spezifische Expression eines Luciferasereporters steuert, generiert. Hierbei wurde ein 
lentivirales Konstrukt genutzt, welches sowohl die Luciferase, als auch eine short-hairpin 
RNA (shRNA) Expressionssequenz beinhaltet, um einen Genknockdown unter Kontrolle 
des spezifischen Insulinpromotors der Ratte (RIP) zu erlauben.  Diese Mäuse werden bei 
zukünftigen nicht-invasiven bildgebenden Untersuchungen des Beta-Zell Phänotyps, der 
aus dem Knockdown von Zielgenen resultiert, von großem Nutzen sein. In zukünftigen 
Untersuchungen wird sich die Generierung dieser Reportermauslininien für 
Diabetesstudien sicherlich als wertvoll erweisen. Des Weiteren sollte die Erkenntnis, dass 
der Verlust von IL-17A die Anfälligkeit für Typ-1-Diabetes nicht verändert, zu einem 
besseren Verständnis der kontrovers diskutierten Beteiligung der Th17 Zellen führen. 
10
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1.1 Immune system 
 
The immune system is a complicated system of structures, which protects an organism 
against diseases. It does this by means of identifying and eliminating pathogens. To 
function properly, the immune system needs to correctly distinguish between harmful 
pathogens and the organism’s own cells and tissues. In higher organisms, the immune 
system is highly evolved and includes a complex and dynamic system made up of 
countless different proteins, enzymes, cells and tissues that interact with each other1, 2.  
 
The pathogens when trying to invade the body first encounter the mechanical, chemical 
and biological barriers. These prevent the pathogens from entering an organism or in 
some cases, eject them from the body upon entry. The uninterrupted skin usually acts as a 
mechanical barrier preventing the entry of pathogens into the organism. Coughing and 
sneezing ejects pathogens from the body while the mucus in the respiratory system traps 
microbes. Examples of chemical barriers include the β-defensins secreted by skin and the 
respiratory system and the lysozymes and phospholipase A2 in the tears and saliva. These 
have antimicrobial properties. Gastric enzymes that protect against ingested pathogens 
are another example of chemical barriers. The commensal flora in the gut competes with 
harmful bacteria for food and space. They modify the gut environment and eliminate the 
pathogenic bacteria thus acting as a biological barrier3.  
 
The immune system is broadly divided into two separate but complementary parts: the 
innate immune system and the adaptive immune system3. Innate immune responses are 
non-specific while adaptive immunity is characterized by antigen specificity. Innate 
immune system is usually the most dominant defense system and the innate immune 
responses are not specific to distinct antigens3. The innate immune cells identify 
pathogens using the pattern recognition receptors (PRRs) that identify pathogen 
associated membrane patterns (PAMPs), which are associated with a broad range of 
microbes. This is turn lead to broad range specificity4, 5. The innate immune cells include 
mast cells, phagocytes, macrophages, dendritic cells, natural killer cells, neutrophils, 
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eosinophils, basophils and γδ T cells4. The pattern recognition receptors are broadly 
classified into secreted, transmembrane and cytosolic. The transmembrane PPRs include 
toll like receptors (TLR), which are able to activate several classes of adaptive immune 
responses including antibody, B and T cell responses5.  
 
The pathogens are eliminated by a variety of mechanisms including phagocytosis, 
respiratory burst and release of toxic molecules. The complement system includes a 
cascade of several plasma proteins and plays an important role in enhancing the removal 
of microbes. The complement system enhances the recruitment of inflammatory cells, 
causes the opsonization of pathogens and eliminates the neutralized antigen antibody 
complexes from the body. It also destroys the pathogen-infected cells by disrupting the 
cell membranes and causing subsequent cell death3, 6. Many pathogenic organisms have 
evolved methods to evade elimination by the innate immune system. These evasion 
mechanisms include intracellular replication, mimicking host cells, receptor 
modifications to avoid phagocytosis and even direct killing of phagocytes. 
 
Innate immune responses are able to fight and clear a large number of infections. In cases 
where innate immunity is insufficient to do so, adaptive immune responses are elicited. 
The innate immune system plays an important role in activating the adaptive immune 
responses through antigen presentation. The adaptive immune responses are pathogen 
specific3, 4. The adaptive immune system is composed of highly specialized cells, which 
can recognize and remember specific pathogens4. The lymphocytes could either be naïve 
cells that have never encountered their antigen; effector cells that have encountered their 
cognate antigen and are involved in an active response or memory cells that retain the 
memory of already encountered antigens for future reference. The memory enables the 
adaptive immune system to mount increasingly efficient responses against previously 
encountered pathogens upon re-encounter3, 4. 
 
The adaptive responses are activated by the innate immune system and the major players 
are the   B and T lymphocytes.  The adaptive immune cells exhibit a wide range of 
specificities. This adaptability arises from the process of somatic recombination that 
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happens during the development of B and T cells in the central lymphoid organs. This 
recombination generates cells with unique antigen receptor specificity leading to a large 
number of cells capable of recognizing a large number of different antigens4. B cells play 
a major role in humoral immune responses owing to the production of antibodies. These 
are proteins that can bind to specific antigens and result in their elimination. T cells on 
the other hand are crucial for cell-mediated immune responses and they are able to cause 
direct cell death7.  
 
1.2 Autoimmune diseases: 
 
Disorders of the immune system can lead to autoimmunity or immunodeficiency. 
Autoimmune diseases are caused by a breakdown of immunologic tolerance that ends up 
with the immune system attacking the body’s own cells. Immune tolerance is the ability 
of the immune system to tolerate or ignore the body’s own cells and non-pathogenic 
organisms and to react only to non- self. It is reported that approximately 3% of the 
populations in developed countries suffer from autoimmune diseases8. Immunologic 
tolerance has two different yet complementary arms, central tolerance and peripheral 
tolerance. 
 
Central tolerance occurs in the thymus where the maturing lymphocytes are exposed to 
self-antigens in these organs either endogenously expressed or made available from 
peripheral sites9. The process includes two stages of lymphocyte selection. Positive 
selection leads to the selection of lymphocytes, which can recognize self-MHC molecules 
and these selected lymphocytes are further whittled down by the process of negative 
selection. During negative selection, the lymphocytes that react with high affinity to the 
self-antigens are deleted before they can mature and leave these organs so as to prevent 
auto immunity9- 11. Peripheral tolerance occurs after the T cells mature and reach the 
periphery. Many tissue specific antigens are not expressed in the thymus and hence some 
of the mature T cells exiting from the thymus could potentially be reactive to these tissue 
specific antigens in the periphery and lead to autoimmunity. Peripheral tolerance 
mechanisms are in place to prevent this possibility. The autoreactive T cells are usually 
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deleted or subjected to a state of unresponsiveness called anergy. Regulatory T cells also 
contribute to peripheral tolerance by suppressing autoreactive T cells9, 12.  
 
A defect in either central or peripheral tolerance mechanisms could lead to the survival of 
autoreactive T cell clones, which could potentially react to self-antigens thus leading to 
autoimmunity. Central tolerance weeds out the autoreactive T cells and prevent their 
entry into periphery. Autoreactive specificities that manage to escape this first line of 
elimination are actively controlled by the peripheral tolerance mechanisms. It is known 
that despite these tolerance mechanisms, autoreactive T cells still persist in the peripheral 
T cell repertoire indicating that the tolerance mechanisms are not absolute. Inefficient 
tolerance in the thymus by means of altered selection of T cell repertoire or impaired 
negative selection could contribute to autoimmunity as this might lead to the presence of 
additional autoreactive specificities in the periphery12.  
 
Once the T cells are in the periphery, several possibilities could contribute to 
autoimmunity. T cells require homeostatic signals for survival in the periphery. Increased 
survival of T cells and increased TCR signaling could lead to preferential stimulation of 
self-reactive T cells. Defects in the removal of self-reactive clones could lead to an 
accumulation of autoreactive cells causing autoimmunity13. There is also some data 
indicating that presentation of self- antigens by activated mature APCs could lead to 
activation of autoreactive T cells and not the induction of tolerance. As mentioned earlier, 
autoreactive specificities are found to be present in the peripheral T cells repertoire. Some 
pathogens have antigens similar to self- antigens and the pathogen activated T cells could 
cross react with self-antigens and cause autoimmunity. Regulatory T cells play a crucial 
role in peripheral tolerance. Any defect in this cell population also contributes to 
autoimmunity12.  
 
The breakage of immune tolerance leads to the immune system mounting a severe 
response against self-antigens and leading to autoimmune diseases. Some people are 
more susceptible to developing autoimmunity. This increased susceptibility is found to 
depend on several genetic and environmental factors. Genetic susceptibility to 
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autoimmune diseases is associated with multiple genes7, 14. The three main gene sets 
associated with disease are immunoglobulins, T cell receptors and the major 
histocompatibility complexes15-19. Gender is also thought to be important as more than 
75% of people who suffer from autoimmunity are women8, 20. Pregnancy, hormonal 
changes and imbalanced X chromosome inactivation are some of the factors suggested to 
be responsible for the increased susceptibility of women to autoimmunity21, 22. Higher 
estrogen and lower testosterone levels in females are also believed to contribute to this 
increased incidence23.  
 
Several environmental factors are also found to be associated with autoimmunity. There 
is a lot of evidence suggesting a role for bacterial, viral and parasitic infections in 
autoimmunity. These include the observation of autoimmunity following infections and 
the detection of high titers of antibodies against infectious agents in patients with 
autoimmune diseases7, 24. A number of explanations have been put forward to explain 
how infections might trigger autoimmunity. A possible mechanism is molecular mimicry 
where the infectious agent displays structural similarity to some of the host proteins and 
the antibodies generated end up attacking the host proteins owing to their similarity to the 
pathogen25. It is also possible that the infectious agent could act as a superantigen thereby 
activating a large number of T cells in the absence o f appropriate costimultion26.  The 
infectious agent may also be able to cause polyclonal activation where it acts as an 
adjuvant and exacerbates pre existing autoimmune reactions27. All these could lead to 
breakage of tolerance and result in autoimmunity. Both Klebsiella pneumoniae and 
coxsackievirus B have been found to be associated with Type 1 diabetes28.  
 
Autoimmune diseases are broadly classified into systemic disorders and localized 
disorders. Systemic disorders are the autoimmune disorders in which the immune 
responses are not directed towards tissue specific antigens and examples include systemic 
lupus erythematosus and rheumatoid arthritis. In localized disorders, immune responses 
are directed towards antigens that are tissue or organ specific and examples include type 
1 diabetes, vitiligo and celiac disease1. Autoimmune diseases are usually diagnosed and 
monitored using autoantibody tests, symptoms and measurement of inflammation and 
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organ function. There is currently no cure for these diseases and the treatment usually 
varies from patient to patient. It is usually aimed at relieving the symptoms, minimizing 
the tissue damage and preserving the organ function.  
 
1.3 Type 1 Diabetes:  
 
Type 1 diabetes mellitus (T1D) is an autoimmune disorder, which involves the 
irreversible and selective destruction of the insulin producing β cells of the pancreas29. 
This causes the reduction and eventual loss of insulin production leading to increased 
glucagon secretion by the α- cells. Insulin insufficiency and excessive glucagon secretion 
finally result in hyperglycemia and ketoacidosis30. The disease accounts for about 10% of 
all diabetes cases while Type 2 Diabetes accounts for the remaining 90%. Type 1 
Diabetes incidence varies geographically and it affects 0.5% of the total population in 
developed countries230. Gillespie31 in her review observed that one study of incidence 
rates mentioned a yearly incidence increase of 3%32 while another reported that the 
diabetes incidence was expected to increase by 40% in 2010 as compared to 199833. 
Patterson et al.34 in 2009 reported that the prevalence of cases in individuals younger than 
15 years is expected to rise by 70%, suggesting a shift towards an earlier age 24. 
 
As in the case of other autoimmune diseases, both T- cells and B-cells are believed to be 
responsible for the disease. Though both CD4+ and CD8+ T-cells are found to be 
required for development of T1D35, the initial role is found to be played by CD8+ T cells 
35-37. Several mechanisms have been reported for the process of β- cell destruction by T-
cells. These include direct killing by cytotoxicity, release of factors like proinflammatory 
cytokines (which can result in the production of inducible Nitric oxide synthase, iNOS) 
or by signaling through the programmed cell death (PCD) pathway38-40. CD4 cells mostly 
provide help to CD8+ T cells and B cells by providing cytokines like IL-21 thereby 
enhancing the autoimmune response24. The exact role played by B-cells and their 
autoantibodies is still not clear though most of the autoantigens in diabetes were 
identified from the presence of autoantibodies41-43. It is likely that B cells are active 
participants in the disease process owing to their ability to present antigen to diabetogenic 
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CD4 and CD8 T cells24. Several proinflammatory cytokines including MIF, IFN-γ, IL-1, 
IL-17, TNF-α and IL-21 have been implicated in the development of T1D and these 
cytokines are believed to play a role by the recruitment of effector cells to the pancreas 
and also by enabling the release of reactive oxygen and nitrogen species44-46. 
 
Autoimmune diseases are caused by improper immune responses against self-antigens. In 
case of type 1 diabetes, several autoantigens have been identified so far. The 4 principal 
autoantigens are believed to be glutamic acid decarboxylase (GAD65)47, insulinoma- 
associated antigen- 2(IA-2)48, insulin49 and zinc transporter 8 (ZnT8)50. 90% of the 
people diagnosed with type 1 diabetes have autoantibodies to at least one of these 
antigens31. It has been found that as the disease progresses, the number of islet antigens 
recognized by T-cells and autoantibodies increases and this phenomenon is termed as 
epitope spreading. Recently, Krishnamurthy et al.51 reported that eliminating the immune 
response to insulin in NOD mice can protect from the development of the disease but the 
same effect could not be observed on elimination of the immune response to islet- 
specific glucose-6- phosphatase catalytic subunit related protein (IGRP) indicating that 
there is a hierarchy of antigens and that insulin might be the primary autoantigen and that 
IGRP might be secondary thereby supporting the idea of epitope spreading. 
 
Both genetic and environmental factors are believed to contribute to the development of 
type 1 diabetes. The role played by genetic factors is well supported by experimental 
studies but the environmental role is still not well elucidated. Some studies suggest a role 
for viruses including enteroviruses52, rotavirus53 and rubella54. There is a clear link 
between the bacterial composition of the intestine and type 1 diabetes24. Mycobacterium 
avium subspecies paratuberculosis (MAP) has also been shown to be a risk factor in 
diabetes. Other reported environmental triggers include cow’s milk, wheat proteins and 
vitamin D24. Several genes have been identified to be associated with type 1 diabetes and 
the most important one among these is the HLA locus. Some HLA haplotypes like DR4-
DQ8 and DR3-DQ2 are found to be associated with a high risk of disease55 whereas 
another haplotype, DR15-DQ6 is found to be protective56.  To date, several other 
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candidate genetic loci have been identified including insulin57, CTLA-4 (cytotoxic T 
lymphocyte antigen 4), PTPN2224 and KIAA0350 (Fig. 1 Todd et al.58).  
 
 
 
Fig. 1: Todd et al. Nature Genetics (2007). 39(7): 857-864.58 
 
 
Type 1 Diabetes is divided into two phases. During the first phase called peri- insulitis, 
mononuclear infiltrates surround the islets and this stage is also called non destructive 
insulitis. The second stage is destructive insulitis when the infiltrates invade the islets and 
destroy them leading to overt diabetes when there is no longer sufficient insulin 
production to regulate blood glucose levels230. It is believed that the clinical 
manifestations are observed only after about 80- 90% of the β- cells is destroyed24, 31.   
 
1.4 Background and the relevance of current work: 
 
To date, there is no cure for type 1diabetes and the only long-term therapy option 
available to patients is daily injections of insulin. Even in ideal cases, insulin replacement 
still shortens life expectancy by at least around 10 years24. In addition to being 
cumbersome, this approach is incapable of preventing the long term pathologies 
associated with type 1 diabetes including kidney and heart disease, neuropathy, and 
retinopathy. This has led to an intensive search for potential therapeutic strategies.  
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Current research is focused on 3 main objectives. These include islet cell transplantation, 
modulation of autoreactive immune cells and endogenous β- cell regeneration. Islet cell 
transplantation is an attractive option but the islets are obtained from cadavers and the 
patients have to subjected to life long immune suppressive regimen. If we could enable 
endogenous β- cell regeneration, it would eliminate the need for immune suppression and 
this would offer a better choice for the patients. Even if we could achieve successful islet 
function by transplantation or regeneration, the autoreactive immune cells are still present 
in the patients and they could destroy the new β- cells leaving all therapy fruitless in the 
absence of immune suppression. Hence it is quite critical that the role played by the 
immune system in the disease development be elucidated so that we could eliminate the 
autoreactive cells and the key immune factors and give the β- cells a chance to survive. 
This would be a task of epic proportions as the exact roles played by the various immune 
cells and the immune molecules are largely unknown and new factors are being identified 
with more research. 
 
The promise of islet cell transplantation as a potential therapy was improved on 
significantly when Shapiro et al.59, 60 established the protocol which later came to be 
known as the ‘Edmonton protocol’. Though the transplanted islets can restore the insulin 
production, they are susceptible to the same autoimmune attack, which causes the initial 
destruction of the patient’s β- cells. Hence the approach carries the disadvantage of the 
need for a lifelong immunosuppressive regimen. Even with severe immune suppression, 
long-term transplant survival is rarely achieved. Another major disadvantage is the 
scarcity of available donor islets for transplant. In addition, the current isolation 
procedures are not efficient enough and not all the isolation attempts produce transplant-
ready islets, further complicating the matter. Han et al.61 mention that islets are subjected 
to extreme conditions including mechanical shear, enzyme digestion, inflammatory 
cytokines, free radicals and osmotic shock during isolation and transplantation. They are 
also deprived of their trophic support. Upon transplantation into diabetic patients, the 
islets face additional unfavorable conditions like high serum lipid and glucose levels61. 
Islets have also been shown to become fully vascularised only 1-2 weeks after 
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transplantation and this results in lack of nutrients and oxygen62 in the initial weeks after 
transplantation. All these fact   ors contribute to significant islet loss and dysfunction 
after transplantation, thereby undermining the efficiency and purpose of the procedure.  
 
The difficulties encountered with islet transplantation and the destruction of the 
transplanted islets by the immune system have clarified the need for identifying strategies 
to protect the β - cells from immune destruction or to enable endogenous β - cell 
regeneration. Even if immune tolerance can be induced, it might be critical to enable β- 
cell regeneration in cases where the disease is already apparent. Several studies have 
looked at the potential of generating β - cells. Seaberg et al.63 identified a pancreatic 
precursor which can differentiate into cells which resemble β - cells. Recently Zhou et 
al.64 reported that adult pancreatic exocrine cells can be reprogrammed to β - cells by 
expression of the transcription factors Ngn3, Pdx1 and MafA. Though much work needs 
to be done before the search for a cure can be realized, the greatest promise might lie with 
endogenous beta cell regeneration coupled with tolerance induction.  
 
The two projects encompass these two separate yet complementary fields of research. 
The first project dealt with unraveling the role played by IL-17A, the key cytokine 
produced by one of the T helper subsets in type 1 diabetes. The second project involved 
generation of reporter mice in which the endogenous β- cell mass could be monitored in 
real time. We aimed at coupling the real time monitoring of beta cell mass with tissue 
specific knockdown of target beta cell modulator genes.  
 
1.5 The NOD Mouse Model: 
 
The development of autoimmune diabetes results from a combination of genetic 
susceptibility and environmental factors. A thorough understanding of the disease process 
is required for the development of a successful therapy. The difficulty of studying the 
disease in humans has necessitated the use of animal models, which ideally mimic the 
characteristics of the human disease closely. There are several diabetes models, the use of 
which offers different perspectives for understanding the disease. These include the 
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diabetes prone BB (biobreeding) rat, the NOD (non-obese diabetic) mouse, in silico 
models based on the NOD mouse, humanized mouse models, transgenic pseudo- self 
antigens expressed in the islets (RIP-OVA) and beta cell damage models like 
streptozotocin induced diabetes65.  The NOD mouse is the most widely used model for 
studying autoimmune diabetes in vivo.  
 
The NOD mouse provides a spontaneous model where aggressive insulitis is observed 
around 12 weeks of age and around 80% of the females develop hyperglycemia by 30 
weeks of age66. NOD mice were first described in 198067, 68 and since then they have 
been widely used as an experimental model for type 1 diabetes. The mice develop 
spontaneous diabetes with the incidence rates being 60% - 80% in females and 20%- 30% 
in males68, 69. The pattern of diabetes occurrence is different between females and males 
in that diabetes onset occurs between 12 to 14 weeks of age in the female mice whereas 
in the case of males, it is slightly later. In their review, Anderson and Bluestone70 report 
that the mouse strain is a good model for type 1 diabetes as it develops spontaneous 
autoimmune diabetes that is quite similar to the human T1D. In both cases, the disease is 
primarily mediated by autoreactive T cells (both CD4+ and CD8+), the disease is under 
complex polygenic control and there is an abundance of pancreas specific 
autoantibodies70 . 
 
The NOD mouse has become an invaluable model for unraveling the mystery of type 1 
diabetes. Ever since its inception, the model has been used for a staggering number of 
investigations that have been aimed at improving our understanding of T1D i.e. the whole 
process of disease development, the role played by autoantigens and the immune cells 
and also aimed at developing potential therapeutic strategies. Numerous transgenics and 
knockout strains have been developed in the NOD background. All these efforts have 
helped enormously in the study of the disease pathology.  
 
Though more than 170 approaches have been found to delay or prevent T1D onset in the 
NOD mice71, very few have been found to be effective in human T1D70. In their review, 
Shoda et al.72 analyzed the multitude of successful interventions in NOD mice and the 
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reasons for the difficulty in translating these to treat or cure human type 1 diabetes. They 
noted that out of the 463 agents evaluated, only 23 were initiated in diabetic NOD mice 
though 16 out of the 23 were considered successful. Anti- CD3 treatment has been found 
to be beneficial in both NOD mice and in recently diabetic patients31, 70, 72, 73. Though 
some of the other therapies including oral insulin and nasal insulin administration showed 
success in animal models, most have shown none or very little efficacy in treating human 
T1D. Shoda et al. 72 attribute this lack of success to discrepancies in timing, dosage and 
protocols. Roep73  notes that some of the candidate therapies derived from animal models 
proved unsafe and that most animal studies end their assessments too early.  The animal 
studies were done in prediabetic mice while the human studies included diabetic patients. 
The dosages used in human studies were also significantly lower than the ones found to 
be beneficial in animal studies. They recommend that careful consideration of dosage, 
timing, protocols and species-specific differences might permit better clinical translation.  
 
1.6 Models of induced diabetes in research: 
 
Spontaneous diabetes models like the NOD mouse need 4-5 months to develop the 
disease. This is a long duration, which in some cases is inconvenient. There are some 
models of induced and accelerated diabetes, which help overcome this problem. Diabetes 
can be induced by the injection of several substances including cyclophosphamide, 
streptozotocin and alloxan. Upon injection, the mice develop diabetes within a short 
duration ranging from 2-3 days to 2-3 weeks. This depends on the nature and the dosage 
of the chemical used. These induced models can be used to gain more insight into the 
pathogenic mechanisms involved in T1D and also to test novel therapeutic approaches.  
 
Cyclophosphamide (CY) is a nitrogen mustard compound. It is a widely used 
chemotherapeutic agent and is able to cause DNA alkylation.  High dose CY to pre 
diabetic NOD mice leads to synchronous onset of T1D 1-2 weeks after CY treatment. 
This is attributed to CY being detrimental to B cells and Treg cells. Several studies have 
reported the B cell cytotoxicity of CY74, 75. In their study, Brode et al.76 observed that CY 
treatment could cause rapid changes in the various lymphoid subsets. They observed 
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major reduction in the number of B cells and minor decreases in the CD4+ and CD8+ T 
cell numbers. These changes were found to be transient with the numbers going back to 
pre treatment levels over time. They found a sharp decrease in the number of CD25+ 
Tregs with the reduction being most drastic in the pancreas. The reduced Treg numbers 
failed to go up over time. It was observed that CY treated Tregs had reduced suppressive 
potential and had increased apoptosis. All these data together suggests that in pre diabetic 
mice, CY could cause accelerated diabetes by taking away the regulatory compartment 
and thus enhancing inflammation. 
 
Streptozotocin (STZ) is a cytotoxic glucose analogue. It is also used as a 
chemotherapeutic agent. STZ is transported into the cells via the Glut2 glucose 
transporter and preferentially accumulate in the pancreatic beta cells, which express high 
levels of Glut2. Hence it exhibits pancreas specific toxicity. On uptake, streptozotocin is 
split into glucose and a methylnitrosurea moiety. The methylnitrosurea moiety has 
alkylating properties and upon transfer from STZ to DNA, causes the fragmentation of 
DNA. This in turn destroys the beta cells. It is believed that in addition to DNA 
methylation, protein methylation might also play a small contributing role in the loss of 
beta cell function. Both NO and ROS are also reported to play minor roles in the 
destruction process. Thus streptozotocin can cause a state of insulin dependent diabetes 
via the necrosis of beta cells77.  
 
STZ at high doses causes non-immune toxic form of diabetes as described before. 
Multiple low doses of STZ on the other hand results in the expression of β-cell 
autoantigens (eg. GAD autoantigens)78. This triggers a β-cell specific inflammatory form 
of diabetes in susceptible rodent strains79. STZ is also able to cause damage in other 
organs expressing the Glut2 transporter, mostly kidney and liver80, 81.  STZ is relatively 
stable at room temperature at least for up to an hour. 
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Fig.2: Chemical structures of glucose and streptozotocin respectively. 
 
 
1.7 RNA interference (RNAi) as a tool for elucidation of gene function: 
 
RNA interference or RNAi has emerged as a powerful research tool in functional 
genomics where it being used to analyze gene function and to ablate specific genes for 
therapeutic purposes82, 83.  In RNA interference (RNAi), double stranded RNA introduced 
into cells silences the gene expression of the homologous84. RNA interference occurs in 
mammalian cells in response to small RNAs including small interfering RNAs (siRNAs) 
and microRNAs (miRNAs) and the process results in sequence specific gene silencing. 
These molecules direct sequence specific cleavage of perfectly complementary mRNAs 
and transcript degradation and translational repression of imperfectly complementary 
targets.  
 
The RNAi pathway is initiated by the enzyme Dicer, which cleaves the long double 
stranded RNA molecules into 21-23 base pair (bp) fragments. In the case of siRNAs, the 
passenger strand/ sense strand is then cleaved by a process mediated by the endonuclease 
argonaute 2 (AGO2) and the antisense strand is incorporated into the RNA induced 
silencing complex (RISC). In the case of miRNAs the passenger strand is unwound and 
discarded by helicase activity instead of cleavage and the antisense strand is loaded onto 
RISC. The antisense strand then guides the complex to complementary sequences in 
target mRNAs, which are then cleaved by AGO2 resulting in silencing 82, 84- 86. In cases 
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where there is imperfect matching with 3’ UTRs, cleavage of target mRNA does not 
occur. Instead, translation of the mRNA is prevented leading to translational repression 
and subsequent reduction in protein levels and silencing87.   
 
RNAi with long double stranded RNA is of limited use in mammalian systems owing to 
their ability to elicit strong interferon responses. Both siRNAs and shRNAs are widely 
used to achieve the silencing of target genes in mammalian systems. A major 
disadvantage with siRNA is the lack of stable transfection. siRNAs once inside the cell, 
do not integrate into the host cell DNA and hence every time the transfected cell divides, 
siRNAs are diluted out86. This leads to a gradual loss of gene knockdown making them 
an ideal for transient gene silencing experiments. On the other hand, endogenously 
expressed shRNAs can be used to achieve long term and stable knockdown of their target 
transcripts86. The integration into host genomic DNA allows shRNAs to be expressed for 
long periods of time in a stable manner leading to a long term and stable silencing of 
target gene expression82.  
 
shRNAs could be used to genetically encode siRNAs in an organism and the siRNAs 
generated by cleavage do not activate immune responses due to their small size. Hence 
shRNAs could be used to induce long term stable silencing in mammalian systems. They 
are usually delivered into cells using vector molecules and once transcribed, resemble 
pre-microRNA, the endogenous substrate of Dicer.  shRNA sequences are 21- 29 bp long 
and their expression is usually driven by polymerase III promoters. Once transcribed, 
they form hairpin structures and are then cleaved by the cellular machinery resulting in 
siRNA molecules. These are then loaded onto RISC and can result in gene silencing84, 86. 
  
Conventional shRNA vector systems have the shRNAs under the control of pol III 
promoters like U6 or H1. Pol III promoters are expressed in all cell types and hence this 
would lead to a ubiquitous and constitutive gene silencing pattern. The Pol III promoters 
are strong and generate large amounts of transcription products, which sometimes lead to 
toxicity. Hence conventional shRNA systems could be used to achieve systemic silencing 
of target genes in cases where it is desired. Though ubiquitous expression of shRNAs 
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could be used efficiently in a wide variety of experimental setups, some experimental 
setups demand a strict control on the timing, expression levels and sites of shRNA 
expression84. There are some cases where a systemic silencing is not required or is 
deleterious. Some genes are found to be critical for the organism’s development and 
hence systemic silencing of these genes could be embryonically lethal eg. menin. In these 
cases, a tissue or cell specific silencing of the genes might be desirable and might be 
sufficient for the purpose of the study. Some genes are found to be important during the 
early developmental stages of an organism and hence it might be advisable to silence 
them at a later time point83, 84. All these different circumstances require shRNA 
expression systems, which can be regulated in accordance with the needs of the 
experiment setup. Conditional shRNA expression would allow the shRNAs to be 
expressed only when needed and only in the tissues / cells where needed83.  
 
Several recently discovered vector systems allow for spatial and temporal regulation of 
shRNA expression. There are vector systems in existence, which allow conditional 
/inducible knockdown and tissue/ cell specific knockdown. Inducible knockdown systems 
generally use Pol II or Pol III promoters under the control of drug responsive repressors 
or transactivators. In this case, the expression of the shRNA can be turned on or off at 
will by the addition or withdrawal of the corresponding drug83. This technique provides 
an easy and economical way to regulate the timing of gene silencing with the added 
advantage that the knockdown is reversible. The cre/ loxP recombination method can be 
used to generate transgenic animals with conditional shRNA mediated gene knockdown 
for genes whose constitutive silencing could be embryonically lethal. In this method, two 
loxP sites flanking a stop signal that hinders constitutive shRNA expression are inserted 
within the promoter driving the shRNA expression to generate transgenic mice. These 
transgenic mice are then crossed with cell/ tissue specific cre expressing mice in which 
cre mediates the deletion of the stop signal and results in activation of the shRNA 
expression. Thus the cre/ loxP recombination method provides both spatial and temporal 
control over shRNA expression with the disadvantage being that once induced, the 
expression is irreversible83.  
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It is now believed that the best way to induce effective gene silencing in a constitutive 
and tissue/ cell specific manner is by using the endogenous miRNA pathway to generate 
shRNAs83. The miRNA based shRNA system involves substitution of the miRNA stem 
with the desired shRNA to induce specific gene silencing.  In the commonly used miR30-
based vectors, the mature miR30 encoding region is replaced with shRNA sequences 
targeting the transcript of interest84. These artificial miRNAs resemble endogenous RNAi 
substrates and are more amenable to Pol-II transcription leading to tissue- specific 
expression of the shRNAs82. In their review, Sharma and Rao88 suggested that efficient 
delivery is obtained when the hairpins are transcribed by RNA polymerase II. When 
using Pol II promoters, the transcript levels are similar to the low levels of endogenously 
expressed miRNAs. Though the level of shRNA produced with miRNA based system is 
much lower than that produced with overexpression in a conventional system, the shRNA 
works equally well.  It is suggested that adopting a more physiologic way might render 
the shRNA functionally more competent and additionally, less toxic83. Usually molecular 
markers are integrated into these vectors and both the shRNA and the marker are 
transcribed as a bicistronic transcript. Thus only the shRNA expressing cells would 
express the molecular marker84. 
 
 
 
 
Fig.3: Sharma & Rao. Nature Immunology (2009). 10(8): 799-804.88 
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Both siRNAs and shRNA constructs are highly charged and do not cross hydrophobic 
cell membranes by diffusion. Therefore for delivery into in vivo systems, vehicles are 
needed which could help these molecules bypass the biological membranes82. The serum 
RNases degrade naked siRNAs rapidly and hence it is better to have these delivered to 
cells using appropriate carriers. A variety of methods have been used for the delivery of 
these molecules and these include the use of cholesterol, aptamers and nanoparticles for 
siRNAs and viral vectors including adenovirus and lentivirus in case of shRNAs. 
Nanoparticles are found to protect siRNA from vascular degradation and can deliver 
them into cells through endocytosis. Cholesterol formulations like polyelectrolyte 
complex (PEC) form micelles, which can efficiently deliver siRNA without eliciting 
interferon responses. Neutral nanoliposomes are extremely efficient in tissue delivery 
with no identifiable toxicity85. As opposed to siRNAs, shRNAs have to be delivered into 
the nucleus and hence the carriers have to be able to penetrate the nuclear envelope. 
Viruses are their derivatives are widely used as carriers for shRNA delivery82. 
 
1.8 Viral vectors and generation of transgenic animals: 
 
For delivery of transgenes (foreign DNA) into mammalian systems, efficient delivery 
methods are needed. Viral vectors are now being actively researched and used for this 
purpose. These vectors are derived from viruses where the viral genes in the vector 
genome are replaced with foreign sequences. The packaging capacities of the viral 
vectors vary. Adenoviruses are able to infect both dividing and non dividing cells, show 
high levels of transgene expression and grow to very high titers in vitro. All of these 
features make them attractive for use as vectors. They are able to replicate inside the 
nucleus of mammalian cells but do not integrate efficiently into the host genome. Hence 
there is a need for repeated administration, which in turn could trigger strong immune 
responses and liver toxicity. Similar to adenoviral vectors, adeno- associated viral vectors 
can transduce both dividing and non-dividing cells and they are non-integrating with no 
reported toxicity. Being non- integrating, both adenoviral vectors and adeno-associated 
virus vectors are unsuitable for long-term therapy82.  
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Retrovirus vectors on the other hand integrate their genome stably into the host cell DNA 
thereby allowing the long-term expression of the inserted transgene. The viral genome 
usually has several essential genes and at each end of the genome, there are long terminal 
repeats (LTRs), which contain promoter/ enhancer regions and sequences involved in 
integration. Lentiviruses are a subclass of retroviruses and include among others, the 
Human Immunodeficiency Virus (HIV). Since the native viruses can cause fatal disease, 
non- replicating viruses are used for transgene expression82, 83. 
 
Viral vectors containing either ubiquitous or tissue-specific promoters are used to ensure 
ubiquitous or when desired, tissue specific expression of the transgene. Owing to its 
integration into the host genome, the genomic backbone of lentivirus could be used as a 
means for the life long expression of the transgene. A continuous expression of the 
transgene without generation of the infectious virus is required. HIV based vectors are 
primarily used as the biology of HIV replication has been characterized extensively. To 
avoid the generation of replication competent virus particles, a number of precautionary 
steps are taken. These include removing the accessory genes from the viral genome and 
splitting the packaging genes between different expression cassettes83.  
 
In their review, Singer & Verma89 note that third generation lentiviral vectors consists of 
four plasmids; the transfer vector, Gag-pol, Rev and an envelope protein. The transfer 
vector contains the transgene to be delivered in the viral backbone. Gag-pol codes for 
integrase, reverse transcriptase and structural proteins. Rev enhances the nuclear export 
of the viral genomic RNA thereby enhancing viral titers. The envelope protein is usually 
pseudotyped with VSV-G (Vesicular Stomatitis Virus protein G) and this broadens host 
tropism82, 83, 89. A deletion in the 3’ LTR generates replication defective particles and this 
adds a level of safety to the entire process by preventing the replication of viral genomic 
RNA. These four plasmids are transfected into human embryonic kidney cells and the 
viral particles that accumulate in the supernatant can be collected and concentrated by 
ultracentrifugation thus giving high titer viral preparations83, 89, 90. These viral 
preparations are then injected into single celled embryos to generate transgenic animals.  
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One of the major concerns associated with this technique is the unknown integration 
pattern. The virus integrates randomly in the genome and hence could integrate within 
gene sequences and disrupt endogenous gene expression. Though this is an alarming 
concept, a study by Yang et al.91 demonstrated that lentivirus integrated preferentially 
within intragenic regions and especially in the introns. Lentiviral vector mediated 
transgene expression can be maintained for long periods of time and the approach has 
been found to be effective in generating transgenic mice in strains which have been found 
to be difficult to manipulate with the other transgenic approaches. Though lentiviral 
transgenesis has many advantages compared to conventional methods, there are several 
problems that have to be overcome. Some of these include genetic mosaicism, variability 
of transgene expression, the limits on construct size, vector toxicity problems with 
insertional mutagenesis and finally biosafety concerns90.  
 
1.9 Combining RNAi and lentiviral transgenesis for analyzing gene function in 
transgenic mice: 
 
As mentioned before, viral vectors provide a near perfect delivery method for shRNA 
containing plasmids. Lentiviruses are widely used as vectors for shRNA expression 
cassettes as they integrate stably into the host genome and hence are suitable for long-
term gene silencing82, 89. In their review, Sliva and Schnierle give a schematic 
representation of gene knockdown using lentiviral transgenesis (Fig. 4). shRNAs are first 
cloned into plasmids and then these are used to generate high titer lentivirus. The 
lentivirus is then injected into single celled embryos to generate transgenic animals with 
reduced gene expression levels. Since lentiviral vectors integrate into the host genome, 
progeny from the transgenic animal usually inherit the provirus and express the 
transgene89. Hence progeny from the transgenic founder are usually found to inherit 
stable knockdown of gene expression.  
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Fig.4: Sliva K, Schnierle BS. Virol J. (2010) 7:248.82 
 
 
In the search for elucidating the function of over 30,000 genes in the human genome, one 
of the widely used techniques is the generation of gene knockout mice. This involves the 
generation of ES knockout lines and the injection of the knockout cells into a 
blastocyst89. The ES knockout line must first be generated, characterized and finally 
injected into a blastocyst. The resulting chimeric founder has to be then bred back to 
homozygosity82, 89. Hence though it is an extremely useful approach, it is time 
consuming, expensive and labor intensive. Traditional pronuclear injections result in 
multiple transgene copies integrated at a single locus, with not all copies being expressed. 
However this will result in all the copies being transmitted together to the future 
generations89, 92.   
 
Using lentiviral transgenesis and RNAi for generation of transgenics on the other hand, is 
time and cost effective and less labor intensive.  While knockout of a gene ensures a 
complete lack of the target protein and gene function, RNAi results in the expression of 
the gene albeit to a significantly lower degree. However, in vivo inhibition of gene 
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products by RNAi have been found to yield phenotypes quite comparable to classical 
knock out animals82. A reduction in protein levels might better reflect a normal 
physiologic state than a complete lack of it. The technique has the added advantage that it 
allows quite a large degree of regulation and control over gene modulation as opposed to 
classical knockout models.  
 
Lentiviral vectors can be used to generate large and small transgenic animals with high 
efficiencies via transduction of fertilized eggs89, 90. Though other retroviral vectors are 
also able integrate into host genome, they are unsuitable to generate transgenic animals as 
the provirus expression is silenced during embryogenesis89. Embryo viability is found to 
be very high following lentiviral transduction. Also, large number of founder animals can 
be generated with this approach90. Lentiviral transgenesis is found to result in several 
independent copies of integrated provirus that will segregate independently in the future 
generations. Thus though the founder may carry different transgene copies depending 
upon the developmental stage of the manipulated embryo, these copies are found to 
segregate independently in the subsequent generations as each provirus integrates 
independently. In many cases, injection cycles result in mosaic founders (F0) and once 
the transgenic F1 mice are generated and the different copies segregated, the transgene is 
usually transmitted stably into future generations. Once germline transmission is 
achieved, the knockdown phenotype generally stays unaltered89.  
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Analyzing the role of IL-17A in type 1 diabetes 
 
1.10 T cells: 
 
T cells originate from the haematopoietic stem cells in the bone marrow. The early 
progenitors derived from the stem cells migrate to the thymus where they lose their 
potential to develop into B cells and natural killer cells. They then undergo rigorous cell 
division and expand to form a large population of immature thymocytes93. In the thymus, 
T cells develop and mature under the influence of thymic hormones and peptides1. The 
early thymocytes do not express either CD4 or CD8 and hence are referred to as double 
negative (CD4-CD8-). During the process of maturation, these double negative cells 
under TCR rearrangement and develop into a population of double positive cells 
expressing both CD4 and CD81, 93. Finally they lose the expression of one of the 
transmembrane glycoproteins and become single positive cells (either CD4+CD8- or 
CD8+CD4-), which are then released from the thymus into the periphery10, 11. 
 
T cells play the central role in cell-mediated immune responses. The majority of T cells 
have a TCR composed of two glycoprotein chains called α chain and β chain and these T 
cells are referred to as αβ T cells1, 93.There is a minor population of T cells where the 
TCR is composed of two different glycoprotein chains called γ chain and δ chain and 
these T cells called γδ T cells constitute about 2% of the total T cell pool. γδ T cells are 
found in high abundance in the gut mucosa. These cells are non-MHC restricted and they 
seem to be able to recognize whole proteins.  
 
The entire process involves two stages of selection during which around 98% of the 
thymocytes that fail the selection processes are removed. The remaining 2% of 
thymocytes that survive leave the thymus for the periphery as mature albeit naïve T cells. 
Double positive thymocytes undergo positive selection in the thymic cortex where they 
are presented with self-antigens complexed with MHC molecules on the surface of 
thymic epithelial cells. All T cells are required to recognize self-antigens in order to 
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mount effective immune responses against foreign antigens. Hence, during the process of 
positive selection, only those thymocytes that can interact with self-antigens with 
optimum affinity are selected and given signals required for survival. Thymocytes with 
no affinity to self-antigens undergo apoptosis (death by neglect) and are removed by 
macrophages10, 11.Thymocytes that are positively selected on MHC class I molecules 
downregulate the expression of CD4 and become CD8 single positive cells. Similarly, 
thymocytes that are selected on MHC class II molecules downregulate CD8 expression 
and become CD4 single positive cells1, 10, 11, 94. 
 
The positively selected single positive thymocytes migrate to the medulla where they are 
again presented with self- antigens complexed with MHC molecules on antigen 
presenting cells. Those cells that interact too strongly with self- antigens are removed by 
negative selection where they undergo TCR mediated apoptosis. The remaining cells 
leave the thymus as mature naïve T cells. The process of negative selection tries to 
prevent potentially autoreactive T cells from reaching the periphery. Together, the 
processes of positive and negative selection play an important role in the generation of 
central tolerance. Autoreactive T cells, which fail to be deleted in the thymus, are usually 
identified and suppressed in the periphery by means of peripheral tolerance mechanisms1, 
10, 11. 
 
Activation of the T cell requires two distinct signals. The first signal is provided by the 
interaction between the TCR and specific antigenic peptide complexed with the MHC 
molecule present on the surface of an antigen-presenting cell. The second signal requires 
the interaction between a co- stimulatory molecule like CD28 present on the T cell and its 
partner protein on the antigen-presenting cell. CD28 is the most important co stimulatory 
receptor present on T cells. Its interaction partner is the B7 protein composed of CD80 
and CD86. This second signal called co-stimulation is critical in T cell activation. In the 
absence of a co- stimulatory signal, the T cell becomes anergic.  
 
Naïve T cells, which have never encountered their cognate antigen, are characterized by 
their surface expression of L-selectin (CD62L). They usually do not express the 
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activation markers like CD25 and CD69.  Upon encountering its cognate antigen, the 
naïve T cell gets activated and downregulates CD62L expression. The various activation 
markers like CD25, CD44 and CD69 are upregulated. Some of these activated cells go on 
to acquire the memory phenotype. Memory T cells are further subdivided into central 
memory T cells (TCM) or effector memory T cells (TEM). Central memory T cells migrate 
to the lymph nodes and facilitate memory responses while effector memory T cells 
migrate to periphery and promote elimination of pathogens3. Central memory T cells 
express CD62L and CCR7 while effector memory T cells do not express these markers. 
Central memory cells secrete IL-2 but do not produce effector cytokines like IL-4 and 
IFNγ while effector memory T cells secrete both IL-4 and IFNγ.  
 
There are several T cell subsets, each with a distinct function. T helper (Th) cells are 
CD4+ cells and they are activated by antigenic peptides complexed with MHC class II 
molecules expressed on the surface of antigen presenting cells. Once activated, Th cells 
undergo major expansion and secrete proteins called cytokines. Cytokines play an 
important role in regulating and assisting immune responses. Th cells also assist in the 
maturation of B cells into plasma cells and also in the activation of cytotoxic T cells and 
macrophages. Cytotoxic T cells or CTLs are CD8+ cells that attack and destroy virally 
infected cells and tumor cells1. They are activated by antigenic peptides complexed with 
class I MHC molecules which are present on the surface of almost all the cells in the 
body. Memory T cells are antigen specific T cells which persist in the body after 
infections. These cells expand rapidly after re- exposure to their cognate antigen and 
thereby provide the immune system with a memory of the infections it has already 
encountered. Regulatory T cells or suppressor T cells are responsible for shutting down T 
cell responses towards the end of an immune response and also for suppressing 
autoreactive T cells which may have escaped from the thymus1. Naturally occurring 
regulatory T cells (nTreg) arise in the thymus while adaptive Tregs are derived in the 
periphery. Tregs can be identified by the expression of their lineage specific transcription 
factor FoxP3.  
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1.11 T helper lineage: 
 
T helper cells play an important role in regulating and enhancing immune responses to 
antigens. They are involved in B cell antibody class switching, activation of cytotoxic T 
cells and enhancement of the bactericidal property of macrophages. Mature T helper cells 
express CD4 and are called CD4+ T cells. They bind to MHC class II molecules and 
hence they interact with antigenic peptides bound to MHC class II molecules expressed 
on the surface of antigen presenting cells. Antigen presenting cells usually take up the 
antigen, processes it and these APCs then travel to the lymph nodes. Once there, the 
antigenic peptides are transported to the APC surface where it is displayed bound to 
MHC class II molecules for recognition by T cells with the specific TCR. Once the T 
helper cell encounters its cognate antigen in the presence of proper co-stimulation, it is 
activated and undergoes rapid proliferation. This is done by the secretion of a potent 
growth stimulatory factor i.e. IL-2. IL-2 can function in an autocrine manner and the 
proliferation is further enhanced by the fact that activated T cells can produce alpha 
subunit of the IL-2 receptor (CD25). The autocrine and paracrine action of IL-2 can lead 
to clonal activation.  
 
1.12 Th1/Th2 Paradigm: 
 
Naïve CD4+ T cells are activated and differentiate into different T helper subsets in the 
presence of their specific antigens. Mossman and Coffman proposed the existence of 2 
different T helper subsets more than 20 years ago. Upon encountering an antigen 
presented by the antigen-presenting cell (APC), naïve CD4+ T cells can differentiate into 
either IFNγ producing Th1 cells or Th2 cells which produce IL-4, IL-5 and IL-13. Proper 
T helper responses play an essential role in the host defense against infections. Th1 
responses enhance cellular responses against viruses and intracellular pathogens while 
Th2 responses enhance humoral immunity and control extracellular pathogens including 
helminthes. On the other hand, uncontrolled and persistent T effector responses can lead 
to deleterious conditions like allergy and autoimmunity. Uncontrolled Th2 responses 
have been found to lead to conditions like asthma95. Abnormal Th1 responses have been 
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implicated to play at least a partial role in the development of several autoimmune 
diseases including inflammatory bowel disease (IBD) and psoriasis96, 97. Over the years it 
has been noticed that several pathological conditions could not be simply explained by 
the Th1-Th2 paradigm. Efforts to resolve these questions have recently led to the 
discovery of several new T helper subsets like regulatory T cells (Treg), Th17 cells and 
Th9 cells.  
 
The first clue suggesting the existence of distinct T cell populations mediating humoral 
and cell mediated responses was provided from the work of Parish and Lew98. Around 
mid 1980s, Tim Mossman’s lab identified 2 distinct T cell types able to produce different 
growth factors. Th1 cells were found to produce IL-2 and IFNγ while Th2 cell produced 
something different. Meanwhile Bob Coffman’s lab had developed an assay to test IgE 
production. Mossman and Coffman tested the supernatants from the two T cell subsets in 
the assay and found that supernatant from the Th1 clone containing IL-2 and IFNγ could 
not induce IgE. On the other hand, supernatant from the Th2 clone when added to LPS 
stimulated B cells could induce IgE responses. They also discovered that when both 
supernatants were added together, the IgE production was inhibited suggesting that a Th1 
factor is able to block the Th2 induced IgE response. They were able to identify this Th1 
factor as IFNγ by using neutralizing antibodies. The growth factor released by Th2 clones 
was identified as IL-4. These observations led to the development of what came to be 
later known as the Th1/ Th2 paradigm.  
 
The Th1/Th2 paradigm was suggested on the basis of the observation that each CD4+ Th 
cell subset has distinct cytokine profile and fulfills different effector functions. Th1 cells 
secrete IL-2 and IFNγ and are crucial for cell- mediated immunity while Th2 cells secrete 
IL-4, IL-5 and IL-13 and mediate humoral immunity. Signal transducer and activator of 
transcription (STAT) proteins are essential for the Th subset differentiation. STAT-1 and 
STAT-4 are required for Th1 differentiation while STAT-6 is required for Th2 
differentiation. T-bet is the lineage specific transcription factor for Th1 development 
while for the Th2 cells, it is GATA-3. IL-12 is also found to be important for the 
induction of Th1 cells. Activation of T cells in the presence of IFNg leads to the 
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activation of STAT-1 and the Th1 lineage specific transcription factor T-bet.  Expression 
of T-bet induces IFNg secretion and IL-12Rβ2 expression which makes the cells 
responsive to IL-12. The engagement if IL-12R by IL-12 causes the activation of STAT-4 
resulting in enhanced IFNg secretion by the cells. The increased secretion of IFNg in 
turn, causes a further upregulation of T-bet and strengthens Th1 commitment. Activation 
of T cells in the presence of IL-4 induces the activation of Th2 lineage specific 
transcription factor GATA-3. Upon engagement is IL-4R by IL-4, STAT-6 is activated 
which enhances the production of IL-4. This leads to a positive feedback loop resulting in 
enhanced Th2 differentiation99. The two T helper subsets were found to be able to cross 
regulate each other. 
 
For quite some time after the introduction of the Th1/Th2 paradigm, it was believed that 
Th1 cells are pathogenic and are responsible for organ specific autoimmunity while a Th2 
response is beneficial and non pathogenic. But this assumption was brought into question 
when data emerged from the EAE (Experimental Autoimmune Encephalomyelitis) 
mouse model contradicting it. EAE is the animal model for multiple sclerosis (MS). It 
was found that neutralizing IFNγ increased the disease severity while administration of 
IFNγ reduced the severity100- 102. It was observed that the disruption of genes encoding 
either IFNγ or IFNγR converted EAE resistant strains to susceptible phenotype103, 104. 
These data indicated a protective role for IFNγ in EAE. Also animals, which lack other 
Th1 molecules like STAT1 and IL-12Rβ2 developed more severe disease105, 106. All these 
data raised the possibility that other Th subsets may exist which mediate tissue damage 
and autoimmunity. 
 
1.13 Discovery of IL-23 and Th17 Cells: 
 
The discovery of IL-23 by Robert Kastelein was finally able to shed some light on the 
contradictory data obtained regarding the role of Th1 in autoimmune diseases. Sequence 
database searches with structure based alignment tools in the laboratory of Fernando 
Bazan and Robert Kastelein led to the discovery of a novel sequence, which they named 
p19.  p19 was found to share an overall sequence identity of 40% with the p35 subunit of 
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IL-12 and they were unable to purify p19 from the supernatant of transiently transfected 
cells. Since it was known that IL-12p35 requires IL-12p40 for secretion, further 
experiments in the line revealed that secretion of p19 requires its partnering with IL-
12p40107. This resulting cytokine was named IL-23108. IL-23 is found to be expressed 
mainly by activated dendritic cells and phagocytic cells. 
 
IL-23 belongs to the IL-12 family of cytokines. IL-12 is a heterodimeric cytokine 
composed of 2 subunits p35 and p40. In mice, the transgenic expression of p19 induced 
elevated levels of pro inflammatory cytokines TNFα and IL-1 leading to fatal systemic 
inflammation due to massive T cell and macrophage infiltration109. The exact role of IL-
23 in the development of autoimmunity (especially in EAE) was elucidated in a landmark 
paper by Daniel Cua and his colleagues. They studied the role of IL-12 and IL-23 in EAE 
development by inducing EAE in mice deficient for each of the subunits forming IL-12 
and IL-23 i.e. IL-12p35, IL-12p40 and IL-23p19 deficient mice. They were able to show 
that animals deficient in IL-23 (p19-/-) and both IL-12 and IL-23 (p40-/-) were protected 
from EAE while IL-12 deficiency (p35-/-) did not have any effect on EAE induction. 
They were able to further show that the delivery of IL-23 gene transfer vectors into the 
central nervous system (CNS) could reconstitute EAE in the p19-/- and p40-/- animals 
while the gene transfer of IL-12 into the CNS did not reconstitute the disease in p40-/- 
mice110. Thus it was demonstrated that IL-23 rather than IL-12 might be the more 
important cytokine for autoimmune inflammation in this mouse model.  
 
Daniel Cua’s group did similar experiments in another autoimmune disease model; the 
collagen induced arthritis and discovered that IL-23 deficient mice were protected from 
the disease while the IL-12 deficient mice developed exacerbated disease. They also 
noticed that the disease resistance correlated with the absence of IL-17 producing CD4+ 
cells despite the normal induction of collagen specific Th1 cells111. Aggarwal et al.112  had 
previously reported that IL-23 activated CD4+ T cells show elevated production of IL-17. 
Further studies showed that IL-23 is essential for the expansion of a distinct CD4+T cell 
population with a unique expression pattern of pro inflammatory cytokines. These cells 
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were found to produce IL-17A, IL-17F, IL-6 and tumor necrosis factor. Passive transfer 
studies demonstrated that these IL-23 dependent T cells are highly pathogenic113.  
 
Studies done by Harrington et al.114 and Park et al.115 showed that Th17 differentiation is 
independent of the transcription factors involved in Th1 (T-bet, Stat1 and Stat4) and in 
Th2 (Stat6 and c-Maf) differentiation. They also discovered that addition of anti IFN-γ 
and anti IL-4 to the Th17 cultures could increase IL-17 expression. This led to the 
suggestion that IFNγ and IL-4 negatively regulates Th17 cells and that IL-23 might 
induce the differentiation of naïve T cells into Th17 cells. This suggestion led to a 
conceptual problem as Aggarwal et al.112 had already shown that unlike memory T cells, 
naïve T cells do not express IL-23R. Later studies demonstrated that IL-6 in combination 
with TGF-β was required for the differentiation of naïve T cells into Th17 cells116- 118. 
This was surprising as TGF-β was considered an immunosuppressive cytokine. It was 
also known that naïve T cells in the presence of TGF-β expressed FoxP3, the 
transcription factor that induces their differentiation to regulatory T cells. It was shown 
that IL-6 could suppress the TGF-β induced differentiation of regulatory T cells and 
redirect the differentiation program to the Th17 lineage.   
 
1.14 Characteristics of Th17 cells: 
 
Th17 cells are a sub population of CD4+ effector T cells. They have a high expression of 
the transcription factors RORγt and RORα while they express little T-bet or GATA-3. 
They secrete a variety of cytokines including IL-17 (IL-17A), IL-17F, IL-21, IL-22, IL-9, 
TNF and GM-CSF119. They also express the chemokine receptor CCR6. TH17 population 
is highly heterogeneous. In addition to IL-17A/ IL-17F double producers, populations 
that are only IL-17A or IL-17F positive are also reported120. Lee et al.121 have reported 
that IL-17F is expressed earlier than IL-17A during Th17 development. In mice, these 
cells develop in the presence of TGF-β and IL-6117. Bettelli et al.116 demonstrated that IL-
6 is able to inhibit the FoxP3 expression induced by TGF-b and thus downregulate the 
Treg differentiation and enhance the Th17 pathway. IL-6 is required for IL-21 
production, which then acts in an autocrine manner to induce more IL-21. This in turn 
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leads to IL-23R expression by the cells122. IL-23 signaling is critical for the survival of 
Th17 cells. Both IL-2 and IL-27 are found to suppress Th17 differentiation123.  
 
In humans, the Th17 differentiation happens in the presence of TGF-β and IL-1b along 
with IL-21 or IL-23124- 126. Human Th17 cells are found to develop from CD161+ 
precursors and virtually all of them express CD161 and are CCR4+CCR6+127, 128. They 
express the cytokines IL-17A, IL-17F, IL-22, IL-26 and IFN-γ. They also express RORγt 
and IL-23R just like murine Th17 cells129. Thus, the current view is that at least in murine 
cells, TGFβ along with IL-6 lead to the differentiation of naïve T cells into Th17 cells. 
Th17 cells secrete IL-21, which acts in an autocrine manner to bring about the 
amplification of the Th17 lineage. IL-23 is believed to be an important survival factor 
that is essential for the stabilization and expansion of Th17 cells. The Th17 pathway in 
humans seems to reflect this to an extent. 
 
Murine Th17 cells express high levels of a master transcription factor, RORγt. They are 
also found to express a second orphan receptor, RORα the presence of which is found to 
have an additive effect on Th17 differentiation130, 131. STAT3 is also found to play a 
crucial role in Th17 differentiation132, while STAT5 is found to negatively regulate the 
pathway133. IRF4 plays an important role in this pathway, as it is able to induce IL-21, 
which in turn leads to amplification of Th17 cells134. The presence of natural agonists for 
AHR in the medium is found to enhance the differentiation of Th17 cells in vitro135.  
 
1.15 IL-17 and its functions: 
 
IL-17 was first cloned in 1993 by Rouvier et al.136. IL-17 is the founding member of the 
IL-17 family, which includes IL-17A, IL17-B, IL-17C, IL-17D and IL-17E (also called 
IL-25) and IL-17F. The others members of the family were identified as a result of 
bioinformatics strategies based on the IL-17A sequence137. Genes for IL-17A and IL-17F 
are located on the same chromosome in both mouse and humans. Genes for the other 
family members are located on different chromosomes. IL-17A and IL-17F share the 
highest sequence identity of around 50% while IL-25 is the most divergent (16%)120, 138. 
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Murine IL-17A and human IL-17A share 62% homology. Hymovitz et al.139 
demonstrated that all family members except IL-17B exist as homodimers consisting of 
five highly conserved cystine residues forming a cystine knot structure. IL-17A is also 
able to form heterodimers with IL-17F. IL-17A homodimers are found to be the most 
potent with the heterodimers and IL-17F homodimers having decreasing potencies140- 142.  
 
IL-17 family cytokines signal through IL-17 receptor family members. There are 5 
different IL-17 receptors, IL-17RA to IL-17RE143. Functional receptors are believed to be 
composed of homodimers or heterodimers. IL-17RA is able to associate with IL-17RC 
and transduce signals from both IL-17A and IL-17F as well as IL-17A/ IL-17F 
heterodimers. IL-17RA is expressed primarily in immune cells while IL-17RC is 
expressed mainly in non-immune cells144, 145. IL-17A has a higher affinity for IL-17RA 
while IL-17F has a higher affinity for IL-17RC139. IL-17F is able to signal through IL-
17RA but its affinity is almost 10 fold lower than that of IL-17A. Upon binding of IL-
17A, IL-17RA recruits IL-17RC to form the IL-17RA/ IL-17RC complex.  
 
IL-17A and IL-17F are pro inflammatory cytokines, which act on cells to induce the 
production of a variety of cytokines (IL-6, IL-8, GM-CSF, G-CSF), chemokines 
(CXCL1, CXCL10) and metalloproteinases99, 108. Both IL-17A and IL-17F are produced 
by a variety of cell types including CD4+ cells, CD8+ T cells, NKT cells, γδ T cells and 
neutrophils. NKT cells also found to secrete IL-17 under proper stimulation. During 
airway inflammation, invariant NKT cells that lack NK1.1 marker are found to secrete 
copious amounts of IL-17A146. γδ T cells are found to secrete large amounts of IL-17 
during both Mycobacterium tuberculosis and Escherichia coli infections147, 148.  
 
IL-17 is involved in protective immune responses against bacterial and fungal infections. 
It does so by activating the production of pro-inflammatory cytokines and chemokines 
and by recruiting and activating neutrophils and macrophages. IL-17R deficient mice 
succumb to K. pneumoniae infections due to reduced chemokine production and 
neutrophil recruitment149. On the other hand, Overexpression of IL-17 in the lungs led to 
enhanced production of pro- inflammatory cytokines, increased neutrophils recruitment 
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and clearance of the infection150. This suggests a partial role for IL-17 in protection 
against K. pneumoniae. A complementary role for IL-17 is suggested in the protective 
immunity against M. tuberculosis, B. pertussis, S. aureus and L. monocytogenes151- 154. 
IL-17 deficient mice have increased mortality from C. albicans infections155. IL-17 is 
also found to be protective in other fungal infections including Pneumocystis carinii and 
Aspergillis fumigatus156- 157.   
 
1.16 Th17/ IL-17A in autoimmune diseases: 
 
There is a plethora of evidence suggesting a role for Th17 cells and the various Th17 
factors in a variety of autoimmune diseases. Despite this, much confusion exists 
regarding the extent to which these cells are pathogenic. Tzartos et al.158 were able to 
identify IL-17+ CD4+ and CD8+ cells in active lesions in the brain from MS patients. 
There is evidence for the presence of IL-17 and IL-22 receptors on inflamed endothelium 
in MS lesions and these cytokines were found to enhance the migration of T cells across 
the blood brain barrier159. In vitro differentiated Th17 cells have been found to transfer 
EAE but the disease is significantly milder in comparison with Th1 cells. In this model, 
the authors were able to detect IFNγ much earlier than IL-17 in the CNS, which led them 
to conclude that Th17 cells could contribute to EAE but need Th1 cells to disrupt the 
blood brain barrier first160. IL-17A knockout and IL-17F knockout mice develop a milder 
form of EAE and only marginal differences in clinical EAE scores are observed 
indicating that neither vitally contributes to the disease161, 162.  
 
 Fossiez et al.163 found that IL-17 could induce the secretion of pro inflammatory 
cytokines including IL-6, IL-8 and G-CSF from stromal cells. Th17 cells found in 
arthritic synovium express RANKL (receptor activator of nuclear factor kappa B ligand), 
which is found to enhance osteoclast formation164. These data suggest a role for Th17 
cells in rheumatoid arthritis. A number of studies point to a role for this Th lineage in 
psoriasis. Increased levels of RORγt, IL-17, IL-22 and IL-23 mRNA are reported in 
psoriatic lesions129, 165- 167.  IL-17 deficient mice develop experimental autoimmune 
uveitis168 thereby precluding a major role for this cytokine in EAU. But anti- IL-17 is 
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found to prevent or at least diminish the disease169 indicating that IL-17 is able to 
contribute to this autoimmune condition.  
 
As mentioned, before the discovery of Th17 cells, autoimmune pathologies were 
attributed solely to Th1 cells. Contradictions in the data led to questions and finally the 
characterization of Th17 subset. The autoimmune diseases were then attributed to Th17 
cells and their effector cytokines. But it has been observed that both Th17 cells and Th1 
cells are able to induce several autoimmune conditions like EAE and EAU with distinct 
disease pathologies. Hence, data to date indicate that though Th17 cells may play a role 
in some autoimmune diseases, this role is not exclusive and Th1 cells might still be 
pathogenic in autoimmune disorders with critical roles in induction or effector phases. 
Thus it seems that both Th17 cells and Th1 cells seem to be involved in the development 
of autoimmune pathologies.  
 
1.17 Th17 / IL-17A in type 1 diabetes: pathogenic or not?  
 
Preliminary evidence has suggested that in the NOD mouse during the course of T1D, IL-
17 is expressed in the pancreas170. Jain et al.171 observed that inhibiting Th17 cells with 
the induction of IFNγ inhibited IL-17 production and it could restore normoglycemia in 
the pre diabetic NOD mice. Two separate studies which used the adoptive transfer effects 
observed that transfer of islet specific Th17 cells could induce diabetes but only after the 
cells converted to IFNγ producing cells172, 173. Bradshaw et al.174 observed that the 
monocytes from T1D patients spontaneously secrete pro inflammatory cytokines like IL-
6 and IL-1β and these monocytes in turn could induce more IL-17 secreting cells from 
memory T cells. This led them to speculate that the activated innate immune system 
might drive the expansion of Th17 cells in T1D patients. Emamaullee et al.175 analyzed 
the role of anti-IL-17 and recombinant IL-25 in type 1 diabetes using the NOD mouse 
model. They reported that these strategies failed to have any benefit in the young mice 
but could prevent diabetes when the mice were treated around 10 weeks of age. They 
found that both strategies reduced the number of peri islet infiltrates and GAD65 
autoantibody levels and led to an increase in the number of T regulatory cells. This led 
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them to conclude that Th17 cells are involved in the development of autoimmune 
diabetes and that therapeutic strategies directed against Th17 cells may be beneficial. 
These data seem to suggest that though IL-17 might play a role in the development of 
insulitis, the progression to overt diabetes might depend on IFNγ176. Arif et al.263 were 
able to observe increased IL-17 reactivity in type 1 diabetes patients in comparison with 
control subjects. They could detect IL-17A, IL-22 and RORC in the islets close to disease 
diagnosis, though the observation was from a single patient. They found that IL-17A on 
its own had no proapoptotic effect on cultured beta cells, but could exacerbate beta cell 
death induced by the combination of IL-1β and IFNγ or TNFα and IFNγ. All these 
observations led them to conclude that IL-17 could be used as a biomarker as well as a 
therapeutic target in autoimmune diabetes. Munegowda et al.264 recently reported that 
both CD4+ Th17 cells and Th17 stimulated CD8+ CTLs play distinct roles in T1D and 
EAE. They found that Th17 stimulated CTLs but not CD4+ Th17 cells themselves were 
critical in type 1 diabetes development whereas CD4+ Th17 cells and not Th17 activated 
CTLs could induce EAE.  
 
1.18 AIM:  
 
As mentioned in the previous section, a lot of evidence point to a role for Th17 cells and 
their signature cytokine IL-17A in the development of type 1 diabetes. But so far, the 
results are conflicting and do not conclusively prove a pathogenic role for IL-17A in 
T1D. Hence, we aimed to identify the role, if any of IL-17A in autoimmune diabetes and 
to conclusively prove a positive or negative role for this cytokine in autoimmune 
diabetes. So far, studies have made use of adoptive transfer experiments of in vitro 
differentiated Th17 cells or anti IL-17 antibodies. Both these strategies do not seem to be 
optimal owing to the widely described plasticity observed with Th17 cells and the 
conflicting results obtained with antibodies. 
 
We felt that the best way to study the role of this cytokine in the context of type 1 
diabetes would be to generate NOD mice in which IL-17 is systemically silenced. As 
mentioned earlier, RNAi is an extremely useful tool to analyze gene functions and 
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lentiviral transgenesis could be used in conjunction with RNAi to generate transgenic 
animals in which desired genes are silenced. Hence we aimed to use lentiviral 
transgenesis and RNAi to generate transgenic NOD mice with reduced IL-17A levels. 
We then aimed to analyze diabetes incidence in the transgenic line to identify whether IL-
17A plays a contributing role in diabetes. Diabetes incidence levels in these mice would 
better reflect the role of IL-17A, as this strategy does not involve or require additional 
manipulations.  
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  Generation of β- cell reporter mouse models and modulation of 
β- cell mass 
 
1.19 Pancreas and β-cells: 
 
Pancreatic β-cells, responsible for the synthesis and secretion of insulin in response to a 
glucose challenge, are located in the islets of Langerhans. Islets are comprised of a 
heterogeneous population of endocrine cells, including insulin-producing β-cells (approx. 
65–90%), glucagon-secreting α -cells (15-20%), somatostatin-secreting δ -cells (3-10%) 
and polypeptide (PP)-secreting cells (1%)177. Recent studies have shown that pancreatic 
β- cells harbor immense powers of self-renewal. Systemic insulin demand is found to 
change and β- cell mass undergoes compensatory changes correspondingly. Some 
physiological and pathological states such as aging, pregnancy, insulin resistance and 
obesity increase the insulin demand and facultative β- cell proliferation is essential to 
meet the increasing demands for insulin178. Some studies have reported an increase of 40-
50 fold179, 180 and the failure to increase beta cell mass according to the demand may 
result in hyperglycemia and subsequent development of diabetes.  
 
Though pancreatic development is first morphologically discernable in mice at 
embryonic day (e) 8.75-9.0, the differentiation of the five endocrine cell types i.e. β, α, δ, 
ε and pancreatic polypeptide (PP) cells starts only by e13.5181. Expression of Ngn3 in the 
pancreatic progenitors is crucial for the commitment to endocrine lineage182. Following 
differentiation, the endocrine cells in mice cluster to form functional islets from e16.5 
onwards. Cell adhesion molecules and matrix metalloproteinases are believed to be 
involved in islet formation. The transcription factors MafA and MafB are crucial for 
terminal β- cell development. β- cells acquire glucose responsiveness during the early 
postnatal period and this requires the expression of Glut2 glucose transporter and PC1/3, 
which cleaves proinsulin to active insulin181. 
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A number of different factors are found to be involved in regulating the β- cell mass 
postnatally and include nutrients, hormones, growth factors and cell cycle regulators 
among others. Several mitogenic factors including glucose, insulin, prolactin, placental 
lactogen, growth hormone, glucagon –like peptide- 1 (GLP-1), platelet derived growth 
factor, insulin like growth factor (IGF)-1 and IGF- 2 stimulate β- cell growth and 
proliferation. Moderate increases in glucose levels can enhance β- cell proliferation and 
survival. It is suggested that glucose can increase the number of cells entering the cell 
cycle and that it has antiapoptotic effects. On the other hand, consistent exposure of β- 
cells to increased glucose levels could lead to oxidative stress and β- cell apoptosis. 
Increased insulin / IGF signaling in β- cells is found to enhance proliferation. The 
increase in β- cell mass is found to be augmented on costimulation with glucose. 
Pregnancy causes an increased insulin demand owing to increased maternal body weight 
and insulin resistance. This facultative β- cell growth during pregnancy is controlled by 
several hormones including prolactin (PRL), placental lactogen (PL), estrogen and 
progesterone. All the pregnancy related adaptations in the maternal pancreas are reversed 
upon parturition and the β- cell mass goes back to pre partum levels. Upon pregnancy in 
rodents, β- cell mass is found to increase by about 150% and it is accompanied by 
increased insulin synthesis and secretion. Insufficient maternal β- cell adaptation could 
lead to gestational diabetes178, 183.  
 
Cell cycle regulators like cyclins, cyclin dependent kinases (CDKs) and cyclin dependent 
kinase inhibitors (CKIs) are found to play a major role in post natal β- cell proliferation. 
Many of the insulinotropic factors induce the expression of cyclins. Cyclin D2 is found to 
be crucial for normal postnatal β- cell expansion. Cyclin D1 is involved in β- cell 
proliferation though it is not required for β- cell development. Though cyclin D3 and E 
are also expressed in the islets, no role for these in β- cell proliferation has been reported 
so far. Both CDK4 and CDK2 are expressed in the islets. CDK4 is the best-characterized 
CDK in the pancreas and is found to be indispensable for β- cell proliferation and for 
maintaining normal β- cell mass in vivo. CKIs including Cip/Kip proteins and INK4 
(inhibitors of CDK4) members are expressed in mature β- cells and play an essential role 
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in regulating β- cell growth. Two of the four INK proteins, p18Ink4c and p15Ink4b inhibit β- 
cell proliferation. There are three Cip/ Kip family members- p21Cip1, p27Kip1 and p57Kip2. 
They are all expressed in islets, and play essential roles in limiting β- cell proliferation. 
All three are found to inhibit facultative β- cell proliferation and growth. Several 
transcription factors including E2F, Rb and p53 also regulate postnatal β- cell mass 178, 
183.  
 
Intracellular proteins and pathways that transduce the β- cell mitogenic signals are 
currently being elucidated and include several transcription factors like FoxO1, Pdx1, 
NFAT and menin. NFAT, STAT5 and Wnt signaling pathways are believed to be 
involved in cyclin and CDK expression in the islets183.  FoxO1 is found to inhibit β- cell 
proliferation and it is partially mediated by enhanced expression of p27Kip1. It is 
suggested that FoxO negatively regulates β- cell proliferation by controlling the 
expression and function of proliferation enhancer, Pdx1. Signaling through the insulin / 
IGF pathway promotes the exclusion of FoxO1 from the nucleus thereby enhancing the 
expression, nuclear localization and activity of Pdx1. β- cell mitogens enhance 
intracellular Ca2+ and Ca2+ signaling mediates β- cell proliferation. Calcineurin/ NFATc 
signaling is suggested to be involved in the regulation of β- cell proliferation and there is 
some evidence that mitogens like glucose and GLP-1 are able to stimulate NFAT activity 
at the insulin promoter.  Menin is a tumor suppressor and loss of menin expression is 
found to be sufficient to trigger β- cell proliferation and subsequent islet hyperplasia. 
Menin regulates the expression of p18Ink4c and p27Kip thereby influencing β- cell 
growth and proliferation178.  
 
Though many of the factors and pathways involved in pancreatic development and β- cell 
growth and proliferation have been identified, most of them are yet to be fully 
characterized. Advances in understanding the factors which govern β- cell growth and 
maintenance would accelerate progress in generating successful therapies for a multitude 
of pathologies including type 1 diabetes. β- cell  mass at any given time is governed by 
neogenesis, cell differentiation, cell proliferation, cell size and cell death183. Improved in 
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vivo imaging would allow the quantification of β- cell mass, growth and death in both 
normal physiological states and in pathological conditions and the data would 
significantly contribute to the search for therapy. As mentioned earlier, an ideal therapy 
for type 1 diabetes would require the ability to achieve β- cell neogenesis and 
regeneration in parallel with immune tolerization approaches and a thorough knowledge 
of the whole process of pancreatic development is crucial for this.  
  
1.20 in vitro models for β-cell studies: 
 
As mentioned before, isolation and purification of β- cells is a tedious process. Once in 
culture, primary β- cells do not proliferate easily and since all cells have a finite life span, 
they soon submit to senescence and die.  It is also extremely hard to maintain the native 
characteristics of primary β- cells (eg. glucose responsiveness) in culture over time. 
Hence diabetes research has involved the use of β- cell tumour lines, which have an 
infinite life span. They are extremely useful in studying the molecular basis of β- cell 
function. They are also ideal tools for testing potential drugs for the development of 
therapeutic options. Cell culture offers research possibilities that are difficult to be 
performed in vivo. During cell culture, various parameters including culture conditions, 
cell growth and cell density can be kept controlled and the various secreted factors can be 
assayed from the culture media. A number of rodent, human and hamster β- cell lines are 
currently in use and most of them have been derived from insulinomas or neoplastic 
islets184, 185.  
 
β- cell lines have been generated using various transformation approaches including 
irradiation, viral infection and targeted expression of recombinant oncogenes. RIN and 
INS cell lines were derived from radiation treated rat cells.  Mouse cell lines including 
NIT-1 and MIN6 were generated from insulinomas of transgenic mice expressing the 
large T antigen of SV40. Though they are exceedingly useful β- cell research tools, they 
do not recapitulate primary β- cell physiology perfectly. A major disadvantage with the 
cell lines is the induction of hexokinase in the cells while in culture. Normal β- cells 
express the high-Km glucokinase isotype and this enables them to secrete insulin only 
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when the glucose concentration exceeds the physiological threshold. But the induction of 
low-Km hexokinase in the cell lines makes them responsive to sub physiological glucose 
levels. Hence compared to normal β- cells, most cell lines usually have a hypersensitivity 
to glucose. They have defective secretory characteristics and do not respond to glucose in 
the physiological range184, 185.  
 
For the purpose of this thesis, I would like to briefly describe the rat insulinoma cell line 
INS-1E and the mouse insulinoma cell line NIT-1. INS-1E cell line is a rat β- cell line 
that was derived from the parental INS- 1 cell line. INS-1 cell line was isolated from a 
radiation induced rat insulinoma186 and the cell line displays many important features of 
β- cells including high insulin content and glucose responsiveness within the 
physiological range185. But these cells were found to be heterogeneous and hence Janjic 
et al.187 improved on the original cell line by generating Ins-1E cell line based on their 
insulin content and also their secretory response to glucose. Later they characterized the 
cell line over a period of 2 years and found that the cells could maintain β- cell phenotype 
over 116 passages and that the glucose-induced response was dose dependent188. Menin 
has been found to inhibit insulin production in INS-1 cells189. 
 
NIT-1 cell line is derived from NOD/ Lt mice which are transgenic for the SV40 large T 
antigen under the control of RIP promoter and which develop β- cell adenomas184, 185. 
SV40 or Simian vacuolating virus 40 is a circular DNA virus, which is a member of the 
polyomavirus family. It is able to infect eukaryotic cells and has the potential to cause 
tumours. It is believed to suppress the transcription of the tumour suppressor p53 and 
hence is able to transform a variety of cell lines185. NIT-1 cell line expresses high levels 
of insulin mRNA but the cells are not responsive to glucose in the physiological range 
and the insulin secretion is responsive to the glucose concentration in the media. The 
cells when cultured shed a mature ecotropic type C virus190.  
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1.21 Relevance of a RIP- luciferase NOD mouse model: 
 
For the development of an effective therapeutic intervention for T1D, it is imperative that 
we have a clear understanding of the disease process as a whole, the main culprits and the 
critical checkpoints that are overridden in disease. Conventionally, the investigations 
have used an approach where representative groups of animals are sacrificed at required 
time points for analyses and data collection. This approach carries some disadvantages in 
that the number of animals which are required for each experiment is high, which might 
put limitations on the scope of experiments as well as the frequency.  
 
Type 1 diabetes is caused by the destruction of β- cells by the immune system and one of 
the most promising therapeutic strategies being intensively pursued is endogenous β- cell 
regeneration. Hence the ability to monitor β- cell mass either in the normal course of 
disease development or in the presence of therapeutic interventions is absolutely critical. 
The project proposes to address this issue by generating transgenic mice in the NOD 
background in which the β- cell mass can be imaged non- invasively using 
bioluminescence. In vivo imaging of luciferase expressing cells is already well 
established191 and luciferase constructs have been used to transduce islets that were then 
monitored non-invasively post- transplantation 192, 193.  Also, transgenic mice which 
express mouse insulin promoter (MIP)/ RIP driven luciferase gene have been reported 
though the work has been done in mouse strains which are not T1D relevant194, 195. We 
propose to build on this concept by generating pancreas specific luciferase transgenic 
mice in the NOD background and combine it with pancreas specific silencing of target 
genes. The mice will express the luciferase gene in the pancreas under the control of rat 
insulin promoter (RIP). We anticipate that during the normal course of the disease 
development, beta cells are destroyed over time and this should lead to reduced 
luminescence intensity with time. This strategy will also be used to generate transgenic 
mice in which target genes are constitutively silenced exclusively in the beta cells using 
RNA interference (RNAi). The approach would facilitate the non-invasive monitoring of 
β- cell mass in NOD mice and simultaneously allow beta cell specific gene silencing.  
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1.22 Bioluminescence Imaging (BLI): 
 
Bioluminescence is the process by which visible light is emitted by living organisms. 
Bioluminescence imaging (BLI) is widely used in the study of biological processes as it 
allows non- invasive imaging eliminating the need for killing the animal and as multiple 
measurements can be obtained from the same animal over time, this reduces the 
biological variations. A number of bioluminescent systems have been identified in nature 
so far and the most widely used luciferase is from the North American firefly (Photinus 
pyralis).  The enzyme is usually expressed as a molecular reporter in vivo and the 
imaging includes the detection of visible light, which is produced when the enzyme 
causes the oxidation of its substrate196. In systems using firefly luciferase as the reporter, 
the substrate D- luciferin has to be injected into the animal before imaging. Lipshutz et 
al.197 reported that firefly luciferase has a half-life of about 3 hours in vivo. The reaction 
has been found to require ATP and magnesium in addition to the substrate198 and the light 
emission is found to peak at around 560 nm199.  In the presence of magnesium and ATP, 
firefly luciferase causes the oxidation of luciferin and the reaction releases photons. In 
their review, Sadikot and Blackwell196 explain that the emitted photons can be detected 
by a charge coupled device (CCD) camera, which can convert the emitted photons into 
electrons and then spatially encode the intensity of the photons into electrical charge 
patterns and thus generate an image. 
 
Bioluminescence imaging is economical, non- invasive and easy to execute196. Also, it is 
completely non- toxic and hence it is an ideal approach for long term studies in living 
cells, tissues and animal models. Another important advantage is the high sensitivity due 
to the low background levels of bioluminescence in mammalian tissues.  But the 
approach has several disadvantages as well. Bioluminescent reporters are dimmer than 
fluorescent reporters and hence the resolution is limited. The limited transmission of light 
through animal tissues and the loss of photon intensity with increasing tissue depth is 
another consideration to be overcome. And the sources which are closer to the surface 
appear brighter compared with sources which are located deeper196, 200.  
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1.23 Menin as a modulator of β- cell growth and proliferation: 
 
As mentioned earlier, menin is a transcriptional regulator, which is highly conserved 
across vertebrates and which is found to regulate β- cell proliferation. It shares little 
homology with other known proteins201, 202. In both mice and rats, the protein is broadly 
expressed and expression is observed in almost all tissues with the highest expression in 
neuroendocrine and haematopoietic cells178, 203. Both human menin and rat menin consist 
of 610 amino acids while mouse menin has 611 amino acids. Mouse menin shows an 
overall identity of 96.5% to the to the human protein while rat menin shows an overall 
identity of 97%. Four distinct conservational domains including domain A, domain B, 
domain C and domain D have been identified. Domains A and C- terminal domain D in 
mouse and are highly identical to their human counterparts while short domain C is quite 
divergent between humans and the two rodent species. Domain B shows a small sequence 
divergence in comparison with domain C. The presence of at least two different menin 
splice variants have been identified in all species and these include the long λ transcript 
(2.4 kb product) and the short σ transcript (2.0 kb product). Both are found to be co 
expressed in a variety of tissues203.  
 
Menin is believed to be critical for haematopoiesis, consistent with its high expression in 
haematopoietic cells. Novotny et al.204 observed that menin deficient embryonic stem cell 
lines were unable to undergo proper differentiation into haematopoietic colonies and that 
the differentiation could be reinstated with the reexpression of menin or Hoxa9 leading 
them to conclude that Hoxa9 mediates menin’s function. Maillard et al.205 recently 
reported that menin has only modest effects on haematopoiesis in steady- state conditions 
and they noted a decrease in neutrophils, lymphocyte and platelet numbers on menin 
ablation. However they observed that despite normal initial homing of menin deficient 
progenitors to the bone marrow, there was a marked functional defect in the long-term 
haematopoietic stem cells (HSC) in the context of bone marrow transplantation. This 
suggested that menin is involved in regulating the molecular pathways, which are 
essential during the adaptive HSC response to stress.  
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 Recent studies have identified a critical role for menin in endocrine pancreas. Yan et 
al.206 reported that menin is able to interact with IQGAP1 (IQ motif containing GTPase 
activating protein 1) and enhance the intracellular adhesion of β- cells. Chen et al.207 
suggests that menin has an essential role in Wnt/ β- catenin signaling and that activation 
of the Wnt/ β- catenin signaling can inhibit islet cell proliferation.  Multiple endocrine 
neoplasia type 1 (MEN1) is a tumor syndrome characterized by tumors in multiple 
endocrine organs including parathyroids, anterior pituitary and endocrine pancreas208 
(OMIM 131100). Thakker et al.209 reported that pancreatic islet tumors occur in 30%- 
80% of MEN1 patients and can be a major cause of death in those patients. The condition 
arises from mutations in the gene Men1 that codes for menin. It has been reported that 
80% of the mutations cause loss of protein function210. The remaining 20% is believed to 
involve missense mutations, which result in the mutant protein degradation211.  
 
Larsson et al.212 reported loss of heterozygosity in germline and somatic Men1 mutations 
which gave the indication that Men1 gene is a tumor suppressor. Lin et al.213 
demonstrated that the loss of menin in primary human fibroblasts, when complemented 
with the expression of SV40 large and small T antigen and oncogenic ras, led to a 
transformed phenotype. They reported that menin acts as a direct repressor of hTERT, the 
protein component of telomerase enzyme. Supporting the role of menin as a tumor 
suppressor, homozygous loss of menin in mice causes the death of embryos between 
embryonic day 11.5 to 13.5 and the embryos exhibit several severe developmental 
defects214. Heterozygote Men1 knockout mice gestate normally but after 9-16 months, 
they develop endocrine tumors, which are similar to the ones observed in MEN1 
disease214, 215. To further analyze the role of menin, conditional knockouts in which Men1 
gene was disrupted specifically in the pancreatic islets were generated and these mice 
were reported to develop multiple insulinomas along with elevated serum insulin levels 
and reduced blood glucose levels216, 217. Scacheri et al.218 generated mice with tissue-
specific homozygous loss of menin in the liver but did not observe any tumor formation 
causing them to conclude that Men1 loss might be critical only in endocrine tissues. 
Scacheri et al.219 recently analyzed the genome wide menin binding patterns and found 
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that menin could occupy the promoter regions of thousands of human genes suggesting a 
role for menin as a global regulator of transcription. They also found that the specific bias 
for endocrine tumour formation upon menin loss might be due to the dysregulation of 
distinct genes including HLXB9, that are targeted by menin only in the endocrine tissues.  
 
Karnik et al.220 showed that though the Men1+/-  islets were phenotypically similar to the 
wild type islets, at around 7 months of age, they showed increased BrdU uptake and there 
was islet hyperplasia and hypoglycemia in the mice. It has been reported that menin 
regulates pancreatic islet growth by promoting the expression of cyclin dependent kinase 
inhibitors p27 and p18220. The ability of menin to bind and enhance the expression of 
caspase 8221 has also been reported as a probable mechanism that prevents the 
transformation process. Menin has been shown to interact with a number of transcription 
factors and co- factors including JunD222, Smad1, Smad3, Smad5 223, 224 and MLL1 and 
MLL2225 thereby suggesting a role for it in transcriptional regulation. Menin is reported 
to form a protein complex with the trithorax group members MLL and MLL2 and the 
complex is able to methylate histone H3 on lysine 4. The methylation is associated with 
transcriptional activation and it is believed that menin stimulates histone 
methyltransferase activity of trithorax group containing complexes and thereby inhibit 
endocrine cell growth178, 220.  
 
Schnepp et al.226 reported that depletion of Men1 accelerates S phase entry and this was 
followed by increased cyclin-dependent kinase 2 (CDK2) activity and decreased 
expression of p27 and p18. They also reported that pancreatic islet cells display increased 
proliferation as early as 7 days following Men1 depletion. Recently menin was 
discovered to play a role in controlling the islet cell mass in pregnant mice. It was 
reported that during pregnancy stimulated proliferation of maternal pancreatic islets, 
menin and its targets are repressed by prolactin via STAT5 signaling. Transgenic 
expression of menin in maternal β-cells prevented the expansion process leading to 
hyperglycemia and gestational diabetes227. Recently Yang et al.228 reported that men1 
excision could prevent STZ induced hyperglycemia in mice by increasing the number of 
functional beta cells. They observed an increase in islet size, beta cell proliferation and 
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circulating insulin levels upon men1 excision. In a related study, they also observed that 
men1 excision could cure mice from pre existing hyperglycemia, whether it is 
spontaneous or induced229.  
 
In view of all this research, Men1 is a potential target gene, the knockdown of which can 
be used to study β- cell proliferation and regeneration in the bioluminescent NOD mouse.  
We hypothesized that reducing Men1 expression during T1D onset may prevent or at 
least delay hyperglycemia. Recently Fontanière et al.208 reported that menin is essential 
for the proper development of pancreatic endocrine cells and that loss of menin led to 
failure of the endocrine cell development and altered pancreatic structure. Hence a 
complete disruption of menin may be deleterious due to the potential to cause islet 
dysfunction or malignancies. But the partial reduction, which can be achieved by RNAi, 
could have the benefit of achieving increased β-cell mass and insulin production while 
minimizing the risk of insulinoma development. The ability to monitor beta cell mass by 
BLI was expected to enable us to effectively study how the loss of this regulatory gene 
affects β-cell survival and regeneration in T1D.  
 
1.24 AIM: 
 
We aimed to generate a transgenic β -cell specific reporter mouse line in the NOD 
background. Several groups had already generated transgenic mouse lines with β -cell 
specific expression of luciferase. But none of these reporter mice have been generated in 
the diabetes susceptible NOD background. Hence we aimed to generate a NOD β -cell 
reporter mouse line using lentiviral transgenesis. In addition, we aimed to couple β-cell 
specific luciferase expression with β -cell specific knockdown of target genes. For this 
purpose, we used a construct that carried the luciferase gene and an shRNA expression 
cassette under the β -cell specific RIP promoter. Hence by using a single construct, we 
could ensure specific knockdown target genes in the pancreas and use bioimaging to look 
at the effects of gene knockdown over time. This strategy would allow us to non- 
invasively study β-cell modulation via RNAi using luciferase bioimaging. We decided to 
use menin as a target gene for RNAi to enhance β-cell proliferation and aimed to verify 
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the enhanced β-cell proliferation on menin knockdown in insulinoma cells in vitro as a 
first step and then aimed to generate menin knockdown mice in the pRLM background.  
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Chapter 2 
 
MATERIALS 
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2.1 Chemicals: 
 
CHEMICAL 
 
SUPPLIER 
30% acrylamide solution BioRad 
Agarose Roth 
Beta mercaptoethanol Roth 
Brefeldin A Sigma 
BSA Sigma 
CaCl2 Roth 
Chloroform Roth 
Cyclophosphamide monohydrate Sigma 
DMSO AppliChem 
D-luciferin Gold Biotech 
Dithizone Sigma-Aldrich 
Ethanol Roth 
Ethidium bromide Roth 
EDTA Roth 
Glycine Roth 
Glycerol Roth 
H2SO2 Roth 
H3-thymidine Hartmann Analytic 
Isofluran cp-pharma 
Isopropanol Roth 
Ionomycin Sigma 
KCl Roth 
Ketamine (Ketanest) Pfizer 
KHCO3 Roth 
Methanol Roth 
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MgCl2 Roth 
NaCl Roth 
Na2-EDTA Roth 
NaHCO3 Sigma 
Na2HPO4x2H2O Roth 
NaH2PO4xH2O Roth 
NaOH Roth 
NH4Cl Roth 
PMA Sigma 
Salmon sperm DNA Sigma 
SDS Roth 
Sodium citrate Sigma 
Streptozotocin Sigma 
TEMED BioRad 
Tris Roth 
Tris-HCl Roth 
Tween20 Roth 
Xylazine (Rompun 2%) Bayer 
 
2.2 Reagents: 
 
2.2.1 Antibiotics and Hormones 
 
REAGENT 
 
SUPPLIER 
Ampicillin Roth 
Penicillin streptomycin solution Invitrogen 
Puromycin Roth 
PMS Sigma 
HCG Sigma 
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 2.2.2 Bacterial strains and transfection reagents 
 
REAGENT SUPPLIER 
 
DH5α™ Invitrogen 
MAX Efficiency® DH5α™ Invitrogen 
Novablue Invitrogen/ Merck/ Novagen 
One Shot® TOP10 Invitrogen 
Fugene HD Roche 
Genejammer Agilent (Stratagene) 
Polybrene Sigma 
Polyfect Qiagen 
 
2.2.3 Cell culture reagents 
 
REAGENT SUPPLIER 
 
D-MEM GIBCO 
D-PBS GIBCO 
Enzyme-free Hank’s based cell dissociation 
buffer  
GIBCO 
FCS Invitrogen 
Glutamine Invitrogen 
Ham’s F-12K  Sigma-Aldrich 
HEPES GIBCO 
Histopaque Sigma-Aldrich 
Passive lysis buffer Promega 
RPMI-1640 GIBCO 
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Sodium pyruvate GIBCO 
Trypsin GIBCO 
 
2.2.4 Enzymes and PCR reagents 
 
REAGENT 
 
SUPPLIER 
AgeI, AluI, BamHI, EcoRI, EcoRV, Hpa1, 
NheI, NotI, PmeI, PstI, SalI, XhoI 
Fermentas 
PNK Fermentas 
CIAP Fermentas 
T4 DNA ligase, 10X ligase buffer Fermentas 
Dreamtaq polymerase, Dreamtaq buffer Fermentas 
dNTP Fermentas 
MgCl2 Fermentas 
RNase A Qiagen 
 
2.2.5 General reagents 
 
REAGENT 
 
SUPPLIER 
32P-α-dCTP Amersham GE Healthcare, UK 
Bromophenol blue Roth 
Buffer G, Buffer O Fermentas 
CFA Sigma 
Collagenase P Roche 
Compensation beads BD 
DNA ladder (1Kb plus) Fermentas 
DNA ladder (low range) Fermentas 
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Dual luciferase system Promega 
Dynabeads mouse T activator CD3/CD28 Invitrogen 
ECL Perkin Elmer 
ELISA 96 well plate Nunc 
MicroAmp clear adhesive film Applied Biosystems 
MOG peptide Biotrend 
Pertussis toxin Sigma 
Primer-probe pair Universal probe library, Roche 
Protease inhibitor cocktail Sigma 
Protein ladder BioRad 
Reaction plate (384 well clear optical) Applied Biosystems 
RNAlater Qiagen 
TE buffer Fluka Analytical 
Trans-Blot transfer medium nitrocellulose 
membrane 
BioRad 
HybondTM-N+ membrane Amersham GE Healthcare,UK 
Absolute Blue SYBR Green ROX mix  Thermo Scientific 
Trizol Invitrogen 
Universal probe master mix (ROX) Roche 
Whatman paper VWR 
X-ray film Fujifilm 
 
2.3 Antibodies: 
 
2.3.1 Western blot 
 
ANTIBODY 
 
SUPPLIER 
Rabbit anti menin Bethyl Laboratories 
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Anti rabbit HRP Santa Cruz Biotechnology 
 
2.3.2 Cell culture and FACS 
 
ANTIBODY 
 
SUPPLIER Concentration/ dilution  
Anti CD3 eBioscience 5µg/ml 
Anti CD28 eBioscience 1µg/ml 
Anti IL-4 eBioscience 1µg/ml 
Anti IFNg eBioscience 1µg/ml 
B220 PE BD 1:300 
B220 APC e780 eBioscience 1:400 
CD4 APC Cy7/ V500 BD 1:800 
CD4 APC eBioscience 1:800 
CD8 PE Cy7 BD 1:800 
CD8 e450 eBioscience 1:1600 
CD25 PerCp Cy5.5 eBioscience 1:300 
CD25 PE Cy7 BD 1:300 
CD44 PE Cy5.5 BD 1:300 
CD45 eFluor450 eBioscience 1:800 
CD62L PE eBioscience 1:300 
FoxP3 PE eBioscience 1:50 
IL-17A PE eBioscience 1:50 
IFNg APC BD 1:50 
TCR APC BD 1:300 
Anti CD16/32 (Fc block) eBioscience 1:100 
Purified anti mouse CD25 eBioscience 1µg/µl 
Purified anti mouse CD62L BioLegend 1µg/µl 
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2.4 Cytokines: 
 
CYTOKINE SUPPLIER 
 
rmIL-1b R&D 
IL-2 R&D 
IL-6 R&D 
IL-12 eBioscience 
IL-23 R&D 
rhTGF-b R&D 
 
2.5 cDNA and cell lines: 
 
REAGENT SUPPLIER 
 
IL-17A cDNA OpenBiosystems 
Mouse menin cDNA OpenBiosystems 
Rat menin cDNA OpenBiosystems 
293F Invitrogen 
INS-1E Kindly provided by Prof. Wollheim CB 
NIT-1 LGC Standards 
 
2.6 Kits: 
 
KIT SUPPLIER 
 
DNeasy blood and tissue kit Qiagen 
FoxP3 staining kit eBioscience 
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QIAquick Gel Extraction kit Qiagen 
Intracellular cytokine staining kit BD 
MACS separation kit (CD62L) Miltenyii Biotech 
QIAfilter Plasmid Maxi kit Qiagen 
QIAquick PCR purification kit Qiagen 
RNeasy kit Qiagen 
Transcriptor first strand DNA synthesis kit Roche 
Rediprime II labeling kit Amersham GE Healthcare UK 
Probe Quant G-50 MicroColumns  Amersham GE Healthcare, UK 
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2.7 PCR primers and probes: 
 
 
GAPDH:  fwd: 5’- agcttgtcatcaacgggaag-3’ 
                rev: 5’-tttgatgttagtggggtctcg-3’ 
                Probe: #9 
 
IL-17A: fwd: 5’-tgtgaaggtcaacctcaaagtct-3’ 
             rev: 5’- gagggatatctatcagggtcttcat-3’ 
             Probe: #50 
 
IL-17F: fwd: 5’- caagaaatcctggtccttcg-3’ 
             rev: 5’-gagcatcttctccaacctgaa-3’ 
             Probe: #45 
 
IL-21: fwd: 5’- tcagctccacaagatgtaaagg-3’ 
          rev: 5’- gccttctgaaaacaggcaaa-3’ 
          Probe: #100 
 
IFNg: fwd: 5’- atctggaggaactggcaaaa-3’ 
             rev: 5’- ttcaagacttcaaagagtctgaggta-3’ 
             Probe: #21 
 
RORgt: fwd: 5’- gcagaactgccccattga-3’ 
             rev: 5’-gacattcggccaaacttga-3’    
             Probe: #21 
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 Hluc primers: fwd: 5’-atggccgatgctaagaacat-3’ 
                          rev: 5’- ggatgatctggttgccgaaa-3’ 
 
SCID primers: fwd: 5’- ggaaaagaattggtatccac-3’ 
                           rev: 5’- agttataacagctgggttggc-3’ 
 
 
2.8 shRNA sequences:  
 
IL-17 shRNA oligos (NM_010552) 
 
#176  
target – ccaaggacttcctccagaa 
fwd- tccaaggacttcctccagaattcaagagattctggaggaagtccttggttttttc 
rev- tcgagaaaaaaccaaggacttcctccagaatctcttgaattctggaggaagtccttgga 
 
#188  
target - tccagaatgtgaaggtcaa 
fwd- ttccagaatgtgaaggtcaattcaagagattgaccttcacattctggattttttc 
rev- tcgagaaaaaatccagaatgtgaaggtcaatctcttgaattgaccttcacattctggaa 
 
#203  
target - tcaacctcaaagtctttaa 
fwd- ttcaacctcaaagtctttaattcaagagattaaagactttgaggttgattttttc 
rev- tcgagaaaaaatcaacctcaaagtctttaatctcttgaattaaagactttgaggttgaa 
 
#288  
target - gactctccaccgcaatgaa 
fwd-tgactctccaccgcaatgaattcaagagattcattgcggtggagagtcttttttc 
rev- tcgagaaaaaagactctccaccgcaatgaatctcttgaattcattgcggtggagagtca 
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#303 
target – tgaagaccctgatagatat 
fwd- ttgaagaccctgatagatatttcaagagaatatctatcagggtcttcattttttc 
rev- tcgagaaaaaatgaagaccctgatagatattctcttgaaatatctatcagggtcttcaa 
 
#362 
target - gtgtcaatgcggagggaaa 
fwd- tgtgtcaatgcggagggaaattcaagagatttccctccgcattgacacttttttc 
rev- tcgagaaaaaagtgtcaatgcggagggaaatctcttgaatttccctccgcattgacaca 
 
#497  
target - gcacctgcgtggcctcgat 
fwd- tgcacctgcgtggcctcgatttcaagagaatcgaggccacgcaggtgcttttttc 
rev- tcgagaaaaaagcacctgcgtggcctcgattctcttgaaatcgaggccacgcaggtgca 
 
 
Menin shRNA oligos (NM_008583.1) 
 
Start position: 780  
22_mer: ggtctcggatgtcatatggaac  
tgctgttgacagtgagcgagtctcggatgtcatatggaactagtgaagccacagatgtagttccatatgacatccgagacctgcct
actgcctcgga  
 
Start position: 803  
22_mer: gcctcagccgctcctacttcaa  
tgctgttgacagtgagcgacctcagccgctcctacttcaatagtgaagccacagatgtattgaagtaggagcggctgaggctgcc
tactgcctcgga  
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 Start position: 1170 
22_mer: cactgactctttggaactgttg 
tgctgttgacagtgagcgaactgactctttggaactgttgtagtgaagccacagatgtacaacagttccaaagagtcagtgtgcct
actgcctcgga 
 
Start position: 1206 
22_mer: gctgctctggctgctgtatgac 
tgctgttgacagtgagcgactgctctggctgctgtatgactagtgaagccacagatgtagtcatacagcagccagagcagctgcc
tactgcctcgga 
 
Start position: 1447  
22_mer: gacactgccactgttatccaag  
tgctgttgacagtgagcgaacactgccactgttatccaagtagtgaagccacagatgtacttggataacagtggcagtgtctgcct
actgcctcgga  
 
Start position: 1449  
22_mer: cactgccactgttatccaagac  
tgctgttgacagtgagcgaactgccactgttatccaagactagtgaagccacagatgtagtcttggataacagtggcagtgtgcct
actgcctcgga  
 
Start position: 2079 
22_mer: tttccagagtgagaagatgaaa 
tgctgttgacagtgagcgcttccagagtgagaagatgaaatagtgaagccacagatgtatttcatcttctcactctggaaatgccta
ctgcctcgga 
 
Start position: 2213  
22_mer: actacacactctctttcctaaa  
tgctgttgacagtgagcgcctacacactctctttcctaaatagtgaagccacagatgtatttaggaaagagagtgtgtagttgccta
ctgcctcgga 
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 Start position: 2760  
22_mer: agctccgactcttatctgtgaa  
tgctgttgacagtgagcgcgctccgactcttatctgtgaatagtgaagccacagatgtattcacagataagagtcggagcttgcct
actgcctcgga  
  
2.9 Linker: 
 
Not1-Xho1 Linker sequence: 
 
5’ GGCCGATCTCGAGATC 3’ 
 
2.10 Buffers: 
 
ELISA: 
 
Wash solution for ELISA (PBS.Tween20) 
 
500 ml of 10X PBS is diluted with 4.5 L of distilled water to obtain 5L of 1X PBS. 2.5 
ml Tween20 is added to PBS to obtain a 0.05% wash solution.  
 
FACS &MACS: 
 
ACK lysis buffer 
 
Dissolve 8.29g ammonium chloride, 1.0g potassium bicarbonate and 37.3 mg Na2EDTA 
to 800ml of distilled water and adjust the pH to 7.2-7.4. Make up the volume to 1L with 
distilled water.  
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 Annexin binding buffer 
 
Make 1L binding buffer containing 10mM Hepes (2.38g/L), 150mM NaCl (8.766g/L), 5 
mM KCl (0.372g/L), 1mM MgCl2 (0.203g/L) and 1.8mM CaCl2 (0.199g/L). Make up the 
volume with NaOH pH-7.4.  
 
MACS buffer 
 
Prepare a solution containing PBS pH-7.2, 0.5% FCS and 2mM EDTA.  
0.3722 gm EDTA is added to 500 ml PBS and left on a shaker at 50°C for 4-5 hours.  2.5 
ml FCS is added to the buffer, which is then filtered and stored at 4°C.  
 
PBS. EDTA for blood collection 
 
0.3722 gm EDTA is dissolved in 500 ml PBS to make a 2mM solution and it is then 
stored at 4°C.  
 
Southern Blot:  
 
10XSSC 
 Make a solution of pH 7.6: Sodium citrate 150 mM and NaCl 1.5 M. 
Denaturation buffer 
Make a solution of NaCl 1.5 M, NaOH 0.5 M. 
Neutralization buffer 
 
Make a solution of Tris-HCl 0.5M (pH 7.2), NaCl 1.5M and EDTA 1mM and autoclave. 
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 Sodium phosphate buffer 0.5 M, pH7.2 
Make a solution of Na2HPO4x2H2O (1M) 34.2%, NaH2PO4xH2O (1M) 15.8% and adjust 
pH to 7.2.  
Church buffer 
Mix sodium phosphate buffer 0.25M, EDTA 1 mM, Bovine serum albumin (BSA) 1%, 
SDS 7% and salmon sperm DNA 0.1 mg/ml. 
Church wash (5L) 
 
Mix 200 ml 0.5M sodium phosphate buffer pH7.2 and 250 ml 20% SDS. 
 
Western Blot: 
 
SDS PAGE Running buffer 
 
To obtain a 10X solution, dissolve 10g SDS, 30.3g Tris and 144.1g glycine in 800ml 
distilled water. Adjust the volume to 1L with distilled water. Store at 4°C.  
 
Laemmli Buffer 
 
For a 2X solution, mix 10ml 1.5M Tris (pH-6.8), 6 ml 20% SDS, 30 ml glycerol, 15 ml 
β-mercaptoethanol and 1.8 mg bromophenol blue. Adjust the volume to 100ml with 
distilled water. Make 10ml aliquots and store at -20°C. Store the working solution at 4°C. 
 
Transfer buffer for wet blots 
 
For a 1X solution, dissolve 2.9 g glycine, 5.8 g Tris and 0.37 g SDS in 200 ml methanol. 
Adjust the volume to 1L with distilled water.  
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 TBS.T 
 
Dissolve 6.05 g Tris (50 mM) and 8.76 g NaCl (150mM) in 800 ml of distilled water and 
adjust the pH to 7.5. To make 0.2% TBST, add 500 µl of Tween 20 to the solution and 
make up the volume to 1L with distilled water. 
 
Blocking solution for western blot 
 
Dissolve 5g of nonfat dried milk powder in 100ml of 0.2% TBST to obtain a 5% milk 
powder blocking solution. 
 
GENERAL BUFFERS: 
 
Na- citrate buffer 
 
Dissolve 1.47 gm of Na- citrate in 50 ml distilled water and adjust the pH to 4.5. Buffer 
should be made fresh with each round of streptozotocin injections. 
 
Cell depletion buffer 
 
Prepare a solution containing PBS pH-7.2, 0.1% FCS and 2mM EDTA.  
0.074 gm EDTA is added to 100 ml PBS and left on a shaker at 50°C for 4-5 hours.  100 
µl FCS is added to the buffer, which is then filtered and stored at 4°C.  
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Chapter 3 
 
METHODS 
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 3. Experimental Techniques:  
 
3.1 Bacterial Culture Techniques: 
 
3.1.1Transformation of bacteria 
 
Transformation is done using competent bacterial cells.  The cells are thawed on 
ice and 1 µl of the DNA (ligation) is added to the cell suspension. The suspension 
is left on ice for a minimum of 30 minutes. The cells are then subjected to heat 
shock at 42°C for 60 seconds and immediately cooled on ice.150 µl of LB media 
with ampicillin is added to the suspension and the suspension is plated onto LB- 
ampicillin plates and incubated at 37°C overnight in an incubator. 
 
3.1.2 Miniprep preparation 
 
Nova Blue™ or Top10™ competent cells are transformed with the desired 
construct and cultured overnight to obtain colonies. The colonies are picked 
randomly and cultured in LB-ampicillin media (8 hours in the day or 16 hours in 
the night). The cultures are then spun down and used to make minipreps. 
 
3.1.3 Maxiprep preparation 
 
      For maxipreps, the positive minipreps are diluted 1:100 and used to transform 
either DH5α™ or MAX Efficiency® DH5α™ cells and are plated onto LB-
ampicillin plates and allowed to grow overnight. Colonies are picked and allowed 
to grow in LB- ampicillin media as above, following which 150 µl of the cultures 
are transferred to 2L flasks containing 150 ml of LB- ampicillin media and 
cultured overnight. The cultures are then spun down and used to make maxipreps 
with the Qiaquick maxi kit. The DNA is then resuspended in 200 µl distilled 
water or TE buffer. The concentration is checked using a spectrophotometer.  
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 3.2 Molecular Biology Techniques: 
 
3.2.1 Cloning 
 
shRNA sequences targeting the protein of interest are designed using either 
primer3 program or using the RNAi central gateway. Forward and reverse oligos 
are obtained and then phosphorylated using PNK enzyme. The oligos are then 
annealed and cloned into a suitable vector. For this the vector is digested using 
suitable enzyme pairs and gel purified. The annealed oligos are purified using the 
PCR purification kit. The shRNA is then ligated with the digested vector using the 
ligase enzyme. The ligation is used to transform NovaBlue competent bacteria.  
 
3.2.2 Verification of insert- vector ligation 
 
The transformation of competent bacterial cells with the vector- insert ligations 
lead to the growth of bacterial colonies on the LB agar plates. These colonies 
have to be analyzed and the presence of the vector- insert sequence in the 
bacterial colonies verified. Before ligation, the vector sequence is cut with 
appropriate restriction enzymes and the phosphate group from the 5’ terminus is 
removed using alkaline phosphatase. This prevents the digested vector sequence 
from recircularising without taking up the insert. In principle, all bacterial 
colonies that grow should have taken up a vector-insert construct. This is because 
only those cells are able to grow on ampicillin plates owing to the presence of an 
ampicillin resistance gene in the vector. Though the addition of alkaline 
phosphatase prevents the vector sequences from religating, there is a possibility 
that sometimes the vector sequences ligate without taking up the insert. The 
bacterial cells that take up these recircularised vectors do not contain the insert, 
but are still able to grow on ampicillin plates. Hence it is critical to verify the 
presence of the insert in the bacterial cells before starting minipreps.  
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 This is done using 2 different methods. The first one is restriction digestion of the 
minipreps. Here, bacterial colonies are randomly selected and minipreps are made 
from them. The DNA is then digested with the same enzyme pair used during 
cloning. The DNA samples are run on a gel after digestion. Only those minipreps 
containing the insert would give 2 bands on the gel, one corresponding to the 
vector backbone and the other a smaller band corresponding to the insert. The 
minipreps containing the recircularised vector would give a single band 
corresponding to the vector backbone. Those minipreps, which give 2 bands, are 
sent for sequencing to further verify that the vector- insert sequences are in the 
correct orientation.  
 
The second method is colony PCR. This method is more time saving and less 
labor intensive than restriction digestion. Here, small amounts of the bacterial 
colonies are used as template for a PCR reaction using primer sequences 
complementary to the appropriate vector. Only those colonies that have taken up 
the vector sequence would give an amplified product. The colonies with the 
vector- insert constructs would give a larger sized band compared to the colonies 
with recircularised vectors, owing to the presence of the insert. These colonies, 
which give the larger sized bands on gel, are then picked and used to make 
minipreps. Hence the additional work making minipreps from incorrect ligations 
can be avoided. The minipreps are then sent to sequencing for further validation.  
 
3.2.3 Luciferase assay 
 
For luciferase assay, 293F cells were plated out at a starting density of 2.5 X 105 
on 24 well plates. The next day, cells were co transfected with psi-check 2 
containing the target cDNA and the shRNA constructs. Psi-check 2 contains two 
luciferase sequences- a firefly luciferase (expressed constitutively and used for 
normalization purposes) and a renilla luciferase. The cDNA is cloned into the 3’ 
UTR of the renilla luciferase gene. 100 ng of the reporter (psi- check 2) along 
with 300 ng of the shRNA construct is used per well along with the transfection 
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 reagent polyfect (Qiagen). The plates are left in the incubator for 2 days after 
which the cells are washed once with PBS and lysed with a passive lysis buffer 
(Promega). 5 µl of each sample is then transferred to an opaque 96 well plate and 
the luciferase activity is measured with a Fluostar Optima luminometer. For this, 
the dual luciferase system from Promega is used. The values obtained for firefly 
luciferase are used to normalize the values obtained for renilla luciferase. The 
sequences that give the lowest values for renilla luciferase are selected as they are 
expected to have the highest knockdown efficiencies.  
 
3.2.4 Tail DNA synthesis 
 
Tail DNA synthesis is done using the DNeasy Blood and Tissue kit from Qiagen. 
Tails samples are obtained from mice and they are placed in eppendorf tubes. To 
each tube, 180µl of buffer ATL is added along with 20µl Proteinase K. The tubes 
are vortexed and the samples are digested overnight at 56°C in a water bath.  The 
tubes are then vortexed and to each tube, 200µl buffer AL is added. The tubes are 
mixed thoroughly and 200µl ethanol (96-100%) is added. The mixture is then 
pipetted into a DNeasy mini spin column placed in a 2ml collection tube. 
Centrifuge at ≥8000 rpm for 1 minute. Discard the flow through and the collection 
tube. Place the column in a fresh 2 ml collection tube, add 500µl buffer AW1 and 
centrifuge at ≥ 8000 rpm for 1 minute. Discard flow through and collection tube. 
Place the column in a fresh collection tube, add 500µl buffer AW2 and centrifuge 
at 14000 rpm for 3 minutes. Discard flow through and collection tube. Place the 
column in a clean 1.5 ml eppendorf tube and add 200µl buffer AE directly onto 
the membrane. Incubate at room temperature for 1 minute and then centrifuge for 
1 minute at ≥8000 rpm to elute the DNA. 
 
3.2.5 RNA extraction  
 
Samples are usually resuspended in 1 ml trizol and frozen till needed. For RNA 
extraction, the samples are thawed and incubated at 15-30°C for 5 minutes. 0.2 ml 
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 chloroform is added to each tube and the tubes are then shaken vigorously by 
hand for 15 seconds. The tubes are incubated at 15-30°C for 2-3 minutes and then 
centrifuged at 12000 G for 15 minutes at 2-8°C. The solution separates into a 
lower red phenol-chloroform phase, an interphase and an upper colorless aqueous 
phase, which contains the RNA. The aqueous phase is transferred into a fresh 
eppendorf tube. 0.5 ml isopropanol is added to the tubes and then incubated at 15-
30°C for 10 minutes. The samples are then centrifuged at 12000 G for 10 minutes 
at 2-8°C. The supernatant is removed and the pellet is resuspended in 1 ml 75% 
ethanol. The tubes are vortexed and centrifuged at 7500 G for 5 minutes at 2-8°C. 
The supernatant is then removed and the pellet is air-dried. 100µl distilled water 
is added to the tubes and RNA is dissolved by incubating the tubes at 55-60°C on 
a thermal shaker for 10 minutes. 
 
Alternatively, samples are saved frozen in 1ml of RNAlater RNA stabilization 
reagent from Qiagen. RNA is then extracted from these samples using the 
RNAeasy mini kit. The samples are first thawed and appropriate amounts are 
weighed out. 600µl buffer RLT is added to the samples which are then 
homogenized using a homogeniser. The lysates are then centrifuged at full speed 
for 3 minutes. The supernatants are transferred to fresh tubes. Equal volumes of 
70% ethanol are added to the tubes and mixed by pipetting. ≤700µl of the liquid is 
then transferred to an RNAeasy spin column placed in a 2 ml collection tube. The 
column is then centrifuged for 15 seconds at ≥8000 G and the flow through is 
discarded. The column is placed in a new 2 ml collection tube and 700µl buffer 
RW1 is added to the column. The column is centrifuged for 15 seconds at ≥8000 
G and the flow through is discarded.  The column is placed in a new 2 ml 
collection tube and 500µl buffer RPE is added. The column is centrifuged for 15 
seconds at ≥8000 G and the flow through is discarded. The column is placed in a 
new 2 ml collection tube and 500µl buffer RPE is added for a second time. The 
column is again centrifuged for 2 minutes at ≥8000 G and the flow through is 
discarded. The column is again placed in a new 2 ml collection tube and then 
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 centrifuged for 1 minute at full speed. The collection tube is then discarded. The 
column is then placed in a fresh 1.5 ml eppendorf tube. 30-50µl RNAse free water 
is pipetted straight onto the membrane. The column is then centrifuged for 1 
minute at ≥8000 G to elute the RNA. 
 
3.2.6 cDNA Synthesis 
 
cDNA is synthesized using the Transcriptor First Strand cDNA Synthesis kit from 
Roche. Up to 1µg of RNA is used per reaction. In each reaction tube, 1µg of RNA 
is mixed with 2.5µM Anchored oligo (dT) primer and 60µM random hexamer 
primer. The volume is made up to 13µl. The RNA is then denatured by heating 
the tube for 10 minutes at 65°C in a thermal block cycler. The tube is then 
immediately cooled on ice. To the tube, a master mix containing 4µl reaction 
buffer, 20 units RNase inhibitor, 2µl of a 1mM dNTP mix and 10 units of reverse 
transcriptase enzyme is added. The final volume of each reaction is 20µl. The 
tubes are then centrifuged and the final reaction is done on a thermal cycler. The 
cycle involves 10 minutes at 25°C, 30 minutes at 55°C followed by 5 minutes at 
85°C. Placing the tubes on ice stops the reaction. The reaction mixture is then 
diluted 1:2 or 1:4. In cases where the mRNA expression levels are quite low, 
undiluted cDNA samples are used for qPCR. 
 
3.2.7 PCR 
 
Genomic PCR 
 
Genomic PCR is done on tail DNA samples obtained from mice. Genomic 
DNA is extracted from tail samples and subjected to PCR. For genotyping 
purposes, PCR is carried out using specific primers for example GFP, 
luciferase, SCID etc.  
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 qPCR (Real time quantitative PCR) 
 
cDNA is synthesized using the first strand cDNA synthesis kit from 
Roche. cDNA is usually diluted 1:2 or 1:4 and used for qPCR. The 
reactions are done using the primer-probe pair systems from Roche 
Universal probe library and Universal probe master mix (ROX). PCR 
setup is done using QIAgility from Qiagen. The reactions are set up on a 
384 well plate and real time PCR is carried out using the ABI 7900HT 
sequence detection system from Applied Biosciences. Primers used are 
GAPDH (fwd: 5’- agcttgtcatcaacgggaag-3’, rev: 5’-tttgatgttagtggggtctcg-
3’, probe: #9); IL-17A (fwd: 5’-tgtgaaggtcaacctcaaagtct-3’, rev: 5’- 
gagggatatctatcagggtcttcat, probe: #50); IL-17F (fwd: 5’- 
caagaaatcctggtccttcg-3’, rev: 5’-gagcatcttctccaacctgaa-3’, probe: #45); IL-
21 (fwd: 5’- tcagctccacaagatgtaaagg-3’, rev: 5’- gccttctgaaaacaggcaaa-3’, 
probe- #100); IFNg (fwd: 5’- atctggaggaactggcaaaa-3’, rev: 5’- 
ttcaagacttcaaagagtctgaggta-3’, probe- #21); RORgt (fwd: 5’- 
gcagaactgccccattga-3’, rev: 5’-gacattcggccaaacttga-3’, probe: #21). 
 
For analyzing luciferase expression in mice organs, we use a slightly 
different protocol. Organs are taken out and immediately saved in 1.5 ml 
of RNAlater reagent. The organs are then stored at -20°. RNA is made 
from around 30 mg of dehydrated organs and cDNA is synthesized using 
the first strand cDNA synthesis kit. Undiluted cDNA is then subjected to 
real time PCR using the hluc primers and a SYBR green master mix 
instead of using specific probes. The reactions are set up on a 384 well 
plate and real time PCR is carried out using the ABI 7900HT sequence 
detection system from Applied Biosciences. 
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 3.2.8 Western blot 
 
The blot is done using the Protean 3 system from BioRad. Samples are run on a 
12 % running gel. For preparation of the cell lysates, the cells are spun down and 
resuspended in a 1:10 mix of RIPA buffer (Sigma) with protease inhibitor 
cocktail, left on ice for 30 minutes with occasional shaking. The suspensions are 
then spun down; the supernatants are transferred to fresh tubes and frozen. The 
cell lysates are mixed with equal volumes of Laemmli buffer and boiled for 10 
minutes at 95°C. The samples are then loaded onto the gel along with a protein 
marker and the gel is run in the running chamber using the running buffer. Once 
the samples have run enough, the gel is removed from the chamber. The samples 
are then transferred to a nylon membrane in a transfer chamber with the transfer 
buffer and this usually takes an hour and a half. Once the transfer is complete, the 
membrane is cut to size and blocked for 1-2 hours at room temperature with a 5% 
milk powder solution. The primary antibody diluted in 5% milk powder solution 
is added at the end and the membrane is left overnight. The next day, the primary 
antibody solution is removed and the membrane is washed 4 times for 20 minutes 
with a 0.2% TBST solution. The secondary antibody is diluted in the milk powder 
solution and is added to the membrane and incubated for 1.5- 2 hours. The 
membrane is again washed with 0.2% TBST solution. The membrane is then 
incubated in the ECL (enzymatic chemiluminescence) reagent for a minute. The 
membrane is then exposed to a film that is then developed in a developer. 
Alternatively, the membrane is exposed to a camera and the image captured 
directly. 
 
3.2.9 Southern blot 
 
           Around 10µg of genomic DNA are digested overnight at 37°C with 25 U/sample 
of EcoRI restriction enzyme. Next day fragments are separated on a 1.0% agarose 
gel by electrophoresis for several hours and separation of the bands is documented 
together with a ruler on a UV imaging system (Herolab GmbH Laborgeraete, 
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 Germany). The gel is left under UV for around 10 minutes to enhance DNA 
fragmentation and is then washed in denaturation solution 2 times for 20 minutes 
and finally in neutralization solution again 2 times for 20 minutes. DNA transfer 
is performed by capillarity in 20x SSC buffer on HybondTM-N+ membranes. 
Membranes are air-dried and the DNA is covalently bound to the membrane using 
a UV-linker (1200 J/m2, UV Stratalinker®1800, Stratagene, California).  
 
            Radioactive labelling of the probe: GFP sequence is cut out from pLBM vector 
using appropriate restriction enzymes and is gel purified. 50-100 ng of GFP is 
used as the probe. It is denatured at 95°C for 5 min and labelled with radioactive 
32P-α-dCTP (50 µCi) using the Rediprime II labelling kit (Amersham GE 
Healthcare, UK) according to the manufacturer’s instructions. To reduce 
unspecific background, unincorporated nucleotides are removed by gel filtration 
with Probe Quant G-50 MicroColumns. The probe is ready for hybridization 
reaction after denaturation at 95°C for 5 minutes. 
 
           Hybridization: Membranes containing the DNA samples are blocked for 2 hours in 
church buffer at 65°C in a water bath shaker and after 2 hours the labelled probe 
is added and hybridized for 16 hours under the same conditions. Next day 
membranes are washed twice for 20 minutes in church washing buffer. Signal is 
detected by exposure of the hybridised membrane to X-ray film for 5-7 days at -
80°C. 
 
3.2.10 ELISA 
 
ELISA kits were obtained from eBioscience and the 96 well plates from nunc. 
The assay was carried out following the manufacturer’s instructions. All the steps 
are followed by thorough wash steps and the incubation is done on a shaker. The 
plates are coated overnight with the capture antibody. For this, the antibody is 
resuspended in coating buffer and added to the wells and the plates are then left 
on a shaker at 4°C. The next day, the wells are washed thrice. Assay diluent is 
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 added to the wells and left for an hour on the shaker. Top standard and its 
dilutions (7 dilutions of twofold starting from 1:2) are made with assay diluent 
along with sample dilutions when needed. The standards and the samples are 
added to the wells of the plate in replicates and left on the shaker for 2 hours. The 
plates are then washed. The detection antibody diluted in the assay diluent are 
added to the wells and left for an hour. Following this, the wells ware washed 
thoroughly. Diluted HRP antibody is added to the wells and left for 30 minutes. 
The wells are then thoroughly washed. TMB substrate is added to the wells and 
the plates are left on the shaker for the reaction to proceed. When suitable, the 
reaction is stopped by the addition of 2N sulfuric acid. The plates are then read in 
an ELISA reader.  
 
3.3 RNAi and Lentiviral Transgenesis Techniques: 
 
3.3.1 Lentivirus Production 
 
           The selected sequences are used to generate lentiviral vectors expressing the 
corresponding constructs. 293 F cells are plated on 15 cm plates and transfected 
the next day with the viral components and the shRNA construct. 3 µg pCMV-
VSVg, 3 µg RSV-rev, 4 µg pMDL-gag/pol and 5 µg pAdvantage are added to 1 
ml serum free media along with 20 µg of shRNA construct and 70 µl Fugene HD. 
The mixture is incubated at room temperature (RT) for 30 minutes and then 
pipetted onto the cells. Medium is replaced after 24 hours. Viral supernatant is 
collected, spun down and filtered both after 48 hours and 72 hours. Viral 
preparations are then ultra centrifuged and the supernatant is removed. Viral 
pellets are resuspended in 100 µl PBS by overnight incubation at 4°C. The virus 
samples are then aliquoted into eppendorf tubes, flash-frozen in liquid nitrogen 
and stored at -80°C. 1 µl of each virus sample is used for virus titrations.  
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 3.3.2 Virus Titration 
 
                  293 F cells are plated on 6 well plates at a starting density of 4 x 105 cells/ well. 
The plates are left in the incubator overnight. 1 µl of the virus sample is added to 
the first well while 1:10 and 1:100 dilutions of the virus are used to infect the 
second and third wells respectively. The plates are left in the incubator for 2-3 
days after which, the percentage of infected cells is determined by FACS. The 
virus titers are calculated from the percentage of GFP+ cells.  
 
                   Calculation of virus titer:  
 
                   If 4 x 105 cells are plated out per well for infection, it is assumed that by the time 
of infection (addition of virus) next day, there would be around 8 x 105 cells per 
well. It is also assumed that one virus infects one cell and vice versa. 
 
                   If 30% of cells are GFP+ in the sample infected with 1µl of virus suspension, 
 
                   Number of virus particles in 1µl= 30 x 800000= 2.4 x 105 
                   Number of viral particles / ml= (2.4 x 105)  x 1000 
                    
                   Final virus titer= 2.4 x 108/ ml 
                    
3.3.3 Viral infection of cells 
 
For infection with the virus, cells are plated out on 24 well plates at a starting 
density of 2.5 x 105 cells/well. The plates are left overnight in the incubator. Virus 
is added to the cell media with or without polybrene. Due to the really slow 
growth of insulinoma cells, they are cultured for 2-3 days before infection with 
lentivirus. Polybrene seems to be toxic for both Ins-1E and NIT-1 cells and hence 
they are infected just with the virus in the absence of any transfection reagent. 
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 The cells are cultured and passaged when needed and are used for various 
analyses. 
 
3.3.4 Generation of transgenic mice 
 
The virus samples with titers above 1x108 viral particles/ ml are used to inject 
embryos and generate transgenic mice. Female mice are injected I.P. with 
pregnant mares serum (PMG) and 48 hours later, with human chorionic 
gonadotropin (HCG). They are then mated with males overnight. The next day, 
oviducts are excised from the female mice and the embryos are collected under a 
microscope.  
 
Viral particles are injected into the perivitelline space of single celled embryos. 
The embryos are then implanted into pseudopregnant female recipients, which 
then carry them to term.  
 
3.4 Immunology Techniques: 
 
3.4.1 Purification of CD4+CD62L+ T cells 
 
Naïve T cells are isolated using the CD4+CD62L+ T cell isolation kit from 
Miltenyi biotech using the kit protocol. A single cell suspension is made from 
pooled lymph node and spleen cells. Up to 108 cells are resuspended in MACS 
buffer to which the 100µl CD4+ T cell biotin-antibody cocktail is added. The 
cells are incubated in the fridge from 10 minutes. To the suspension, 300 µl 
MACS buffer and 200µl anti-biotin micro beads are added. After an incubation of 
15 minutes in the fridge, the cells are washed after the addition of 10 ml MACS 
buffer. The cells are then resuspended in 500 µl MACS buffer. Depletion of non-
CD4+ cells is accomplished using a LS column. The LS column is placed in the 
magnetic filed of a MACS separator and the column is rinsed by the addition of 
3ml of MACS buffer. The cell suspension is then applied onto the column. The 
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 unlabeled cells that pass through the column are collected into a tube and the 
column is washed 3 times with 3 ml of buffer. This contains the CD4+ T cell 
fraction. The CD4+ cells collected are spun down and resuspended in 800 µl of 
buffer to which 200 µl of CD62L micro beads are added. The cell suspension is 
then refrigerated for 15 minutes. The cells are then spun down after the addition 
of 10ml of buffer. Positive selection of CD4+CD62L+ cells is achieved through a 
second cycle of magnetic separation using an MS column. The MS column is 
placed in the magnetic filed of a separator and rinsed by the addition of 500 µl of 
buffer. The cell suspension is then applied to the column and the column is then 
washed 3 times with the addition of 500µl of buffer. This contains the non-
CD62L+ fraction. At the end of washing, the column is removed from the 
separator and placed on a falcon tube. 1 ml of buffer is pipetted into the column 
and pushing the plunger into the column flushes out the labeled CD4+CD62L+ T 
cells. The CD4+CD62L+ cells are resuspended in RPMI.  
 
3.4.2 T helper differentiation in vitro 
 
Lymph nodes and spleens are obtained from mice. The tissues are ground and the 
cells are then treated with an RBC lysis buffer to remove the red blood cells. The 
cells are then passed through a cell strainer to obtain a single cell suspension. The 
naïve CD4+CD62L+ cells obtained from MACS are resuspended in RPMI 
supplemented with 10% FCS, penicillin / streptomycin, glutamine, HEPES and 
sodium pyruvate. Differentiation is done on 24 well plates. 0.5-1 X 106 naïve T 
cells are plated out per well. The cells are then stimulated with 5µg/ ml anti CD3 
and 1µg/ ml anti CD28 in the presence of cytokines. The cytokine concentrations 
used for are as follows: Th17: TGFβ- 2ng/ml, IL-6- 30 ng/ ml, IL-23- 15 ng/ ml, 
IL-1β- 10 ng/ml, aIFNg- 1µg/ ml; Th1: IL-2- 2 ng/ ml, IL-12- 10 ng/ml, aIL-4- 
1µg/ ml. The cells are cultured for 5 days. On day 5, the cells are replated in 
restimulation media (RPMI supplemented with 10%FCS, penicillin/streptomycin, 
glutamine) and restimulated with ionomycin (750ng/ml) and phorbol- myristate- 
acetate (50ng/ml) for 4 hours in the presence or absence of Brefeldin-A (5 µg/ 
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 ml). The cells restimulated in the presence of Brefeldin-A are used for 
intracellular cytokine staining. The media from the cells restimulated without 
Brefeldin-A are used for ELISA and trizol is added to the cells and RNA 
synthesized from these samples is used for real time PCR. 
 
3.4.3 aCD3/CD28 bead stimulation 
 
A single cell suspension is made from the spleens of mice. Splenocytes are then 
plated out on 24 well plates with aCD3/CD28 beads in the 2:1 bead to cell ratio. 
The cells are cultured for 2 days. The cells are then separated from beads, spun 
down and the supernatants are used for ELISA. 
       
3.4.4 MOG peptide stimulation 
 
Splenocytes from MOG35-55 immunized mice are stimulated with MOG35-55 
peptide (10µg/ ml). The cells are cultured for a period of 2 days. The supernatants 
are collected and used for ELISA. 
 
3.4.5 Cell depletion and NOD-SCID transfer 
 
6-week-old NOD-SCID mice are used for transfer studies. CD25 and CD62Lhi 
depleted splenocytes are transferred from either wt or transgenic mice into the 
recipient NOD-SCID mice. Spleens are first obtained from groups of mice and are 
ground to make single cell suspensions. The cells are then pooled and counted 
after which they are spun down and resuspended in 1 ml depletion buffer. 10 µg 
each of CD25 antibody and CD62L antibody is then added to the cell suspension. 
The cells are then incubated on a roller for 20 minutes at 4°C. The cells are 
washed with 4 ml depletion buffer, spun down and resuspended in 1 ml depletion 
buffer.  
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 Antibody bound cells are depleted from the cell suspension using sheep anti- rat 
IgG dynabeads. 50 µl dynabeads is used per 107 cells. Required volume of 
dynabeads is taken out and washed with depletion buffer. The beads are then 
resuspended in the initial volume of depletion buffer and required volume of the 
dynabeads is added to the cell suspension. It is then incubated on a roller for 30 
minutes at 4°C. 1 ml of depletion buffer is added to the cell suspension and the 
tube is then placed in a magnet. The bead bound cells stick to the magnet while 
the unbound cells remain in the suspension and can be decanted. The beads are 
washed thoroughly several times to obtain all unbound cells. The cell suspension 
containing unbound cells is then spun down and this would contain the CD25/ 
CD62Lhi double negative cells. Cells are then resuspended in PBS at the desired 
concentration and injected into the tail veins of NOD- SCID recipients (used 
1x107 cells per mouse).   
 
3.4.6 Islet isolation and in vitro culture 
 
Pancreata are digested using Collagenase P and the islets are isolated according to 
the protocol from Bluestone lab230. The islets are purified using histopaque. The 
purified islets are then resuspended in RPMI-10 and cultured using the basic 
protocol from DiLorezo lab231with modifications. The islets are resuspended in 
RPMI 10 with 50 units of IL-2/ml and cultured on 24 well plates overnight. The 
next day, the cell suspension is passed through a 40µm strainer and the filtrate is 
then spun down. The pelleted cells are resuspended in the restimulation media and 
restimulated for 4 hours with PMA (50ng/ml) and ionomycin (750ng/ml) with or 
without Brefeldin-A. The samples are then used for intracellular cytokine 
staining, ELISA or qPCR. 
 
3.4.7 FACS analyses 
    
       Extracellular Staining: Single cell suspension is prepared from mouse 
organs. The cells are spun down and the cell number is counted. Required 
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 numbers of cells are resuspended in PBS. The cells are blocked for 10 
minutes at 4°C with an Fc blocking antibody to prevent excessive antibody 
binding. A mix of the desired antibodies for staining is made and added to the 
cell suspension. The cells are stained for 30 minutes at 4°C. The cells are then 
washed twice with PBS and analyzed using a FACS Canto. 
 
      Intracellular Staining: FoxP3 staining is done using the FoxP3 staining kit 
from eBioscience. The intracellular cytokine staining is done using the 
intracellular cytokine staining kit from BD.  
 
3.5 Bioimaging Techniques: 
 
3.5.1 Preparation of D-luciferin/ Anesthetic mixture 
 
The anesthetic is prepared by mixing 10 ml of PBS with 8 ml Ketamine 
(25mg/ml) and 2 ml Xylazine (2%). It is recommended to use 5 µl of D-luciferin 
(dissolved in PBS at 30mg/ml) along with 10 µl of anesthetic per gram of body 
weight. For a mouse weighing 30 grams, 300 µl of anesthetic is mixed with 150 
µl of luciferin. During our experiments, we found out that the anesthetic 
concentration was mostly high enough to be fatal and hence started using 4µl 
anesthetic instead of 10µl per gram of body weight. The luciferase signal from 
our mouse line was also very high and hence we modified the protocol to use 3µl 
luciferin per gram of body weight. 
  
3.5.2 Imaging of cultured cells 
 
Cells are cultured in 24 well plates and 2 µl of D-luciferin is added to each well 
just prior to imaging. 
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3.5.3 Imaging of whole mouse 
 
The anesthetic/ D-luciferin mix is prepared as above. The appropriate amount of 
the mix to be injected is calculated and injected I.P. prior to imaging. As 
sometimes mice die during imaging, around 70-75% of the recommended dose of 
anesthetic- luciferin mix is injected to avoid unnecessary death. The time of 
injection is noted and the first image is taken at 10 minutes after injection. The 
earlier images were taken using Night Owl Molecular Light Imager from EG&G 
Berthold. With this machine, the images were acquired and processed using the 
WinLight 32 software. The first image was taken with a 20 second exposure time 
and the second image was taken immediately after with a 1-minute exposure time. 
Halfway through the project, we were able to obtain IVIS® Spectrum, a high end 
imaging system from Caliper Lifesciences. In this case, the images were acquired 
and processed using the Living Image® 4.1 software and we used a one second 
exposure time. We were able to pick up a strong signal from the thymi of 
luciferase positive mice with the IVIS system, which we were unable to do with 
the Night Owl imager. 
 
3.6 Cell Culture Techniques: 
 
3.6.1 Preparation of media 
 
293F Media:  
 
25 ml FCS is filtered into 500 ml DMEM. To the bottle, penicillin/streptomycin 
and glutamine are added. The media is stored at 4°C. 
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Ins-1E Media: 
 
RPMI- 1640 media is supplemented with 10% FCS, P/S, glutamine, HEPES 
(5mM), sodium pyruvate (0.5mM) and 2- mercaptoethanol (25µM). The media is 
then stored at 4°C.  
       
NIT-1 Media: 
 
1 vial of nutrient mixture F-12 Ham Kaighn’s modification (Ham’s F-12K) 
powder is resuspended in 500 ml autoclaved water. 1.5 g of sodium bicarbonate is 
added to the solution and it is then filtered and split into 2 bottles each of 250 ml. 
To each bottle 25 ml of filtered FCS, penicillin/streptomycin and glutamine are 
added. The media is stored at 4°C. 
 
3.6.2 Cell culture and passaging 
 
293 F Cell Line: 
 
           The 293 F human embryonic kidney cell line is maintained on advanced DMEM 
supplemented with 5% FCS, penicillin/ streptomycin (P/S) and glutamine in 10 
cm plates. The cells are passaged every 3 days. For this, the media is removed by 
aspiration; the cells are washed with PBS and trypsinized with 1 ml trypsin. 
Trypsin is then inactivated by addition of 9 ml media. 1 ml of cell suspension 
from the plate is transferred to a new plate along with 9 ml fresh media to obtain a 
1:10 ratio. The plates are maintained in the incubator at 37°C and at 5% CO2 
concentration. 
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 INS-1E Cell Line: 
 
                  Ins-1E cell line is maintained on RPMI- 1640 media supplemented with 10% FCS, 
P/S, glutamine, HEPES, sodium pyruvate and 2- mercaptoethanol. Media is 
renewed every 3 days. Since the cell line grows slower than HEK cells, the cells 
are passaged every 5-7 days depending on the confluency. Instead of using 1 ml, 2 
ml of the cells are used to plate out fresh plates. The plates are maintained in the 
incubator at 37°C and at 5% CO2 concentration. 
 
NIT-1 Cell Line: 
 
NIT-1 cell line is maintained on Ham's F12K medium with 2 mM L-glutamine 
adjusted to contain 1.5g/L sodium bicarbonate and heat-inactivated dialyzed fetal 
bovine serum, 10%. The cell line grows considerably slow; the cells are passaged 
every 7-8 days depending on confluency. Fresh media is added every 3 days. The 
cells are maintained in 25ml TC flasks in a volume of 5 ml. Cells are found to 
grow better in TC flasks compared to plates. For passaging, the cells are 
dissociated using an enzyme- free Hank’s- based cell dissociation buffer (GIBCO) 
instead of trypsin. The cells are incubated with the buffer for 4-5 minutes; the 
flasks are tapped vigorously to dissociate the cells. The cells are resuspended in 
media, spun down and replated in fresh media. As with INS-1E cells, cells are 
plated out at a 1:5 ratio. 
 
3.6.3 Puromycin selection 
 
The cells are fist cultured on 24 well plates and infected with virus containing the 
puromycin construct. The media containing the virus is removed and the cells are 
maintained on normal media till they are really confluent. Once they are 
confluent, the normal media is replaced with media containing puromycin. The 
cells are maintained in the puromycin media for a while to ensure proper removal 
of puromycin susceptible non-infected cells. The cells are transferred to 6 well 
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 plates and then to 10 cm plates or 5 ml TC flasks once they start getting confluent. 
Finally the puromycin media is removed and the selected cells are then 
maintained in normal media.  
 
The puromycin concentrations to be used are determined by puromycin titrations 
of WT cells. The highest concentration where the cells are still surviving is 
selected. For Ins-1E cells, a concentration of 1µg/ ml is used; while for NIT-1 
cells, a concentration of 0.5µg/ ml is used. For 293F cells, a concentration of 5µg/ 
ml is used. 
 
3.7 General assay techniques: 
 
3.7.1 PI/ AnnexinV Staining for apoptosis 
 
The staining is done on serum-starved cells, as cell death is more dramatic 
compared to cells grown in the presence of serum. The cells are cultured in serum 
deficient media, are harvested over time and the apoptosis levels are analyzed by 
staining with PI and annexin. The cells are first manually dissociated and washed 
once with PBS followed by 1 ml of annexin binding buffer. The cells are then 
spun down and resuspended with 1:50 dilution of Annexin-PE antibody and 
stained for 15 minutes in the dark at room temperature. The cells are then washed 
once with PBS and stained with a 1:50 dilution of PI for 30 minutes in the dark at 
room temperature. The cells are then washed once with PBS and analyzed by 
FACS. 
 
3.7.2 PI Staining for cell cycle analyses 
 
The cells are washed with PBS and spun down. To the cells, 3 ml of ice cold 70% 
ethanol is added drop wise while vortexing at a slow speed. The cells are then 
incubated for 30 minutes on ice at the end of which they are washed once with 
PBS. A 1:50 dilution of PI is then added to the cells. 1µl RNase enzyme is also 
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 added to ensure the degradation of RNA in the sample. Incubation is done for 30 
minutes in the dark at room temperature. The cells are then washed once with 
PBS and analyzed by FACS.  
 
3.7.3 EFluor670 Staining 
 
0.5µM eFluor670 is resuspended in 1ml of PBS without FCS. 106 cells are then 
resuspended in the eFluor670 solution and stained for 10 minutes in the dark at 
37°C. The cells are then washed twice with PBS containing 1%FCS, resuspended 
in media and plated out. Usually around 2X105 cells are plated out per well of a 
24 well plate.  
 
3.7.4 Cyclophosphamide (CY) Injection 
 
For CY induced diabetes studies, mice older than 6 weeks are used. A solution of 
20mg/ml CY in PBS is prepared. The tube is left on a roller for 1-2 hours to 
ensure complete dissolution of CY in PBS. 2mg of CY per 10 gm of body weight 
has to be injected I.P. The mice are given a second injection of CY 14 days into 
the time course, if desired.  
 
3.7.5 High dose Streptozotocin (STZ) Injection 
 
High dose STZ injections were done according to the AMDCC protocol232. Mice 
are fasted for 4 hours prior to injection. Appropriate amount of STZ is weighed 
out and added immediately before injection to sodium citrate buffer to obtain a 
final concentration of 22.5 mg/ml. This is done as STZ degrades within 15-20 
minutes in the solution. The mice are usually lightly anaesthetized with isoflurane 
and the appropriate amount of the STZ solution is injected I.P. The final dosage 
required is 150mg STZ per kg of body weight. The injection usually leads to a 
peak in insulin release and hence mice are provided with 10% sucrose water 
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 overnight to prevent hypoglycemia. The mice are tested 2 days later for 
hyperglycemia.  
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Analyzing the role of IL-17A in autoimmune diabetes 
 
As mentioned in the introduction, Th17 cells are reported to be pathogenic in a variety of 
autoimmune diseases mainly by way of their primary effector cytokine IL-17A. IL-17A 
deficient mice are found to be partially protected from experimental models of MS and 
rheumatoid arthritis242, 261. This has led the scientific community to believe that IL-17A 
might be pathogenic in other autoimmune diseases as well. Though a number of studies 
have already suggested a pathogenic role for this cytokine in type 1 diabetes171- 176, none 
of these results seem to show a direct link between IL-17A and autoimmune diabetes. 
The remarkable plasticity observed in Th17 cells seems to further complicate the 
scenario. Hence, we decided to look at the relationship between Th17 cells and type 1 
diabetes in the context of IL-17A. We used the common model for type 1 diabetes, the 
NOD mouse. We felt that this would be an ideal system as these mice develop 
autoimmune diabetes spontaneously and the disease closely resembles type 1 diabetes in 
humans.  
 
We resorted to RNAi to generate transgenic NOD mice with reduced IL-17A expression, 
as we believe that it resembles the normal physiological state much better than a 
complete knockout of the protein. The idea was to follow diabetes development in the 
transgenic mice to see whether reduction in IL-17A levels by RNAi conferred protection 
from diabetes to these mice. If IL-17A is indeed pathogenic in type 1 diabetes as 
suggested, loss of this protein albeit not complete should be able to at least offer partial 
protection from type 1 diabetes.  
 
We first generated shRNA constructs targeting IL-17A and the knockdown efficiencies 
of these shRNAs were then verified in vitro. The construct that led to the highest 
knockdown was then used to generate lentivirus. The high titer lentivirus carrying the 
shRNA was then used to generate the transgenic mice. All these steps are detailed below. 
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 4.1 Generation and validation of shRNA constructs 
 
We decided to opt for a ubiquitous expression of the shRNA.  Since no study has 
reported a role for IL-17A in the haematopoietic system or in lymphocyte development, 
we didn’t see the need to opt for cell specific knockdown or inducible knockdown of IL-
17A. Towards this purpose, shRNA was cloned into the pLBUG vector where it is under 
the control of a ubiquitous promoter leading to systemic expression of the shRNA and 
hence systemic knockdown of the protein.  
 
4.1.1 Generation of IL-17A shRNA construct: 
 
Several shRNA sequences directed against IL-17A coding sequence were designed using 
the algorithm available at RNAi Central244 and ordered from Sigma. The oligos were 
phosphorylated using PNK and then the forward and reverse oligos were annealed to 
obtain double stranded sequence. The shRNAs were then cloned into the pLBUG vector, 
obtained by replacing the CMV promoter upstream of GFP in pLB vector with a 
Ubiquitin promoter (Fig.1A). For cloning in the shRNAs, pLBUG was first digested with 
Hpa1/ Xho1 and the digests were run on a gel and the digested vector band was cut out 
and gel purified. shRNAs were then ligated with the digested vector at a 1:4 vector to 
insert ratio to generate pLBUG constructs containing the desired shRNA sequence. In the 
pLBUG-shRNA construct, the shRNA is under the control of the U6 promoter, which 
leads to systemic expression of the shRNA. The construct also has a GFP sequence under 
the control of another ubiquitous promoter, the ubiquitin promoter and hence GFP 
expression is used as a marker for shRNA expression (Fig.1B). 
  
Once the shRNA constructs are generated, the knockdown efficiencies of the shRNAs 
have to be tested. This is done using an in vitro assay for which the cDNA of interest has 
to be cloned into a reporter construct called psi-check2 (Fig.1C). The setup and the 
principle behind the assay are detailed below. IL-17A cDNA was cloned into the psi-
check2 vector to generate IL-17 psi-check.  
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 IL-17 cDNA was obtained from Open Biosystems as a vector construct (pCR4-TOPO). 
The cDNA had to be cloned into the psi-check2 vector between Xho1/ Pme1 restriction 
sites.  Unfortunately, pCR4-TOPO containing IL-17 cDNA did not have an Xho1 
restriction site. To overcome this problem, we decided to cut pCR4-TOPO at the Not1 
site and insert a Not1- Xho1 linker into the construct. Not1-Xho1 linker was designed 
and obtained from Sigma. pCR4-TOPO was then digested with Not1 and ligated with the 
Not1-Xho1 linker. The ligations were used to transform bacteria and minipreps were 
made. pCR4-TOPO containing the linker was then digested with Xho1/Pme1, the 600bp 
IL-17 sequence was cut out and gel purified. Psi-check2 vector was simultaneously cut 
with Xho1/Pme1 and ligated with the IL-17 cDNA to generate the IL-17 psi-check 
(Fig.1D).  
 
Fig.1 
 
A.       B.  
 
 
  
 
C.    D. 
 
 
 
 
 
 
 
Fig1. A & B. Schematic diagram of pLB. pLBUG was generated by replacing the CMV upstream of GFP 
with Ubiquitin promoter. C. Schematic diagram of psi-check2. D. Schematic diagram of IL-17/ psi-check. 
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 4.1.2 Verification of shRNA silencing efficiency and specificity in vitro by luciferase 
assay:  
 
To verify the knockdown efficiencies of cloned in shRNAs, luciferase assay is used. Psi-
check2 is a reporter construct having 2 luciferase sequences, a firefly luciferase sequence 
and a renilla luciferase sequence. Once mammalian cells are co- transfected with the 
shRNA construct and the psicheck-2 containing cDNA of interest, renilla luciferase 
expression is used as a marker to calculate the knockdown efficiency of the shRNA.  
 
The cDNA of interest is cloned into the 3’UTR of the renilla luciferase sequence in psi-
check2. 293 cells are then transfected with the psi-check2 reporter along with the 
different shRNA constructs. The cells are allowed to grow in culture over a period of ≥ 
48 hours. During this time, transcription results in the formation of mRNAs. Firefly 
luciferase is constitutively expressed. But since the cDNA is cloned into the 3’ UTR of 
renilla luciferase sequence, a fusion mRNA is formed. The shRNAs that are formed after 
transcription from the shRNA constructs can then bind to this fusion mRNA due to their 
complemetarity with the cDNA sequence. This results in cleavage of the fusion mRNA 
and this depends on the knockdown efficiency of the shRNA. The expression of renilla 
luciferase is inversely proportional to the knockdown efficiency of the shRNA tested. 
Firefly luciferase expression levels are constitutive and are used to compensate for the 
difference in transfection efficiencies.  The sequences that can cause the lowest renilla 
expression levels are selected as these are expected to have the highest knockdown 
efficiencies.   
 
293cells were transfected with the different shRNA constructs along with the IL-17 psi-
check reporter. The cells were lysed after a period of 48 hours and the luminescence 
intensities were analyzed. All the sequences were found to have good knockdown 
efficiencies (Fig. 2A). #176 was found to have the highest knockdown efficiency 
consistently and was used to generate high titer lentivirus. 
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 One criticism that is usually directed against RNAi is that the effects of the shRNA could 
be non-specific. To address this, we decided to test the knockdown efficiency of 
sequence #176 against IL-17A psi-check and also against a completely different gene, 
PTPN22. For the experiment, we used #176 and an shRNA already found to be effective 
against PTPN22 cDNA, named P4.  
 
We transfected 293 cells with either #176 or P4 in conjunction with either IL-17 psi-
check or PTPN22 psi-check. Hence we had 4 different experiment conditions.  
 
1. #176 + IL-17 psi-check 
2. #176 + PTPN22 psi-check 
3. P4 + IL-17 psi-check 
4. P4 + PTPN22 psi-check 
 
PTPN22 cDNA had been cloned into psi-check2 to generate the PTPN22 psi-check. 
shRNA directed against PTPN22 (P4) had been cloned into the pLBUG vector. Hence 
only the cDNA and the shRNA differ in the 4 setups and everything else including the 
rest of the parts of the constructs, cells and experiment conditions are identical between 
the 4 different experimental setups. Hence if we see any knockdown, it should be specific 
to the shRNA used. If the #176 shRNA knockdown is specific, we should see a 
significantly reduced luciferase signal only when #176 is transfected in conjunction with 
IL-17 psi-check (option 1) and not when #176 is transfected in conjunction with PTPN22 
psi-check (option 2). 
 
As expected, #176 caused a reduced luciferase signal only against IL-17A psi-check and 
this knockdown effect was not observed against PTPN22. P4 was able to cause a reduced 
signal only against PTPN22 psi-check (Fig. 2B).  The results showed that the knockdown 
observed with #176 was specific to IL-17A and that this shRNA could not knockdown 
the expression of a random gene. These data show that the knockdown efficiency 
measured in this reporter assay reflect the specific targeting of IL-17A cDNA by the 
shRNA#176. 
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Fig.2 
 
A.       B. 
 
 
Fig.2. A. Validation of Il-17a shRNA silencing efficiency by dual luciferase assay. Data are representative 
of several independent experiments. B. Validation of Il-17a shRNA silencing specificity. Knockdown 
efficiencies of #176 and P4 (ctrl) against IL-17/ psi-check (left) and PTPN22/ psi-check (right) are shown. 
Data are representative of two experiments and mean and SEM of triplicate values are shown.  
 
4.2 Generation and lineage of IL-17A KD transgenic mice 
  
Once we identified an shRNA that could significantly reduce IL-17A expression, the next 
step was to generate a NOD mouse line with this vector construct. We used lentiviral 
transgenesis to achieve this. The various steps are detailed below. 
 
4.2.1 Generation of lentivirus and IL-17A KD transgenic line:  
 
To generate transgenic mice, we inject lentivirus carrying the desired transgene into 
single- cell embryos, which then give rise to the transgenic mice. To generate lentivirus, 
293 cells are co- transfected with the shRNA- construct along with the various viral 
components. Inside the cells, the viruses are packaged and the packaged viral particles 
containing the shRNA-construct are released from the cell into the cell media. The viral 
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 particles can be isolated by ultra centrifugation of the cell supernatant. The virus is then 
titrated and a high titer virus (≥1 x 108 particles / ml) is used for embryo injections. 
 
shRNA#176 was co- transfected into 293 cells along with the various viral components 
and a transfection reagent that facilitates the uptake of the constructs. The cells were 
allowed to grow in culture. The transfection efficiency could be tracked by GFP 
expression as all infected cells should be GFP + owing to the GFP sequence in #176-
pLBUG construct.  After a period of 48 hours, the cell media was collected, centrifuged 
down to remove cell debris and was saved. The media collection was repeated at 72 hours 
and the infected cells were then terminated. The cell supernatants were subjected to 
ultracentrifugation and the virus pellet was resuspended in PBS. 
 
To check the virus titers, 293 cells were infected with 1.0 µl, 0.1 µl or 0.01 µl of the virus 
suspension. The cells were allowed to grow in culture for 3 days and GFP expression was 
analyzed under the microscope. At the end of the experiment, cells were taken out and 
the % of GFP+ (infected) cells was calculated by FACS. We were able to obtain a virus 
suspension that could infect around 25% of the cells at 1.0 µl concentration and this came 
out to a virus titer of 2x108 virus particles/ml (Fig.3A). Hence we used this virus 
suspension for generating the transgenic mice.   
 
Female NOD mice were super ovulated by injections of PMG and HCG to induce the 
production of multiple eggs. The super- ovulated females were then mated with males 
and the embryos were collected from the oviducts of the fertilized females. These single- 
cell embryos were used for injections. Lentivirus generated with #176 was injected into 
the perivitelline space of single- cell embryos that were then transplanted into pseudo- 
pregnant females. We used CD1 females as recipients since they make excellent mothers. 
The recipient females carried the embryos to term. 6 pups were obtained from the first 
cycle of injection.  
 
We took out blood from these pups and analyzed GFP expression by FACS.  Out of the 6 
pups, 5 were GFP negative as none of their cells expressed GFP. But the 6th pup had 
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 almost all cells express high levels of GFP (Fig. 3B). This mouse was used as the founder 
for the transgenic line.  
 
Fig.3 
 
A.        B.  
 
 
 
 
Fig.3. A. Flow cytometry data showing around 25% of virus infected cells. B. GFP expression in blood 
samples from the positive founder in comparison with three negative mice.  
 
 
4.2.2 GFP expression levels and lineage studies: 
 
We observed 2 distinct GFP+ populations in the founder mouse. They were designated as 
‘High’ and ‘Low’ based on their higher and lower mean fluorescence intensities (Fig.4A). 
This difference in expression levels could have been due to several reasons. One could 
have been that some cell subsets expressed GFP much strongly than others. But we found 
the 2 GFP populations in all cell subsets indicating that this might not have been the 
reason. Another possibility was that there might have been 2 different viral integrants in 
our founder mouse, which could have led to the 2 expression patterns observed. A third 
possibility was our founder having been a chimera. To get a clearer picture, we bred the 
founder mouse and analyzed the N1 and N2 generations over time.  
 
We had 3 litters of pups from the founder. We took out blood from all the pups and 
looked at the GFP expression. To our surprise, we found that in all the pups we analyzed, 
we could observe only a single GFP expression pattern. Some of the mice had all their 
cells with the high expression and some had all their cells with the low expression 
(Fig.4B). None of the N1 pups were found to have the 2 cell populations together. This 
0 102 103 104 105
FITC-A: GFP
0
50K
100K
150K
200K
250K
SS
C
-A
0.89
0 102 103 104 105
FITC-A: GFP
0
50K
100K
150K
200K
250K
SS
C
-A
25.1 0 102 103 104 105
FITC-A: GFP
0
102
103
104
105
PE
-A
0 102 103 104 105
FITC-A: GFP
0
102
103
104
105
PE
-A
0 102 103 104 105
FITC-A: GFP
0
102
103
104
105
P
E
-A
0 102 103 104 105
FITC-A: GFP
0
102
103
104
105
P
E
-A
115
 observation precluded the possibility of 2 virus particles having been infected the single- 
cell embryo. This observation strongly pointed to the possibility of a chimera.  
 
Fig.4 
 
A.          B.  
 
Fig.4. A. Differential expression of GFP in the founder mouse as measured by flow cytometry. B. GFP 
expression patterns (MFI) in the N1 litters.   
 
 
4.2.3 High & Low Transgenic lines: 
 
Mice in N1 were found to have either the high population or the low population and 
never a mixture. Next, we mated the high mice and the low mice separately as 2 different 
lines. We named them ‘High line’ and ‘Low line’. It should be noted that ‘high’ and 
‘low’ refer to the mean fluorescence intensities of GFP expression and that it has nothing 
to do with IL-17A knockdown efficiencies. For the purpose of this project, mice from 
‘High line’ were used for most experiments unless stated otherwise. Both lines are still 
being maintained separately.  
 
We took out blood from the N2 mice and analyzed the GFP expression levels. Again to 
our surprise, all the pups from a high parent were found to express only the high GFP 
population and all the pups from a low parent expressed only the low GFP population 
(Fig.5A). This segregation was found to hold true in all future generations (Fig.5B).  
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Fig.5 
 
A.                                             B.      
 
 
 
 
 
 
 
Fig.5. A & B. Segregation of high and low cell subsets in N2 (A) and in later generations (B). MFI of GFP 
expressing cell populations in the mice are shown. 
 
This pattern led us to believe that the founder was a chimera and that it had 2 viral copies. 
It seems that at the time of infection, the embryo was in fact 2 celled instead of being 
single celled and each cell was infected with a distinct lentivirus particle. This made our 
founder mouse a chimera, with some cells expressing one construct and the others the 
other construct. During meiosis, some germ cells carried the high GFP expression copy 
and others carried the low GFP expression copy. This led to segregation of the 2 
expression patterns in the subsequent generations.  
  
4.2.4 Southern blot analysis: 
 
To verify this belief, we decided to look for the viral integrants by Southern blot. Each 
mouse line was believed to carry a distinct viral integrant. The integration site is random 
and should be distinct in each transgenic line. Since the viral particle carried the GFP 
sequence, it could be used as a probe to detect the integration site. Unfortunately we did 
not have DNA from the founder mouse. Hence we had to do the assay with the high and 
the low GFP expressing pups. We used EcoR1 to cut the genomic DNA. It cuts the DNA 
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 randomly and since we didn’t know where the integration site was, we couldn’t predict 
the size of the fragment we were looking for. But if the high and the low transgenic lines 
have a single distinct viral integrant as we suspected, they should have different 
integration sites and hence we should ideally detect GFP bands at 2 different sites on the 
gel- one site for all the low mice and another site for all the high mice. It would have 
been really rare if the viral integrants integrated at the same site or if they integrated at 
different sites but gave similar sized bands upon restriction digestion with EcoR1.  
 
DNA samples from 3 each of low and high mice were obtained and analyzed by Southern 
blot using a GFP probe. We observed a single band in both groups of mice but at 
different sizes (Fig.6). This showed that there was a single distinct viral integrant in each 
transgenic line and that the viral integration site was distinct in each line.  This further 
validated our belief that the founder embryo was 2 celled at the time of the injection and 
that each cell got infected with a distinct viral copy and each copy integrated at a distinct 
genomic site.    
 
Fig.6 
                                                      
 
 
 
 
 
 
 
 
 
 
Fig.6. Southern blot analysis of low and high transgenic mice. W represents the wt sample.  
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 4.3 Phenotypic characterization of lymphocyte compartments in 
transgenic mice 
 
We found that the transgenic mice were viable and fertile and they did not present any 
gross phenotypic defects. Though IL-17A has not been reported to play any significant 
role in either the haematopoietic or the lymphoid system, it was still critical to ensure that 
the lymphoid populations in the transgenic mice were normal. Hence we decided to 
characterize the T cell subsets in the transgenic mice and also look at the activation status 
of the transgenic T cells.  
 
Cells were isolated from thymus, spleen and lymph nodes of both WT and transgenic 
mice and stained with a variety of antibodies against T cell markers. Transgenic mice 
showed no defects in any of the lymphoid compartments indicating that loss of IL-17 did 
not compromise lymphoid development.  
 
4.3.1 Characterization of T cell subsets:  
 
T cells undergo maturation in the thymus. There the double positive CD4+CD8+ T cells 
switch off one of the markers and commit themselves to a single lineage, either CD4 or 
CD8. We decided to look at the single and double positive populations in the thymus to 
ensure that the selection processes and overall development of T cells in the thymus is 
not compromised by the transgene. For this, we isolated T cells from the thymi of mice 
and stained them for CD4 and CD8. We then analyzed the results by FACS. The 
percentages of CD4/CD8 double positive cells and CD4+ or CD8+ single positive cells 
were quite similar in the thymi from both WT and transgenic mice (Fig.7A). This 
indicated that the transgene did not alter T cell development in the thymus. 
 
 Once the T cells mature, they migrate out from the thymus into the periphery. To make 
sure that the transgene did not interfere with the T cell populations in the peripheral 
lymphoid organs, we isolated T cells from spleens and lymph nodes and looked at the 
CD4+ and CD8+ populations. We observed similar percentages of CD4+ and CD8+ cells 
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 in the lymph nodes and spleens from both groups of mice (Fig. 7B) indicating that 
peripheral T cell subsets were normal in the transgenic mice.  
 
Fig.7 
 
A.                                                           B.  
  
 
 
 
 
 
 
 
 
 
Fig.7. A. CD4/ CD8 expression in the thymi of wt and KD mice as measured by flow cytometry. B. CD4/ 
CD8 expression in the lymph nodes and spleens of wt and KD mice.  
 
 
4.3.2 Characterization of T cell activation status: 
 
Once T cells are mature, they leave the thymus and enter the periphery. These mature 
cells are still to encounter their cognate antigen and hence are referred to as naïve T cells. 
CD62L is commonly used as a marker to identify these cells as naïve T cells express high 
levels of this marker. Once the naïve T cells encounter their antigen, CD62L expression 
is downregulated. CD44 can be used as a marker to identify these cells, which have 
already encountered their antigen and have now become effector memory T cells. Hence, 
CD62L expression and CD44 expression could be used to analyze the activation status of 
T cells. To ensure that the transgene did not affect the activation status of T cells in the 
periphery, we looked at the CD62L and CD44 expression by transgenic T cells.  
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 T cells from spleen and lymph nodes were isolated and were stained for T cell receptor 
and the activation markers, CD62L and CD44. We then analyzed the T cell populations 
by FACS. Similar percentages of TCR+, CD4+ and CD8+ cells were observed in the 
organs from both WT and transgenic mice (7A, 7B, 8A). The % of CD62L+ and CD44+ 
cells were also quite similar between the 2 groups of mice indicating that the transgene 
did not have any effect on the activation status of peripheral T cells (Fig. 8B). 
 
Fig.8 
 
A.                                                                     B. 
 
 
 
 
 
 
 
 
 
Fig.8. A. TCR expression in lymph nodes and spleens from mice. B. CD62L / CD44 expression (CD62L: 
PE, CD44: PE Cy5.5) in lymph nodes and spleens from wt and KD mice.  
 
 
4.3.3 Characterization of regulatory T cell compartment:  
 
A number of studies have suggested an inverse relationship between Th17 cells and 
regulatory T cells. The current belief is TGFb regulates Th17 and Treg differentiation 
pathways in a concentration dependent manner. At lower concentrations, TGFb enhances 
Th17 differentiation in synergy with IL-6. But in higher concentrations, TGFb 
downregulates Th17 pathway and instead enhances Treg differentiation233.  
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 Since the transgene was expected to downregulate IL-17A expression, this in turn could 
have impaired Th17 differentiation pathway in the transgenic mice. Current reasoning 
then suggested that impairment in Th17 differentiation could have possibly led to an 
enhanced Treg differentiation. To investigate this possibility, we isolated T cells from the 
peripheral lymphoid organs and then looked at the FoxP3+ population. Similar 
percentages of FoxP3+ cells were observed in the spleens and lymph nodes from both 
WT and transgenic mice indicating that the presence of the transgene did not alter 
peripheral Treg compartment in the transgenic mice (Fig.9).  
 
 
Fig.9 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. Treg populations in the lymphoid organs of KD mice in comparison with a wt mouse.  
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 4.4 Verification of RNAi and reduced IL-17A levels in transgenic mice 
 
We had already verified the knockdown efficiency of the shRNA in vitro by luciferase 
assay. Once we had the transgenic mice, the next step was to verify that the shRNA was 
effective in the transgenic mice and that the IL-17A levels in these mice were reduced. 
IL-17A expression is quite low in vivo under normal conditions and hence it is quite 
difficult to pick up a reduction when the normal levels are already low. Hence we decided 
to differentiate naïve T cells in vitro into Th17 cells and then look at the IL-17A levels. 
Once differentiated, Th17 cells produce significant amounts of IL-17A and reduction in 
the cytokine levels could be picked up much better against the high standard expression 
by differentiated cells. 
 
First we isolated naïve T cells from WT, ‘high’ or ‘low’ mice and differentiated them in 
vitro into Th17 cells. We used several different Th17 polarizing cytokine mixes. 
 
1. aCD3 
2. aCD3+ TGFb 
3. aCD3+ TGFb+ IL-6 
4. aCD3+ TGFb+ IL-6+ IL-23 
5. aCD3+ TGFb+ IL-6+ IL-23+ IL-1b 
 
 
Cells were put in culture along with one of these cytokine mixes and allowed to grow for 
5 days. They were then restimulated with PMA and ionomycin for a period of 5 hours. 
The supernatants were then collected and the amount of IL-17A in the supernatants was 
estimated by ELISA. We found that under minimal activation i.e. aCD3, cells produced 
some IL-17A. This minimal production was abolished in the presence of TGFb. Cells 
started to produce significant amounts of IL-17A when IL-6 was added to the mix and the 
addition of IL-23 and IL-1b was found to have an additive effect on IL-17A production 
as reported previously (10A). 
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 But most importantly, we found a significant reduction in the amounts of IL-17A secreted 
by the transgenic cells under all the conditions tested. Th17 cells from both the high and 
low transgenic lines showed similar knockdown of IL-17A (Fig. 10A). The results 
indicated that the shRNA works effectively in cells from transgenic mice and that 
consequently, transgenic cells produce significantly reduced amounts of IL-17A even 
under maximal stimulation. The similar knockdown observed in the cells from the 2 
transgenic lines indicated that both lines show strong IL-17A knockdown regardless of 
their GFP expression pattern and that the knockdown of IL-17A does not seem to be 
related to the strength of the GFP signal.  
 
Since we saw a similar knockdown in both transgenic lines, we used mice from High line 
for all our experiments from now on. Low mice are being bred in our facility and the line 
is being maintained for future use if need arises.  
 
Though we could show a significant KD in vitro in differentiated T cells, it was possible 
that in vivo this was not the case. It has already been suggested that all the requirements 
for full effector Th17 differentiation are not met in vitro and that in addition to the 
cytokine mix, there might be several other requirements, which seem to be satisfied only 
when the differentiation happens in an in vivo environment. Hence it was quite critical to 
show that reduction in IL-17A levels that we observed in vitro could be shown in vivo as 
well. As the % of Th17 cells in the body is quite low and as the IL-17A levels in vivo is 
almost undetectable, this was a really difficult challenge. 
 
To try and overcome this challenge, we decided to use a 2-pronged approach. We 
designated groups of mice either WT or KD and analyzed IL-17A levels in in vitro 
differentiated T cells and in ex vivo pancreatic islets. We took out islets from the mice 
and looked at the IL-17A levels in the islets. We also took out naïve T cells, 
differentiated them in vitro and looked at the IL-17A production by differentiated Th17 
cells. We analyzed IL-17A expression at both the mRNA and protein levels. We hoped to 
show a tight correlation between the knockdown observed in both in vitro differentiated 
cells and diseased islets from the mice. 
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4.4.1 in vitro differentiated cells:  
 
We isolated naïve T cells were from either WT or KD mice. These were then 
differentiated in vitro into Th17 cells by the addition of aCD3, TGF-b, IL-6, IL-23 and 
IL-1b. We also added anti IL-4 and anti IFNg to avoid differentiation of naïve T cells into 
Th2 or Th1 lineages. The cells were grown in culture over a period of 5 days. The cells 
were then restimulated in vitro in the presence of PMA and ionomycin for 4 hours. The 
media was collected and the amount of IL-17A secreted was analyzed by ELISA. mRNA 
was isolated from the differentiated cells and the level of IL-17A mRNA expression was 
determined by qPCR. Compared to the WT mice, KD mice had significantly lower levels 
of IL-17A, both at the mRNA and protein levels (Fig.10B and C). We found similar 
knockdown of IL-17A at both the protein and mRNA levels.  
 
4.4.2 ex vivo pancreatic islets & pancreatic lymph nodes:  
 
We had used mice that were over 5 months old and hence were already suffering from 
insulitis and in some cases, overt diabetes. We assumed that since these mice were 
already in the disease process, we might be able to detect IL-17A in the diseased islets. 
There are data already describing a method to get infiltrating T cells out from the 
pancreatic islets using IL-2231. We decided to modify this method to suit our purposes. 
Pancreatic islets were isolated from WT or KD mice and were put in culture overnight 
with IL-2 to facilitate the emigration of infiltrating T cells. The next day, the cells were 
resuspended in media and were strained through a filter to remove islets. The cell 
suspension containing the T cells was spun down. The cells were then put back in culture 
and restimulated with PMA and ionomycin for 4 hours. Since previous experiments had 
already shown that the islets upon restimulation hardly produce detectable levels of 
cytokines (data not shown), media was not saved for ELISA. 
 
 RNA was extracted from the cells following restimulation and IL-17A levels were 
analyzed by qPCR. IL-17A levels were detectable only in a fraction of the mice tested 
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 and was found to be highly variable between mice. To compensate for this variability, IL-
17A levels were compared relative to RORgt expression in mice. This was done as we 
had seen that RORgt levels were quite comparable between WT and KD mice (data 
shown later). Once normalized to RORgt expression levels, KD islets were found to have 
greatly reduced levels of IL-17A mRNA compared to WT mice (Fig.10D). We also 
looked at IL-17A levels in the pancreatic lymph nodes of wt and KD mice and observed 
similarly reduced IL-17A expression in the lymph nodes of KD mice (Fig.10E). Though 
the observations are based on a limited number of data points, we saw a strong similarity 
between the level of knockdown observed in in vitro differentiated cells and in pancreatic 
islets and pancreatic lymph nodes, which seems to strengthen the case.  
 
All these observations seem to confirm that shRNA expression and function are 
extremely efficient in the transgenic mice leading to significant reduction in IL-17A 
levels.  
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Fig.10. A. IL-17A protein expression levels in low and high transgenic mice. Representative of at least two 
independent experiments. B & C. IL-17 mRNA and protein expression levels in in vitro differentiated Th17 
cells from wt and KD mice (P< 0.0001).  Results are representative of three independent experiments. D. 
IL-17 expression in the pancreatic islets normalized to RORgt expression. E. IL-17 expression in the 
pancreatic lymph nodes.  
 
4.5 Characterization of in vitro differentiated Th17 cells from KD mice 
 
Th17 cells secrete a variety of cytokines including IL-17F, IL-21 and IL-22 in addition to 
IL-17A. Although none of these cytokines have been reported to cross regulate each 
other, such a possibility still existed. Since we saw a significant reduction in IL-17A 
levels in the transgenic mice, it was crucial to verify that none of the other Th17 effector 
cytokines were affected by the presence of the transgene. Since IL-22 is believed to be a 
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 minor cytokine compared to IL-17F and IL-21, we did not look at IL-22 levels. Th17 
cells are also characterized by their expression of a lineage specific transcription factor, 
RORgt. We analyzed the expression levels of RORgt in the transgenic mice to ensure that 
loss of IL-17A did not interfere with Th17 lineage in these mice. 
 
To rule out any perturbation in the levels of IL-17F and IL-21, we differentiated Th17 
cells in vitro and looked at the levels of these cytokines in parallel with IL-17A. No 
significant difference was observed in the levels of IL-17F and IL-21 in the KD mice 
compared to WT mice, either at the mRNA or protein level (Fig.11A and 11B). RORgt 
expression levels were also found to be comparable between the KD and WT mice 
(Fig.11C). This indicated that the KD was specific to IL-17A and did not affect other 
TH17 effector cytokines. The comparable levels of RORgt suggested that loss of IL-17A 
did not compromise Th17 differentiation pathway in the transgenic mice. 
 
Fig.11 
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Fig.11. A & B.  Protein and mRNA expression levels of IL-17F and IL-21 in in vitro differentiated Th17 
cells from wt and KD mice. Data shown are the combined results from two identical experiments with a 
total of 5 mice in each group C. RORgt expression in in vitro differentiated Th17 cells. Data shown are the 
combined results from two identical experiments with a total of 5 mice in each group.  
 
 
4.6 Characterization of in vitro differentiated Th1 cells from KD mice 
 
As mentioned in the introduction, Th1 and Th17 cells seem to share a complicated 
relationship. Before the discovery of Th17 cells, many of the Th17 dependent diseases 
were solely attributed to Th1 cells and their signature cytokine IFNg. Both Th17 cells and 
Th1 cells are believed to be involved in the diabetes disease process. It was possible that 
a reduction in IL-17A could somehow result in an enhanced Th1 differentiation and 
increased IFNg levels. IL-17A deficiency has already been reported to cause higher 
expression of Th1 associated molecules including IFNg in a model of colitis234. Since we 
were trying to analyze the effect of IL-17A KD on diabetes, it was important to verify 
that the transgene had no effect on Th1 differentiation or IFNg levels in our mice. This 
would have enabled us to further restrict any effects observed, specifically to the IL-17 
KD and not to an alteration in the Th1 pathway.  
 
For this purpose, we looked at IFNg production as a measure of Th1 differentiation. We 
took out naïve T cells from both WT and KD mice. These were then differentiated in 
vitro into Th1 cells by the addition of IL-2, IL-12 and anti IL-4. The cells were cultured 
for a period of 5 days and then were restimulated for 4 hours in the presence of PMA and 
ionomycin. The amount of IFNg secreted by the cells was determined by ELISA. RNA 
was extracted from the cells and used for qPCR. We failed to observe any significant 
difference in IFNg production between the WT and KD cells (Fig.12A&B). This data 
showed that the transgene did not impair the ability of the KD cells to undergo Th1 
differentiation.  
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 Fig.12 
 
A.       B. 
 
Fig.12. A. IFNg expression (mRNA) by in vitro differentiated Th1 cells from both wt and IL-17KD mice. 
B. IFNg protein levels in in vitro differentiated T cells from wt and IL-17KD mice. Data is representative 
of three independent experiments.  
 
 
4.7 Cytokine expression profiles in KD pancreatic islets 
 
Though we had looked at the various Th17 and Th1 factors in vitro, we decided to do the 
same with ex vivo pancreatic islets.  This was because in vitro data might not correctly 
reflect the in vivo status and we felt that ex vivo islets from diseased mice might provide 
us with a clearer picture. As mentioned earlier, we wanted to ensure that none of the 
Th17 factors like IL-17F, IL- 21 or RORgt were affected by the transgene and that any 
effect could be traced back only to reduced IL-17A levels. We also decided to look at 
IFNg levels. This in fact was due to 2 reasons. We wanted to ensure that IFNg levels 
were similar between WT and KD islets. Though we could see no difference in vitro, 
reduced IL-17 levels could lead to increased IFNg production by Th1 cells in vivo. Also 
Th17 cells have been described to be extremely plastic and the reduction in IL-17A could 
have made them much more susceptible to Th1 conversion.  
 
Though Th17 and Th1 cells are found to play significant roles in several autoimmune 
diseases, delineating these two cell populations and their individual roles in the disease 
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 state has been quite difficult. This is confounded by the fact that Th17 cells exhibit a 
significant degree of plasticity and have been reported to take on a Th1 phenotype over 
time. Th17 cells were able to transfer diabetes but the authors found that adoptively 
transferred Th17 cells had somehow converted to IFNg producing cells172, 173. A number 
of studies have demonstrated the presence of cells that co express both IL-17 and 
IFNg235-237. Annunziato et al.238 observed that both IL-17+IFNg+ cells and IL-17+ IFNg- 
cells express receptors for IL-12 and IL-23 and that stimulation with IL-12 can lead to T-
bet expression and subsequent IFNg secretion. Hirota et al.239 recently showed that in 
vivo, Th17 cells are able to switch to IFNg production and this depends on the disease 
condition. All the data leads to the idea that Th17 cells are able to downregulate Th17 
related factors and upregulate Th1 factors and thus convert to a Th1 phenotype and that 
the process might involve a double producer phenotype. 
 
We took out islets from 5 month old mice and put them in culture overnight with IL-2. 
The cells were then strained through a filter and were restimulated in vitro. RNA was 
isolated from the restimulated cells and we did qPCR for the different targets. mRNA 
was detected for all the targets though at different levels. We were able to detect IFNg at 
higher levels compared to the other cytokines implying a role for this cytokine in the 
disease process. We detected comparable amounts of IL-17F, IL-21 and RORgt in the 
islets from WT and KD mice (Fig.13A). This indicated that all the Th17 factors except 
IL-17A are unaffected. We also saw similar levels of IFNg in the islets from WT and KD 
mice indicating that loss of IL-17 did not enhance Th1 differentiation or Th17 conversion 
(Fig.13B). All the data from ex vivo pancreatic islets concurred with the in vitro data 
indicating that the integration of the transgene didn’t have any off target effect as far as 
TH17/ Th1 pathways were concerned.  
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Fig.13. A. mRNA expression levels of IL-17F, IL-21 and RORgt in the pancreatic islets of wt and KD 
mice. B. IFNg mRNA levels in the pancreatic islets of wt and KD mice.  
 
4.8 Analysis of diabetes in IL-17A KD mice 
 
Once we had verified efficient knockdown of IL-17A both in vitro and ex vivo, the next 
step was to study diabetes incidence in the transgenic mice. IL-17A deficient mice are 
found to be protected, at least partially from several autoimmune conditions. This shows 
that IL-17A is at least partially responsible for these autoimmune pathologies. These 
observations have led to the idea that this cytokine might be pathogenic in all similar 
diseases including type 1 diabetes. As mentioned in the introduction, several studies also 
suggest a role for IL-17A in type 1 diabetes, though the results are not really conclusive. 
Hence we felt that our transgenic mice might give us a clearer picture as to the role of this 
cytokine in Type 1 diabetes.  
 
Towards this purpose, we used 3 different models of diabetes: spontaneous diabetes, 
cyclophosphamide induced diabetes and adoptive transfer of diabetogenic splenocytes 
into immunodeficient recipients. Each of this is detailed below. 
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  4.8.1 Spontaneous diabetes: 
 
As mentioned earlier, NOD mice develop autoimmune diabetes spontaneously. Females 
are found to be more susceptible to the disease than males with around 70-80% 
developing the disease with time. Hence they form a valuable model for studying this 
disease. We established large cohorts of female KD or WT mice and maintained them in 
the SPF facility. The mice were maintained for a period of over 6 months during which 
time they developed the disease. The mice were tested every 2 weeks and every 1-week 
towards the later half of the observation period. For testing, urine blood sugar levels were 
checked with diastix. We observed no difference in the disease incidence level between 
the 2 groups of mice. Transgenic mice developed diabetes just like their WT counterparts 
and both the frequency and kinetics of the disease were found to be similar (Fig.14A).  
 
4.8.2 Cyclophosphamide induced diabetes: 
 
Spontaneous diabetes studies take a long time, as we have to wait for the mice to get sick 
spontaneously. This leads to time restrictions and induced diabetes models are used to 
overcome this problem. Cyclophosphamide is a chemotherapeutic drug, which has been 
found to induce diabetes in susceptible subjects. Injection of cyclophosphamide 
accelerates the diabetes process leading to the development of synchronous diabetes in all 
the mice within 2-3 weeks. This is believed to be due to depletion of regulatory T cells 
and B cells from the injected mice.  
 
We had failed to observe protection from diabetes in transgenic mice using spontaneous 
diabetes model. To verify the results obtained with spontaneous diabetes, we decided to 
use cyclophosphamide-induced diabetes. We injected small cohorts of WT or KD mice 
with cyclophosphamide on day 0 followed by a second injection on day 14. Mice were 
tested every 2 days for diabetes. We did this experiment twice and both times we failed to 
observe any difference between the 2 groups of mice. The disease kinetic was found to be 
indistinguishable between both groups of mice. The combined data are shown in the fig. 
(Fig.14B).  
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4.8.3 Adoptive transfer of splenocytes into NOD SCID recipients: 
 
Another widely used model is the adoptive transfer of diabetogenic splenocytes78, 240. 
This is also an induced model of diabetes. Here, CD25 depleted or CD25/ CD62L double 
depleted donor T cells are transferred to immunodeficient recipient mice241. These 
recipient mice lack a functional immune system and hence they act as an empty vessel for 
the adoptively transferred cells. When donor T cells are transferred after depletion of 
regulatory T cells, these cells undergo homeostatic proliferation in the recipients and 
autoimmune specificities can undergo unchecked proliferation resulting in the recipients 
developing severe pathologies. This is a useful model as any effect observed can be 
specifically restricted to donor cells as the recipients lack a functional counterpart. 
 
As a third alternative, we used adoptive transfer. We took out T cells from WT and KD 
mice. We then depleted CD25 from these cells and injected them into NOD-SCID 
recipients. WT CD25 depleted cells were injected into a group of NOD SCID recipients 
while transgenic CD25 depleted cells were injected into a separate group of mice. We 
then tested the mice regularly for diabetes. The experiment did not work properly as very 
few mice became sick. None of the WT mice developed diabetes during the entire period 
of the study. But 3 of the NOD SCID mice that had received transgenic cells developed 
the disease (Fig.14C). Though these data are not entirely conclusive, it suggested to us 
that transgenic cells though had reduced IL-17A, could effectively transfer the disease. 
This at the least showed that loss of IL-17A did not seem to protect the mice. 
 
To improve on the model, we isolated CD25/ CD62Lhi double depleted splenocytes from 
groups of wt or KD mice and transferred them into cohorts of NOD SCID recipient mice. 
The recipient mice were then tested for diabetes development by glycosuria 
measurements every 2-3 days.  We found that cells from the transgenic mice were able to 
transfer disease susceptibility similar to wt cells, confirming the diabetogenicity of KD 
splenocytes, despite the reduced IL-17A levels present (Fig.14D).  
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 To analyze the role of IL-17A in type 1 diabetes, we used 3 different but equally useful 
models. Data from all the three models failed to show any protection that is associated 
with reduced IL-17A levels. KD mice were as susceptible to developing diabetes as the 
WT mice. All the data conclusively suggested that loss of IL-17A did not offer any 
protection from autoimmune diabetes to the transgenic mice and hence IL-17A might not 
have a crucial role in the development of this autoimmune disease. 
 
Fig.14 
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Fig.14. A. Comparison of spontaneous diabetes frequency of wt (n=63) and KD (n=47) mice (P=0.76).  B. 
Comparison of cyclophosphamide induced diabetes frequency of wt (n=23) and KD (n=18) mice (P=0.24). 
Data show the combined results of two similar experiments. C. Comparison of diabetes frequency in NOD 
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 SCID mice injected with wt or KD CD25- splenocytes. D. Comparison of diabetes frequency in NOD SCID 
mice injected with either wt (n=9) or KD (n=9) CD62Lhi-CD25- splenocytes (P=0.23).  
 
4.9 Verification of systemic gene silencing in vivo: 
 
We failed to observe any protection from type 1 diabetes despite reduced IL-17A levels, 
in contrast to the expectation. IL-17A KD transgenic mice still retain residual amounts of 
IL-17A as we use RNAi and not a complete knockout of IL-17A. As shown in previous 
experiments, we detected around 70% reduction in IL-17A levels meaning that the 
transgenic mice were still able to retain around 30% of IL-17A. This led us to question 
whether the lack of protection is related to the residual IL-17A present in the transgenic 
mice. There might be a dose effect where, IL-17A when present even at low doses could 
still contribute to the disease. A protection from diabetes might be observed only with a 
complete removal of IL-17A.  
 
To address this question, we decided to test the systemic efficiency of the knockdown in 
the context of a second autoimmune disease, previously shown to be IL-17A dependent. 
IL-17A has already shown to play a significant pathogenic role in EAE, the experimental 
model for human autoimmune disease, multiple sclerosis (MS). IL-17A knockout mice 
are found have reduced frequency as well as severity of the disease242. We postulated that 
if the reduced IL-17A levels in our transgenic mice are sufficient to offer partial 
protection from EAE, they should by reason, be sufficient to deter type 1 diabetes as long 
as the disease is IL-17A dependent and follows the same disease parameters. This means 
that if our transgenic mice showed protection from EAE due to reduced IL-17A levels, 
then it should mean that autoimmune diabetes is not dependent on IL-17A.  
 
For this we decided to induce EAE in transgenic IL-17A KD mice. EAE is a model for 
brain inflammation and can be induced in susceptible strains by the injection of CNS 
antigens including MOG, MBP, PLP etc.  Depending on the antigen and the genetic 
makeup of the strain used, the animals can exhibit a monophasic form of the disease, a 
relapsing-remitting form of the disease or chronic EAE. The disease manifested is 
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 mediated by T helper cells and is characterized by central nervous system perivascular 
infiltration of lymphocytes and subsequent destruction of myelin sheath, which results in 
paralysis in mice243. The study that showed partial protection from EAE was done in 
C57BL/6 mice and showed a monophasic form of EAE. C57BL/6 mice are ideal for EAE 
studies as they are more susceptible to the disease while NOD mice are not. The disease 
in NOD mice is less severe. We have previously found the NOD mice in our colony to 
develop a relapsing remitting form of the disease. We find that the relapse is much more 
severe compared to the first acute phase of the disease.  
 
We set up small cohorts of WT and KD mice. These were injected with MOG peptide 
emulsified in CFA along with a shot of pertussis toxin. This was followed by another shot 
of pertussis toxin 2 days later. The mice were checked regularly for signs of the disease. 
At the end of the study, the mice were sacrificed and used for cytokine analyses. This part 
of the study was carried out in collaboration with Prof. Heinz Wiendl’s lab and was done 
by Stefan Bittner.  
 
4.9.1 Incidence and disease severity after EAE induction: 
 
We found that in the first acute phase, transgenic mice showed significant protection 
from the disease. This protection was abolished in the relapsing phase (Fig.15A). When 
we analyzed the cumulative disease burden, we found that the KD mice had significantly 
lower disease burden compared to the WT mice (Fig.15B). These observations indicated 
that the transgenic IL-17A KD mice were partially protected from EAE. This led us to 
believe that systemic IL-17A silencing should have been sufficient to impair autoimmune 
diabetes, had it been IL-17A dependent.  
  
4.9.2 Cytokine analyses of T cells from diseased mice upon recall response: 
 
To further investigate the possible reason for this partial protection, we took out cells 
from the diseased mice and analyzed them. We took out diseased splenocytes and 
restimulated them in vitro with CD3/CD28 dynabeads. The cells were cultured along 
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 with the beads for a period of 2 days and the IL-17A levels in the supernatants were 
measured by ELISA. We found that under maximal stimulation, KD cells were able to 
produce IL-17A, though at significantly lower levels than WT cells (Fig.15C). These data 
concurred with previous results.  
 
We also did a MOG recall response where we restimulated the cells in presence of MOG 
peptide and looked at the cytokine levels by ELISA. Upon MOG specific stimulation, 
both WT and KD MOG reactive cells produced comparable amounts of IFNγ (Fig.15D). 
While MOG reactive WT cells produced significant amounts of IL-17A, it was almost 
undetectable in cell supernatants from KD mice (Fig.15E). These data suggested that the 
partial protection from EAE, which we observed, seem to arise from the restricted ability 
of KD cells to produce IL-17A.  
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 Fig. 15 .A. Mean EAE scores of wt (n=6) and KD (n=6) mice. P=0.0014 B. Cumulative disease burden 
(individual disease scores were integrated for each mouse, group averages are shown with SEM, 
P<0.0001). C. IL-17 expression by the cells on stimulation with antibody- coated beads (P<0.0001). D. 
IFNg expression on restimulation of splenocytes from diseased mice with MOG35-55 peptide. E. IL-17 
expression on restimulation of splenocytes from diseased mice with MOG35-55 peptide. 
 
 
 
The results from MOG recall response supported the observations from the EAE 
experiment that systemic silencing of IL-17A was sufficient to impair IL-17A dependent 
autoimmunity. Since the KD mice were partially protected from EAE, the residual IL-
17A in the KD mice was not enough to contribute to EAE development. Following the 
same principle, the lack of any protection from diabetes that we observed could not be 
attributed to the residual IL-17A in the mice. All these observations lead to the 
conclusion that autoimmune diabetes is independent of IL-17A in autoimmune diabetes 
in the NOD mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139
 Generation of β- cell reporter mouse models & modulation of 
β- cell mass 
 
 
Generation of RIP-hluc mouse models 
 
Type 1 diabetes is caused by the autoimmune destruction of the beta cells, which produce 
insulin. As mentioned before, the disease is incurable and the symptoms usually manifest 
only after about 80% of the beta cell mass is already destroyed. There are several models 
available for type 1 diabetes including the NOD mouse that we use. The disease is 
usually followed by measuring the glucose in the blood or urine of the animals. Though 
this gives a clear idea of the disease incidence, glucose measurements do not give any 
idea regarding the extent of beta cell destruction. It is impossible to know the extent of 
autoimmunity unless we sacrifice the animal. Also none of this would allow us to 
accurately follow the autoimmune destruction over time relative to the disease symptoms.  
 
All these challenges paved way for beta cell imaging via one of the several imaging 
modalities currently available. There are several studies that have tried using MRI, PET, 
SPECT, CT and ultrasound imaging for non invasively assessing beta cell mass. A more 
relevant approach is bioluminescence imaging of beta cells. Several research groups have 
already generated beta cell specific bioluminescent reporter mice. These reports have 
indicated that this is a valid approach for following the disease in vivo in a non-invasive 
manner. Though there are already reporter mice expressing luciferase specifically in the 
pancreatic beta cells, none have been generated in any of the spontaneously diabetes 
susceptible models of type 1 diabetes. Hence we aimed to generate a beta cell reporter 
mouse model in the NOD background. In addition, we planned to integrate this with beta 
cell specific RNA interference to achieve modulation of beta cell mass. This will allow us 
to generate a NOD mouse model in which beta cell mass could be non-invasively imaged 
over time to study the process of autoimmune destruction. The simultaneous integration 
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 of RNAi would also allow us to study changes in beta cell mass resulting from the 
pancreas specific knockdown of candidate genes. 
 
We aimed to achieve this by using a construct in which the expression of luciferase and 
shRNA are under the control of a single beta cell specific promoter. We used RIP 
promoter as it has already been shown to drive beta cell specific expression of target 
genes. The construct also has a mir30 motif to facilitate the tissue specific expression of 
the shRNA. Hence we end up with beta cell specific luciferase expression coupled with 
the knockdown of the target gene. When we use shRNAs directed against known beta 
cell modulators, these shRNAs could cause the knockdown of modulators and the 
luciferase expression pattern over time could be used to identify the resulting changes in 
beta cell mass. We named the construct pRLM: R stands for the RIP promoter, l for 
luciferase, m for mir30 motif. 
 
4.10 Generation of pRLM construct: 
 
To generate the pRLM construct, we started with the pLBM construct. pLBM has a CMV 
promoter that drives the expression of GFP (Fig.1). To generate pRLM, we switched 
CMV and GFP for RIP and luciferase. RIP was cut out from a vector with Xba1. Hluc 
was cut out using Nhe1/Not1. CMV was cut out from pLBM using Xba1/ Nhe1 and GFP 
was cut out using Nhe1/ Not1. RIP was then cloned into pLBM between Xba1 and Nhe1 
(as Xba1 has compatible ends with Nhe1) while hluc was cloned between Nhe1 and Not1 
(Fig.1). This gave rise to pRLM vector with CMV/GFP replaced with RIP/hluc.  
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 Fig.1 
  
 
 
 
 
 
 
 
 
 
 
Fig.1. A schematic representation of pLBM vector. CMV/ GFP in pLBM was replaced with RIP/ hluc to 
obtain pRLM construct.  
 
4.11 Verification of specificity of pRLM construct in vitro: 
 
Once we generated the construct, the next step was to ensure that it contained the RIP and 
hluc sequences. The presence of the cloned in RIP-hluc sequence in the construct was 
verified by sequencing. The next step was to ensure the tissue specific activity of the 
promoter. We had to make sure that RIP promoter was active only in insulin expressing 
cells, i.e. primarily in the beta cells of the pancreas. For this we decided to use an in vitro 
approach involving rat insulinoma cell line INS-1E. These cells are beta cell tumor cells 
and are used as in vitro models for pancreatic beta cells. 
 
We decided to test the expression of RIP in 2 different cell lines- human embryonic 
kidney cells line 293F and INS-1E. If RIP activity is tissue specific, we should be able to 
see gene expression only in the INS-1E cell line and not in the 293F cell line. We used 
GFP signal or luciferase signal as markers for gene expression. 
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  To verify the tissue specificity of RIP-luciferase expression, virus samples were made 
with both RIP- GFP construct and a mixture of pLBM/ pRLM. RIP-GFP infected cells 
expressed GFP and hence the infected cells could be identified under a microscope or by 
FACS. But pRLM infected cells could not be identified under a microscope or by FACS 
due to their lack of GFP expression. This makes the estimation of infection efficiency 
impossible. To overcome this challenge, we used a mixture of pLBM/ pRLM to infect the 
cells. When using the mixture, half the cells would be infected with pLBM and the other 
half with pRLM. The pLBM-infected cells could be detected under a microscope and by 
FACS, owing to their GFP expression. This in turn could be used to determine the 
infection efficiency of the virus sample.   
 
293 cells and INS-1E cells were infected with either the RIP-GFP virus or the 
pLBM/pRLM virus mixture. Cells were cultured over time and the GFP expression was 
analyzed under the microscope and also by FACS. Luciferase expression by the cells was 
analyzed by luciferase assay at the end of the culture period after cell lysis.  
 
 GFP expression was observed only in the RIP- GFP infected INS-1E cells and not in 
293F cells. No green cells were observed in RIP-GFP infected 293F cells under the 
microscope. Both 293F and INS-1E cells infected with the pLBM-pRLM virus mixture 
were green under the microscope (Data not shown). To verify the GFP expression 
patterns observed under the microscope, infected cells were further analyzed by FACS. 
As before, GFP expression was observed only in the RIP- GFP infected INS-1E cells. But 
both cell lines showed significant GFP expression when infected with the pLBM/ pRLM 
mixture, though INS-1E cells seem to be better infected as more cells are GFP+ (Fig.2A).  
 
Next we analyzed luciferase expression by the virus-infected cells. After passive lysis, 
luciferase activity in the lysates was measured using Fluostar Optima. Only the cells 
infected with the pLBM/pRLM virus mixture showed detectable luciferase activity and 
the infected INS-1E cells showed a significantly higher expression compared to the 293F 
cells (Fig.2B). The difference could not be attributed wholly to a better infection, as it 
was more than a 17-fold increase.  
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Fig.2 
 
A.  
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Fig.2. A. GFP expression levels in virus infected cells. B. Luciferase expression by the virus infected cells. 
 
 
The expression patterns of both GFP and luciferase observed above indicated that RIP 
promoter activity was switched on only in beta cells while it remained inactive in the 
human embryonic kidney cells. The data showed that RIP promoter is tissue specific and 
could drive luciferase expression only in insulin expressing cells. 
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 4.12 Generation and genotyping of pRLM mice: 
 
Once we had the appropriate construct, the next step was to generate NOD mice with beta 
cell specific expression of luciferase. We generated lentivirus using the pRLM construct, 
as described before. The high titer pRLM virus was then injected into NOD embryos, 
which were then carried to term by pseudopregnant recipient mice. We were able to 
generate several founders. All of these were found to be viable and fertile and exhibited 
no gross phenotypic defects. 
 
pRLM mice could be genotyped by bioimaging but this was a labor-intensive process. 
Due to technical reasons, genotyping was done mostly by genomic PCR for hluc. We 
used 3 different primer sets and all of these were able to detect luciferase sequences in 
genomic DNA samples from mice. The different primer sets gave different sized products 
and we mainly used primer set 3 for genotyping.  
 
Tails were obtained from pups and tail DNA was isolated. Around 100 ng of tail DNA 
was used for genotyping. The PCR setup and program are detailed below. 
 
PCR setup: 
 
100 ng DNA 
0.5 µl fwd primer 
0.5 µl rev primer 
2.5 µl Dreamtaq buffer 
0.5 µl Dreamtaq polymerase 
1.0 µl dNTP 
Made up to a final volume of 25 µl with distilled water 
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 PCR Cycle: 
 
Temperature Time No: of cycles 
94°C  5 minutes 1 
30 seconds 
30 seconds 
94°C 
50°C 
72°C 1 minute 
 
5 
30 seconds 
30 seconds 
94°C 
58°C 
72°C 1 minute 
 
35 
72°C 10 minutes 1 
 
A representative gel from genomic PCR is shown in Fig.3. 
 
Fig.3 
 
 
 
 
 
 
 
 
Fig.3. Representative gel from luciferase genotyping. Positive control is in the far right lane. #20- #28 are 
pRLM+.  
 
4.13 Bioimaging of non-diabetic and diabetic pRLM mice: 
 
Once we had the pRLM mice, we decided to test the luciferase expression via luciferase 
bioimaging. For this we used pRLM+ mice identified from genotyping PCR. We selected 
a random pRLM+ mouse and imaged it along with a negative control. We injected the 
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 mice with the anesthetic along with the recommended amount of D-luciferin. The mice 
were then placed inside the machine and images were taken using the CCD camera. We 
found a robust signal from the + mouse while no signal was observed in the negative 
mouse.  
 
To our surprise, the signal we observed did not seem to pancreas specific. It was 
dispersed all over the abdomen especially under high signal intensity setting. At lower 
intensities, it appeared in kidney shapes on both sides though the signal was stronger on 
the pancreas side (Fig.4A). To try to localize the signal, we took out spleen and pancreas 
from the pRLM+ mouse after sacrificing it. We were able to observe luminescence from 
the spleen in addition to the pancreas. But the signal from the spleen was much lower 
than that from the pancreas (Fig.4B).  
 
This pattern of expression was observed in most pRLM+ mice (figures in following 
sections). The signal is not localized to the pancreas but is dispersed over the abdominal 
area and this is more noticeable under the high signal intensity setting. When the mice are 
imaged under low signal intensity setting, the signal is more localized though still not 
restricted to the pancreas. We also observed a signal from the thymus in the pRLM+ 
mice.  
 
All these observations made us question the specificity of luciferase expression. Hence 
we found it convenient when we had pRLM+ mice that had developed diabetes. We 
decided to image these diabetic mice to see if we could detect a signal even after the 
destruction of beta cells. We took the diabetic mice and imaged them alongside a non-
diabetic pRLM+ mouse. We observed very little signal from the diabetic mice even after 
a long exposure time under maximum intensity conditions (Fig. 4C). The difference was 
really significant in comparison with the non-diabetic + mouse. This observation gave us 
the first indication that although the signal we see in pRLM+ mouse did not seem to be 
localized to the pancreas; the signal might still be coming from the beta cells. Since we 
observed only a faint signal in the diabetic mice, it meant that luciferase expression was 
reduced over the course of the disease leading to an absence of signal once the mice were 
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 diagnosed as diabetic. Once the beta cells were destroyed, the signal went down 
supporting the notion of beta cell specific expression of luciferase.  
 
Fig.4 
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C.  
 
 
 
 
 
 
 
 
Fig.4. A. An image from a pRLM+ mouse in comparison with a negative mouse. B. Luciferase signal from 
the pancreas and spleen dissected out of a pRLM+ mouse. C. Images from 2 pRLM+ diabetic mice in 
comparison with a non-diabetic pRLM+ mouse, under different signal intensities.  
 
4.14 Specificity of luciferase expression: 
 
To further investigate the pattern of luciferase expression in the pRLM mice, we made 
RNA from the pancreata, spleens, kidneys, livers and thymi from 2 wt and 2 pRLM+ 
mice. We then did real time PCR to analyze the expression of luciferase in these organs. 
We found high expression of luciferase in the pancreata from the pRLM+ mice. 
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 Luciferase expression was also detected albeit at much lower levels in the thymi of the 
pRLM+ mice. No luciferase expression could be picked up from any of the other organs 
from the pRLM+ mice. None of the organs from the wt mice showed luciferase 
expression (Fig.5). The data indicated that in the pRLM+ mice, luciferase expression was 
limited to the pancreas with a limited expression in the thymus. None of the other organs 
situated in the abdominal area expressed luciferase indicating that the broad abdominal 
signal exhibited by the mice comes only from the pancreas and that the diffuse signal 
might be due to the really strong expression of luciferase by the beta cells. 
 
Fig.5 
 
 
 
 
 
 
 
 
 
 
Fig.5.  Luciferase expression in the organs from wt and pRLM+ mice.  
 
4.15 Phenotype of pRLM mice: 
 
pRLM mice were found to be viable and fertile and exhibited no gross phenotypic 
defects. We had used a transgene to generate these mice with pancreas specific 
expression of luciferase. We were able to ensure that they express luciferase in the 
pancreas. Hence it was crucial to ensure that the transgene integration and luciferase 
expression did not interfere with the normal metabolic processes in the transgenic mice. 
Hence we took groups of age matched pRLM+ and negative mice and compared their 
weights. We didn’t observe any difference between the two groups. We also looked at the 
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 fasting glucose levels of the mice. Again, the pRLM+ mice were found to have 
comparable fasting blood glucose levels to their WT counterparts (Fig.6 A&B). The data 
indicated that pRLM mice had a normal phenotype.  
 
Fig.6 
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Fig. 6. A. Weight in grams of pRLM+ mice in comparison with wt mice. B. Fasting blood glucose levels of 
pRLM+ mice in comparison with wt mice.  
 
 
4.16 Streptozotocin induced diabetes: 
 
     To further verify the specificity of the luciferase signal, we induced rapid immune 
independent diabetes in pRLM mice with streptozotocin. The mice were injected with 
high dose streptozotocin, which results in non-immune destruction of beta cells and 
development of diabetes within 2 days. The mice were imaged before the injections and 
regularly after the injections.  
 
     We observed robust signals from the mice before the start of the experiment. After 
injection, most mice developed diabetes and the signal went down rapidly over time 
(Fig.7A).  We also observed that a really small percentage of mice gave robust signals 
despite developing severe diabetes (Fig. 7A). The loss of signal in the majority of the 
mice upon development of diabetes further indicated that luciferase expression was beta 
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 cell specific. We could not find any reason for the persistence of signal in the minor 
population of mice that were severely diabetic.  
 
     We also looked at the phenotype of the mice during the course of STZ induced diabetes. 
Once the mice get diabetic, they lose significant amount of body weight. The blood 
glucose levels also go up owing to the severe destruction of beta cells leading to the 
reduction of insulin. Hence we decided to look at the weight loss and blood glucose 
levels in the sick mice. We found that both pRLM+ and negative mice lost comparable 
amounts of body weight upon developing the disease. The increase in blood glucose level 
was also comparable between the two groups of mice (Fig.7B). This further demonstrated 
that pRLM+ mice had a normal phenotype.   
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 Fig.7. A. Luciferase signal in pRLM+ mice over the course of STZ induced diabetes. B. Weight loss and 
blood glucose levels in pRLM+ and wt mice upon disease development. F denotes female mice while m 
denotes male mice in the experiment.    
 
4.17 Cyclophosphamide induced diabetes: 
 
Since we could see a loss of signal upon STZ induced diabetes, we decided to use another 
model, the cyclophosphamide induced diabetes. We injected both wt and pRLM+ mice 
with cyclophosphamide and imaged them regularly. As mentioned before, 
cyclophosphamide injections cause the mice to develop diabetes over a period of 2-3 
weeks. Since diabetes development after STZ treatment is immediate, CY system could 
be a better alternative to study the kinetics of the disease. We felt that the slower course 
of the disease with CY might help us see a gradual reduction of the signal over a longer 
time period. Data in Fig.8 show luciferase expression in one mouse, which developed 
diabetes 10 days after CY injection. We were testing and imaging the mice once a week 
and the diabetic mouse had shown a robust signal the week before and the signal reduced 
significantly the next week and hence we couldn’t obtain a clearer picture of the disease / 
signal kinetics. However, the experiment provided further evidence for the pancreas 
specific expression of luciferase. 
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Fig.8. Luciferase signal over the course of cyclophosphamide induced diabetes.  
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 4.18 Generation and genotyping of NOD-SCID pRLM mice: 
 
Once we had the NOD pRLM line, we felt that it would be useful to generate a NOD-
SCID pRLM line. We regularly do adoptive transfer studies using NOD-SCID recipients 
and felt that a NOD-SCID line expressing luciferase in the pancreas could be a really 
useful model. They could be used as a reporter mouse line to correlate beta cell 
destruction with specific immune cell subsets after adoptive transfer. The loss of 
luciferase expression could give a clearer picture regarding the effect of immune cell 
subsets on diabetes transfer, compared to urine glucose levels.   
 
To generate NOD-SCID pRLM mice, we crossed NOD pRLM mice with NOD- SCID 
mice. The F0 pups were NOD/ NOD-SCID heterozygotes. Brother-sister matings of 
pRLM+ F0 mice gave rise to mice that were NOD homozygotes, NOD-SCID 
homozygotes or NOD/NOD-SCID heterozygotes. pRLM+ NOD-SCID homozygotes 
were identified by genomic PCR and were back crossed into NOD-SCID WT mice to 
generate and maintain the NOD-SCID pRLM+ transgenic line.  
 
To identify NOD-SCID pRLM+ mice, we used two different genotyping PCR 
techniques. The hluc expression was identified using the genomic PCR described before. 
To distinguish between NOD and NOD-SCID strains from the F1 generation, we used a 
second genomic PCR followed by Alu1 digestion of the products. Upon digestion, NOD 
samples give 2 bands; one at 68bp and the other at 11bp while the NOD- SCID 
homozygous samples give 3 bands; at 38bp, 28bp and 11bp. Hence homozygous NOD 
samples gave only 2 bands while homozygous NOD-SCID samples gave 3 bands on the 
gel. Heterozygous samples gave all the 4 bands, making them easy to identify.   
 
We used FACS to verify the results from the genomic PCR.  NOD mice have T and B 
cells while these are absent or present at very low levels in NOD- SCID mice. Hence 
TCR and B220 were used as markers for NOD samples. NOD mice had TCR+ and 
B220+ populations while these were noticeably absent in the NOD-SCID mice samples. 
Representative PAGE gels from NOD-SCID genotyping showing NOD SCID 
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 heterozygous mice, NOD homozygous mice and NOD-SCID homozygous mice are given 
below (Fig.9A).  A representative FACS plot showing both NOD pRLM and NOD-SCID 
pRLM mice is also shown below (Fig.9B). 
 
Fig.9 
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Fig.9. A. Representative page gels showing NOD-SCID heterozygous mice (top left panel) and NOD and 
NOD-SCID homozygous mice (top right panel). B. T and B cell poluations in mice, as measured by flow 
cytometry (bottom panel). TCR staining is on X- axis and B220 staining on Y-axis. #22 and #24 are NOD- 
SCID homozygous.   
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 Modulation of β- cell mass 
 
Type 1 diabetes is caused by the autoimmune destruction of beta cells. As mentioned in 
the introduction, an efficient therapy would have to combine immune cell modulation 
with beta cell regeneration. There are several genes which have been reported to 
modulate beta cell mass. Some of them are found to enhance beta cell division while 
some others are negative regulators of beta cell proliferation. Knockdown of these 
negative regulators could take away the inhibitory effect and result in increased beta cell 
proliferation. This enhanced proliferation might be able to counter act the destruction of 
beta cells by the immune system. Hence this is a viable area of research in the search for 
a cure for type 1 diabetes.  
 
Following this line of thought, we wanted to be able to induce pancreas specific 
knockdown of negative regulators, the effects of which could then be monitored via 
luciferase expression. Menin is a transcription factor, which is found to act as a negative 
regulator of beta cell proliferation. Menin depletion has been shown to increase 
pancreatic islet cell proliferation226. Disruption of Men1 gene in pancreas has been 
reported to lead to the development of insulinomas along with increased serum insulin 
levels216, 217. Hence we chose menin as a target gene for beta cell mass modulation. We 
felt that the knockdown of menin could prevent or at least delay the development of 
diabetes. A partial reduction of menin, which can be achieved via RNAi, was a favorable 
strategy as a complete loss of menin has already been reported to be deleterious208. We 
could track the changes in beta cell mass resulting from menin KD via the expression of 
luciferase. Hence our plan was to generate menin- pRLM mice. These mice would have a 
pancreas specific expression of menin shRNA leading to a pancreas specific menin KD. 
The knockdown of menin should lead to enhanced beta cell proliferation which in turn 
should lead to enhanced luciferase signals. This increased beta cell proliferation might be 
able to protect the mice from diabetes development. The ideology is described in Fig.10.  
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 Fig.10 
 
 
 
 
 
 
 
 
 
 
Fig.10. Schematic representation of the technique. pRLM mice develop diabetes over time and hence the 
luciferase signal goes down relative to the beta cell destruction. However in menin KD/ pRLM mice, 
knockdown of menin results in increased beta cell mass, which might lead to a stable signal over time.  
 
4.19 Generation and validation of Menin constructs: 
 
shRNAs were designed against menin cDNA and were ordered from Sigma. shRNAs 
were first cloned into the pLBM vector to test their knockdown efficiencies. They were 
then subcloned into other vectors for in vitro studies. We decided to validate menin 
knockdown in vitro before generating a menin- pRLM mouse line. For this purpose, we 
used two insulinoma cell lines. These are tumor cell lines that are derived from 
insulinomas. Hence they can be used as in vitro models of pancreatic beta cells. Some of 
the experiments were done in the rat insulinoma cell line INS-1E while others were done 
in the mouse insulinoma cell line NIT-1. 
 
We didn’t have the mouse insulinoma cell line in the beginning of the project and hence 
we did the preliminary experiments in the rat insulinoma cell line. Since we had 2 
different models, i.e. the in vitro INS-1E cell line from rat and the in vivo NOD mouse 
model, we selected shRNAs which were expected to be active against both rat and mouse 
menin cDNA. These shRNAs could ideally knockdown menin in rat insulinoma cells as 
Menin KD/ pRLM Luciferase only (pRLM) 
 1 month 
3 months 
Beta cell destruction 
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 well as in mouse pancreas. We were later able to obtain mouse insulinoma cell line NIT-1 
and were able to select shRNAs active only against mouse menin cDNA. The generation 
of the constructs is detailed below.  
 
4.19.1 shRNA-pLBM Construct generation: 
 
     shRNA sequences were cloned into the pLBM vector first. The knockdown efficiencies 
of the shRNAs had to be tested and for this shRNA-pLBM constructs were used.  shRNA 
sequences were designed using the algorithm available at 
http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA244 . Most sequences were 
complementary to both rat and mouse menin sequences as in vitro experiments were 
being carried out in a rat and a mouse cell line and the in vivo model was a mouse strain. 
#2760 was not active against rat menin cDNA. The corresponding synthetic DNA 
oligomers were ordered from Sigma-Aldrich. The sequences were amplified by PCR to 
generate complementary strands and purified by agarose gel electrophoresis followed by 
gel extraction. Purified sequences were then digested with Xho I / Eco RI and then 
ligated with pLBM vector (Fig.1), cut with the same enzyme pair, which contains an 
ampicillin resistance gene.  
 
4.19.2 Subcloning: 
 
Menin shRNA sequences were sub cloned from pLBM (expressing GFP) into 2 different 
vectors. For each round of sub cloning, the menin shRNA sequence was cut out from 
pLBM using different enzyme sets and then cloned into the new vector. The constructs 
were then used to transform NovaBlue or DH5 cells and minipreps were made which 
were validated by sequencing. The minipreps were then used to make maxipreps. 
 
shRNA- Puro Subcloning:  
 
As mentioned earlier, our plan was to validate menin knockdown in vitro in insulinoma 
cell lines first. For this we had to infect cells with menin shRNA, select the infected cells 
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 and analyze their characteristics. It was important to restrict the analyses to shRNA-
infected cells as they represented the cells with menin KD. We decided to use puromycin 
selection to identify the shRNA-infected cells and use them for further analyses. Hence 
we had to clone in the shRNAs into a construct containing a puromycin resistance gene. 
The cells infected with this shRNA-puro constructs could be selected on puromycin 
ensuring that only menin KD cells survived and were used for in vitro studies.  
 
pLBM-puro contains a puromycin resistance sequence in place of the GFP sequence and 
so the cells containing the construct can be selected using puromycin. Hence the shRNAs 
were cloned into the pLBM-puro construct. The pLBM- menin shRNA constructs were 
digested with Nhe I/ Not I (to cut out GFP) and pLBM-puro construct was digested with 
the same enzyme pair to cut out puro sequence. The digested samples were run on gel, 
the menin backbones and the puro band were cut out from the gel and gel purified. The 
backbones were then ligated with the puro sequence to generate shRNA-puro constructs. 
 
 
shRNA- pRLM (RIP-hluc) Subcloning:  
 
To generate the menin-pRLM mouse line, shRNAs had to be cloned into the pRLM 
construct. Hence shRNAs were cut out from the pLBM vector and cloned into pRLM 
construct. pRLM contains a luciferase sequence in place of the GFP sequence under the 
control of RIP (Rat insulin promoter) promoter. The reporter is expressed only pancreatic 
cell lines and the cells can be imaged under the CCD camera. pRLM vector as well as 
pLBM- menin shRNA constructs were digested with Xba I/ Not I. The digested samples 
were run on gel and the menin shRNA backbones and RIP-hluc sequences were cut out, 
gel purified and ligated to generate shRNA-pRLM constructs. 
 
4.19.3 Luciferase Assay:  
 
The knockdown efficiencies of the different menin shRNA sequences were tested by 
luciferase assay. Since we had to test the menin KD in a rat cell line and a mouse cell 
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 line, we had to ensure that the shRNAs could cause the degradation of both rat and mouse 
menin mRNA. Hence we had to test menin shRNA sequences against both rat and mouse 
menin cDNAs and for this both the rat and mouse menin cDNAs had to be cloned into 
psi-check2 construct.  
 
4.19.4 Menin psi-check generation: 
 
    Rat and mouse cDNA for menin were obtained from Openbiosystems. The bacterial 
samples containing the cDNA were streaked onto LB-ampicillin plates; colonies were 
picked and used to make minipreps. Minipreps were pooled and then digested with either 
Sal I / Not I (mouse menin cDNA) or EcoRV / Not I (rat menin cDNA). The digested 
samples were run on gel and the bands corresponding to the cDNA was cut out and gel 
purified. The psi-check 2 vector (Fig.4) was cut with either Xho I/ Not I (for cloning in 
mouse menin cDNA) or Pme I/ Not I (for cloning in rat menin sequence) and PCR 
purified. The cDNA sequences were then ligated with the digested psi-check 2 vector to 
generate mouse menin psi-check and rat menin psi-check. 
 
9 different shRNA sequences were designed and cloned into the pLBM construct. All 
sequences except #2760 were selected based on their complementarity to both rat and 
mouse menin sequences. Hence most of the sequences were tested against both rat and 
mouse psi-check2 constructs. Most of the shRNAs were found to knock down menin 
expression significantly (Fig. 11A). We found that most shRNAs showed similar 
knockdown against both rat and mouse cDNA sequences indicating that they could cause 
similar menin KD in rat and mouse cells (Fig.11B).  
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Fig.11. A. Validation of menin shRNA silencing efficiencies by dual luciferase assay. Assay was done in 
triplicates against mouse menin cDNA. Results are representative of at least three independent experiments. 
B. Validation of menin shRNA silencing efficiencies against mouse (left) and rat (right) menin cDNAs. 
Assay was done in triplicates.    
 
 
4.20 in-vitro analyses using Ins-1E and NIT-1 Cells: 
 
As mentioned earlier, we wanted to validate menin KD in vitro in addition to the 
luciferase assay. For this, first we subcloned shRNAs into pLBM-puro construct. We 
used these shRNA-puro constructs to generate lentivirus. pLBM-puro was used as the 
control. INS-1E or NIT-1 cells were then infected with the different shRNA-puro virus 
samples or pLBM-puro and were selected on puromycin. shRNA infected cells which 
survived were then grown and the knockdown of menin was verified by western blot. 
Once we verified the knockdown of menin in the NIT-1 cells by #2760, we looked at the 
phenotypic features of the menin KD cells. All these are detailed below.  
 
4.20.1 Viral infection of cells:  
 
To investigate menin KD in vitro, we generated lentivirus carrying the either pLBM-puro 
or the different shRNA-puro constructs. INS-1E cells or NIT-1 cells were cultured on 24 
well plates and were infected with the virus. Since the cells had already been found to be 
really sensitive to transfection reagents, we added the virus suspension to the media in the 
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 absence of any transfection reagent. The cells were allowed to grow for around 3-4 days 
after which the media was replaced with media containing the optimum concentration of 
puromycin. This was already determined by titration as described in the method section. 
The cells were allowed to grow in puromycin media for 2 days. The media was removed 
and replaced with fresh puromycin media. Only cells, which got infected with the 
shRNA-puro virus, would survive. These cells were then allowed to grow confluent in 
the 24 well plates. The cells were then grown out into 6 well plates and finally to 10 cm 
plates or 25 ml TC flasks.  
 
The potency of the puromycin media was checked regularly by growing WT cells in the 
media and ensuring that they failed to survive in it. After selection of the cells, the 
puromycin media was then replaced with normal media and the cells were allowed to 
grow over time and they were used for the various analyses. Once the cells have been 
grown out into 6 well plates, they were grown in media lacking puromycin. This was to 
facilitate cell growth and division. The cells are then reselected on puromycin once in a 
while. This was done as both the cell lines used grow extremely slowly. INS-1E cells 
take at least 5-6 days to be confluent while NIT-1 cells take almost 9-10 days to become 
confluent.  
 
4.20.2 Analysis of menin knockdown: 
 
To verify the KD of menin in the shRNA-virus infected cells, we used western blot. Cells 
were infected with the various shRNA-puro constructs and were then selected on 
puromycin media. Cells were grown out into 10 cm plates and were grown until 
confluent. Cells were then lysed and resuspended in RIPA lysis buffer. The lysates were 
then subjected to western blot. We used a rabbit anti menin antibody from Bethyl 
laboratories. We found that this antibody could pick up menin signals from both rat and 
mouse cell lines as opposed to the menin antibody from Santa- Cruz Biotech. The blots 
were much clearer when using NIT-1 cells in comparison with INS-1E cells. Although 
most sequences showed good KD in the luciferase assay, they failed to cause any 
reduction in the protein levels as detected by western blot (Fig.12A). The only sequence 
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 that seemed to be able to knockdown the protein in NIT-1 cells compared to the control 
(pLBM-puro infected cells) was the 9th sequence tested, #2760 (Fig.12B). We also looked 
at the menin mRNA levels in the KD cells. To our surprise we found that 2760 infected 
cells seemed to have almost double the amount of menin mRNA compared to the control 
cells (Fig.12C). The difference was significant and consistent.  
 
Fig.12 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B.                                                                                  C. 
 
 
 
 
 
 
 
 
 
50 KDa 
75 KDa 
Ctrl #780 #803 #1447  #2213  #2079 
#2760 Ctrl men1 expression
Ctrl #2760
0
1
2
3
162
  
Fig.12. A. Menin protein expression levels in shRNA infected NIT-1 cells in comparison with control cells. 
B & C. Menin protein and men1 mRNA expression levels in #2760 infected NIT-1 cells in comparison 
with control cells.  
 
Western blot indicated that none of the sequences except #2760 could knockdown menin 
at the protein level in the insulinoma cells. This was quite surprising as most of them 
were found to be quite efficient in luciferase assay. The fact that menin KD cells had 
significantly higher levels of menin mRNA further complicates the picture.  
 
4.20.3 Analysis of phenotype of menin KD cells: 
 
Once we detected that #2760 could knock down menin in vitro, we looked at the 
phenotype of the KD cells. For this we infected NIT-1 cells either with pLBM-puro or 
2760-puro virus, cultured the puromycin selected cells and used them periodically for the 
various analyses.  
 
Menin KD has already been shown to result in an increased proliferation and reduced 
apoptosis. Hence we decided to look at the proliferation and apoptosis in the 2760-puro 
infected cells in comparison with pLBM-puro infected cells.  
 
4.20.3.1 Analysis of proliferation: 
 
Menin deficiency has been reported to enhance the proliferation of beta cells in mice. 
This enhancement is a really slow and long process that takes 5-6 moths to manifest and 
hence might not be recapitulated in vitro during the short-term study. The short duration 
might not be enough to pick up the slight increases in beta cell proliferation. Hence we 
decided to apply several complementary approaches to look at beta cell proliferation.    
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 eFluor-670 Staining:  
 
Equal numbers (1x106) of pLBM-puro (control) or 2760-puro infected cells were stained 
with eFluor670 proliferation dye and were plated out in culture at 1x105 per well. 
Staining of the cells was analyzed by FACS on days 0, 3 and 7. No difference was 
observed between the 2 samples on any of the time points analyzed (Fig. 13A). This 
might be because the increase in proliferation might not have been large enough to be 
picked up by eFluor staining.  
 
PI staining for DNA content: 
 
We felt that a minor difference in proliferation might be picked up better if we look at the 
cell cycles using PI. We plated out equivalent number of pLBM-puro and shRNA-puro 
infected cells in 24 well plates. The cells were grown over time. Cell cycle analysis was 
done using PI on several time points including days 2, 5, 8, 12 and 15. PI intercalates 
with the DNA and the signal is proportional to the amount of DNA in the cells. This 
technique could be used to distinguish between cells in G0/ G1 phase or G2/ M phase. 
The taller curve represents non-dividing cells while the shorter curve represents the 
proliferating cells (Fig.13B). No significant difference was observed between the control 
and shRNA infected cells on any of the time points analyzed. Similar percentages of 
proliferating cells were observed in both sample sets over the course of the study 
(Fig.13B).  Both menin KD and control samples had similar percentages of proliferating 
cells.  
 
Cell Counts: 
 
As an alternative measure, equal number of both control and shRNA infected cells were 
plated out and put in culture. Cell counting was done using FACS just to ensure that 
equal starting numbers were used. The cells were split after a few days and the cell 
numbers were counted again using FACS. There were 9 replicates for each sample. 
#2760-puro infected cells were found have an increased number of cells in comparison 
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 with the control (Fig.13C). This indicated that menin KD cells had an increased 
proliferation rate in comparison with the control cells. This is in line with previously 
published results. 
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 Fig.13. A. eFluor-670 staining of cells on days 0, 3 and 7 post plating. The blue and violet lines represent 
two control samples while the orange and red lines represent two #2760 infected samples. B. 
Representative data showing PI staining of cells on day 8 (left panel). The taller curve represents resting 
cells in G0/ G1 while the smaller curve on the right represents the proliferating cells in G2/ M. Percentages 
of proliferating cells in the samples over the course of the study (right panel). C. Total cell numbers in 
samples on day 7 post plating. 9 replicates of each sample were plated out and analyzed.  
 
 
Though we used 3 different techniques, we are not sure about the suitability of these to 
study the proliferation rates in beta cells. The techniques might not be appropriate to 
analyze proliferation rates when the differences are minor and occur over a long duration. 
Still the increased number of cells we observed in menin KD samples indicated that 
knockdown of menin could enhance beta cell division and even slight changes that 
accumulate over time could have a large cumulative effect in the end.  
 
4.20.3.2 Analysis of apoptosis: 
 
Overexpression of menin has been reported to increase apoptosis (70). Menin is believed 
to inhibit insulinoma formation by activation of caspase 8 involved in apoptosis (57). 
Hence it was quite interesting to see if menin KD cells showed a reduced level of 
apoptosis.  
 
Annexin/PI staining of serum- starved cells:  
 
Apoptosis was first analyzed in cells cultured in normal media. Cells were plated out at 
equal starting numbers and were allowed to grow in culture. They were taken out at 
different time points and stained with annexin PE. AnnexinV can bind to 
phosphatidylserine (PS) on the surface of cell membranes. PS is usually located on the 
inner surface of the cell membrane. But cells undergoing apoptosis translocate PS to the 
outer surface. This is an early apoptotic event and hence AnnexinV can be used to 
identify the cells, which start to undergo apoptosis. We failed to observe any difference 
between the 2 samples at any of the time points analyzed (Fig.14A).  
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Since we felt that we might be able to pick up minor differences better by analyzing the 
apoptosis in FCS starved cells, we cultured cells in starvation media lacking FCS and 
then analyzed the apoptosis using PI and annexin PE. In contrast to AnnexinV, PI can be 
used to detect late apoptotic events as it stains dead cells. We observed increased 
apoptosis in shRNA-puro infected cells compared to the control cells at all time points 
analyzed. This was in contrast to previous reports (Fig.14B).  
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Fig.14. A. AnnexinV staining of control and #2760 infected cells. The blue and violet lines represent 
control samples while the red and orange lines represent #2760 infected samples. B. AnnexinV/ PI staining 
of control and #2760 infected cells on days 3 and 5 (top panel). The blue and violet lines represent control 
samples while the red and orange lines represent #2760 infected samples. Percentages of AnnexinV+, PI+ 
and double positive cells in control and #2760 infected samples on days 3 and 5 (bottom panel).  
 
   
4.21 Generation of virus for embryo injection: 
 
Our in vitro results indicated that #2760 could induce the knockdown of menin and that 
menin KD cells exhibited slightly increased proliferation. Hence we decided to use this 
sequence to generate menin KD mice in the pRLM background. High titer virus was 
generated using the 2760-pRLM construct and will be used to generate Menin KD mice 
in the pRLM background. 
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Chapter 5 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
169
  
IL-17A silencing does not protect NOD mice from autoimmune 
diabetes 
 
 
Ever since their discovery, Th17 cells have been intensely studied. The discovery that IL-
23 and not IL-12 is critical for autoimmunity110 led to the idea that Th17 cells are 
responsible for autoimmune diseases as opposed to Th1 cells. A number of studies 
verified this idea as the cytokines secreted by this group of cells were discovered to be 
pathogenic in several autoimmune diseases. IL-21 is found to be pathogenic in several 
autoimmune disease models including EAE and CIA245. IL-21 is also found to be critical 
for the development of type 1 diabetes246, 247. IL-17A is found to be pathogenic in a 
variety of autoimmune conditions including EAE, CIA and chronic colitis242, 245, 261. The 
role played by the other Th17 effector cytokines is less well established. All these data 
strongly point to Th17 cells being extremely pathogenic. But they are also found to play 
critical roles in defense against extracellular bacteria and fungi. The absence of Th17 
subset seriously compromises the immune system with the organism being severely 
susceptible to bacterial and fungal infections149-157. Th17 cells are mainly characterized 
by their signature cytokine, IL-17A. Currently, most of the effects associated with Th17 
cells can be traced back directly to this effector cytokine.  
 
IL-17A deficient mice are found to be partially protected from both CIA and EAE. This 
has led to the belief that this cytokine might play a pathogenic role in other autoimmune 
diseases including type 1 diabetes. Though several studies have hinted at a pathogenic 
role for IL-17A in autoimmune diabetes171-176, the findings are not really conclusive. We 
felt that an IL-17A KD transgenic line could provide valuable insight into the role played 
by this cytokine in the context of autoimmune diabetes. A partial reduction of the protein 
better reflects a normal physiological state. We used a construct containing GFP along 
with the shRNA and used GFP expression as a marker for the KD.  
 
170
 We generated an IL-17A KD transgenic mouse, which was found to express two distinct 
populations of GFP+ cells. One population was found to have a lower MFI than the other. 
They were designated as ‘low’ and ‘high’ respectively. It has already been shown that in 
some transgenic mouse lines, different cell subsets express different levels of GFP248. But 
this didn’t seem to be the case with our founder as all cell lineages had almost 100% of 
the cells expressing GFP but all exhibited the 2 cell populations. Once we bred the 
founder, we saw that the pups had only one GFP population, either the high or the low. 
We further bred the ‘high’ and ‘low’ mice as two separate transgenic lines and found that 
all pups from a ‘high mouse’ had cells with high GFP expression while all pups from a 
‘low mouse’ had cells with low GFP expression. This was found to be true in all future 
generations. When we looked at the integration using Southern blot, we found that both 
the ‘high’ and ‘low’ mice had a single integrant but at different sites in the genome. All 
these data pointed to the possibility that the IL-17A KD founder was a chimera and that 
the 2 virus copies segregated in F0.  
 
Since both the ‘high’ and ‘low’ mice differed in their GFP expression intensity, there was 
a possibility that they had different levels of KD. But the analysis of IL-17A levels in 
differentiated Th17 cells showed that both lines exhibited similar IL-17A reduction, 
despite the difference in the GFP expression. Hence the only difference between the 2 
lines seems to the integration site and the GFP expression pattern. Hence the terms ‘high’ 
and ‘low’ refer only to the GFP expression and not to the level of IL-17A KD in these 
mice.  
 
We were able to see significant KD of IL-17A in vitro and ex vivo. In vitro differentiated 
transgenic Th17 cells produced vastly reduced amounts of IL-17A. Both IL-17A protein 
and mRNA levels were significantly reduced. We were able to see a tight correlation 
between the reduction in both mRNA and protein levels. Though we could find a KD in 
vitro, this might not have been the case in vivo. It has already been suggested that all the 
conditions required for a full effector Th17 differentiation might not be present in vitro. 
This is suggested to the responsible for the incredible plasticity observed with in vitro 
differentiated Th17 cells239. Hence it was possible that though transgenic Th17 cells 
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 differentiated in vitro could not produce significant amounts of IL-17A, under in vivo 
conditions, these cells could achieve full effector function with IL-17A secretion to the 
full capacity.  
 
To investigate this possibility, we decided to look at the IL-17A levels in diseased 
pancreas ex vivo. We took out islets from the pancreas of diseased mice and analyzed the 
cytokine levels by qPCR. We could detect IFNg at quite high levels indicating a role for 
this cytokine in the disease process. On the other hand, we could detect IL-17A only at 
very low levels in a minor proportion of the mice and the expression was found to be 
quite variable. We feel that had this cytokine played a critical role in autoimmune 
diabetes, we should have been able to pick up IL-17A at higher levels. We found a high 
and comparable expression of RORgt in both WT and KD mice. Since RORgt expression 
was already found to be unaffected by the integration of the transgene, we looked at the 
islet IL-17A levels relative to the RORgt expression in the islets. We found that 
compared to WT beta cells, we could detect vastly reduced amount of IL-17A in the islets 
from KD mice. The degree of reduction was found to be quite comparable to the 
reduction observed in in vitro differentiated transgenic Th17 cells. This observation led to 
believe that the in vitro KD we observed seemed to reflect the knockdown in vivo.  
 
Th17 cells produce a number of effector cytokines, in addition to IL-17A. These include 
IL-17F, IL-21 and IL-22119. Th17 cells are also characterized by their lineage specific 
transcription factor, RORγt130, 131. For the purpose of the study, it was critical to ensure 
that the transgene did not disrupt the Th17 pathway or the expression of the other 
cytokines. For this we analyzed the levels of RORgt, IL-17F and IL-21 in both in vitro 
differentiated Th17 cells and ex vivo islets. We found comparable amounts of both 
cytokines in both WT and KD mice at both mRNA and protein levels. This was the case 
with both differentiated Th17 cells and the islets. RORgt levels were also quite similar 
between the WT and KD samples. We did not look at IL-22 as this is considered to be a 
minor Th17 cytokine. All these data suggested that the integration of the transgene and 
the knockdown of IL-17A was specific and did not disrupt Th17 pathway in the 
transgenic mice. 
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For the purpose of the study, we had to ensure that Th1 differentiation in the transgenic 
mice was unaffected. Th17 and Th1 pathways are both believed to be involved in 
autoimmune pathology and it has been quite difficult to specify their distinct roles in 
autoimmune diseases. Th17 cells are also found to quite plastic with the ability undergo 
conversion to alternative phenotypes and are reported to acquire Th1 phenotype over 
time. There is some evidence indicating that in vitro differentiated and purified Th17 
cells can undergo conversion into Th1 like cells once they are transferred into 
immunodeficient recipients173. Hirota et al.239 recently showed that Th17 cells are 
characterized by the differentiation origin rather than the production of IL-17A. They 
discovered that Th17 cells can undergo alternative states depending upon the disease 
environment. Most Th17 studies have observed the development of IL-17A/ IFNg double 
positive and IFNg single positive cells in purified Th17 cell populations. Hence for the 
purpose of this study, we had to ensure that loss of IL-17A did not enhance Th1 pathway 
or Th17 conversion. For this we looked at IFNg levels in both in vitro differentiated Th1 
cells and ex vivo pancreatic islets. We found that KD cells had similar levels of IFNg 
compared to WT cells indicating that reduced IL-17A levels did not lead to increased 
IFNg levels. This suggested the absence of Th17 conversion or enhancement of Th1 
pathway.  
 
Once we had mice in which at least 70% of IL-17A is eliminated, we analyzed the 
diabetes incidence in these mice. We used 3 different models of diabetes. This was done 
to foolproof the observations. We observed that KD mice developed spontaneous 
diabetes similarly to WT mice and that the disease frequency and kinetics were quite 
similar. To double-check the results, we used cyclophosphamide-induced diabetes. 
Cyclophosphamide can accelerate diabetes development in insulitic mice and cause a 
synchronous disease around 14 days after the injection. We did the experiment twice and 
both times, we observed that the transgenic mice were as susceptible to disease 
development as WT mice. All these data led us to believe that reduced IL-17A does not 
protect the mice from autoimmune disease. To check whether transgenic splenocytes 
could transfer diabetes, we transferred splenocytes from diabetic NOD mice into NOD-
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 SCID recipients. None of the mice that got WT splenocytes got sick while 3 of the mice 
that received transgenic cells developed diabetes. Though the general lack of disease 
development suggested that the experimental setup didn’t work properly, the fact that 3 
of the mice that got transgenic cells developed the disease indicated that transgenic cells 
could transfer diabetes despite reduced IL-17A production. The data from the diabetes 
incidence studies together suggested that reduction of IL-17A does not protect NOD mice 
from autoimmune diabetes. This observation indicated that IL-17A might not be critical 
in the development of type 1 diabetes. 
 
One of the major concerns raised regarding our experimental system is the presence of 
residual amounts of the protein in the transgenic mice. Since we use knockdown mice as 
opposed to knockout mice, the protein is not removed completely. The KD cells are 
capable of IL-17A production, though at reduced levels. As shown before, there is around 
30% of IL-17A still left in the transgenic mice. One of the major questions was whether 
this residual amount is capable of contributing to diabetes development. To investigate 
this possibility, we used another model of IL-17A dependent autoimmune disease, EAE. 
It has already been shown that IL-17A deficient mice are partially protected from EAE 
with the disease being less severe and occurring with less frequency242. We postulated 
that if the KD in the transgenic mice is sufficient to protect them from EAE at least 
partially, then it should also be sufficient to offer at least partial protection from 
autoimmune diabetes. This depended on one assumption that both EAE and T1D are 
controlled by the same parameters.  
 
We induced diabetes in the IL-17A KD mice by the injection of MOG peptide emulsified 
in CFA. We have previously found mice in our colony to develop a relapsing remitting 
form of the disease.  We found that the transgenic mice showed significant protection 
from EAE during the fist phase of the disease but this protection was absent in the 
relapse. The transgenic mice had a significantly lower cumulative disease burden 
compared to the WT NOD mice. In our experimental setup, the overall disease severity in 
the mice was low. In the previous study242, the mice developed a severe form of EAE. 
We believe that this can be attributed to the strain differences. Iwakura et al. had done the 
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 EAE study in C57BL/6 mice. These mice develop a monophasic disease and are much 
more susceptible to EAE compared to NOD mice.  
 
Although the disease severity was low, we observed a clear, albeit partial protection in 
the IL-17A KD mice in comparison with the WT mice. This indicated that the KD 
observed in the transgenic mice is sufficient to impair IL-17A dependent autoimmunity. 
Though the mice still retained around 30% of IL-17A they were still partially protected 
from the disease, consistent with results from the IL-17A deficient mice. Hence, had type 
1 diabetes been IL-17A dependent, we would have expected to see at least a partial 
protection from the disease in the transgenic mice. The lack of protection from diabetes 
we observed hence suggested that type 1 diabetes is not dependent on IL-17A and thus 
the removal of it has no effect on the development of the disease. 
 
To investigate the reason for the partial protection from EAE we observed, we took out 
diseased splenocytes from mice and did an in vitro recall response. We stimulated them 
in vitro either non-specifically with beads or specifically with MOG peptide. We found 
that KD cells could produce IL-17A under maximal stimulation though at reduced levels 
compared to WT cells. Upon MOG specific stimulation, both WT and KD cells produced 
comparable amounts of IFNg indicating that the partial protection was not related to 
levels of this cytokine. But KD cells failed to produce any IL-17A in response to MOG 
stimulation while WT cells produced significant amounts of this cytokine. This 
observation suggested that the partial protection seen might have been due to the inability 
of KD cells to produce IL-17A.  
 
We generated a mouse model with vastly reduced amounts of IL-17A. Th17 lineage in 
the mouse was uncompromised. Though the transgenic mice produced significantly lower 
amounts of IL-17A, they were not protected from autoimmune diabetes. The reduction in 
IL-17A was sufficient to protect the mice from EAE, an IL-17A dependent autoimmune 
disorder; indicating that systemic silencing was quantitatively sufficient to impair 
autoimmunity in an IL-17A- dependent context. Our results led us to conclude that 
autoimmune diabetes in the NOD mouse is independent of IL-17A. This does not 
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 preclude the possibility that Th17 cells contribute to type 1 diabetes development. Th17 
cells have been found to transfer diabetes into NOD-SCID mice but only after they 
converted into a Th1 like phenotype. anti-IL-17 was found to be unsuccessful in this 
model especially in young mice172, 175. Though Arif et al.263 recently reported a crucial 
role for IL-17 in autoimmune diabetes, the scope of their results in clarifying the role of 
IL-17A in autoimmune diabetes is limited. The observation of Th17 associated factors in 
the islets was obtained from a single case report and they failed to observe any 
proapoptotic effect for IL-17A on its own.  Though they were able to observe increased 
IL-17A reactivity (54% as opposed to 8%) in type 1 diabetes patients, they observed an 
increased IFNγ reactivity (62% as opposed to 13%) as well. The pattern of IL-17 
reactivity was quite similar to the IFNγ response and the number of IL-17+ autoreactive 
cells was found to be fewer than that of IFNγ+ cells.  There is the added problem that 
their assay was unable to distinguish dual secreting cells from single secretors which 
meant the IL-17 reactivity they observed could have been from double producers i.e. cells 
which produce IL-17 and IFNγ.  
 
Munegowda et al.264 on the other hand observed that Th17 cells on their own could not 
cause diabetes and that they stimulated CD8+ CTLs which could then kill beta cells 
through the perforin pathway and lead to diabetes development. This was in contrast to 
EAE where CD4+ Th17 cells induced EAE and Th17 activated CTLs could not.  They 
concluded that T1D is directly mediated by Th17 stimulated CTLs whereas CD4+ Th17 
cells play a crucial role in EAE pathogenesis by Th17 cytokine mediated tissue 
inflammation. The results from this study could be reconciled with ours in that a classical 
Th17 response involving IL-17 does not seem to be crucial for type 1 diabetes 
development. IL-21 has been reported to be indispensable for the development of 
diabetes in the NOD mouse model246, 247. This cytokine is found to play a crucial role in 
Th17 proliferation and is one of the effector cytokines produced by this subset. Hence 
Th17 cells might still play a role in diabetes development through effector mechanisms 
distinct from IL-17A production. But our results demonstrate that a characteristic Th17 
response that involves IL-17A is not critical in all autoimmune diseases, at least not in 
autoimmune diabetes. 
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So far most studies have seen an extremely close relationship between Th17 cells and IL-
17A that all effects observed with Th17 cells have been attributed to this cytokine. IL-
17A has come to define Th17 lineage and its functions. Our study seems to show that an 
IL-17A dependent response seemed to be involved in other autoimmune diseases is not 
important in type 1 diabetes. Recently it was shown that Th17 cells adopt alternate 
expression profiles in different disease states239. Th17 cells were found to switch off IL-
17 production and switch on IFNg production in chronic inflammatory conditions like 
EAE. But in an example of acute infection i.e. C. albicans, Th17 cells failed to take up 
alternate fates although they switched off IL-17 expression. These observations raise the 
idea that the functional fate of Th17 cells is not invariably linked to IL-17 expression by 
these cells. Hence it seems that the role played by IL-17A might be overestimated. Rather 
than concentrating on an anti-IL-17A therapy, we should follow a broader approach, as 
this might be better applicable to a wider range of disease conditions.  
 
Further work needs to be done to determine whether Th17 cells play a contributing role 
in autoimmune diabetes via any of the alternate effector mechanisms. It would be 
interesting to analyze the role of IL-23 in the disease process. This was a line of research 
that we started on but unfortunately could not follow up. IL-23 is found to be pathogenic 
in several autoimmune diseases and this pathogenecity has been linked to Th17 cells. IL-
23 has been found to be critical for the long-term survival and maintenance of Th17 
subset. It is believed to impart pathogenic potential to Th17 cells. Recently two groups249, 
250separately put forward the idea that IL-23 imparts pathogenic potential to Th17 cells 
via GM-CSF. They found that IL-23 could induce the production of GM-CSF in T cells 
and that GM- CSF was critical for the ability of Th17 cells to drive inflammation in the 
CNS in EAE. In vitro activated T cells required GM-CSF to passively transfer disease 
and GM-CSF neutralization upon onset of disease symptoms could block disease 
progression251. Hence it would be interesting to see whether loss of IL-23/ GM-CSF can 
protect mice from diabetes. It would also be interesting to see whether loss of the Th17 
transcription factor RORgt could have an effect on the disease process. These are all 
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 several avenues that can be pursued to further unravel the role, if any, of Th17 cells in the 
development of type 1 diabetes.  
 
 
Generation β- cell reporter mouse models and modulation of 
β-cell mass 
 
 
An efficient therapy for type 1 diabetes would have to involve beta cell regeneration. It 
would also have to involve the elimination of autoreactive immune cell specificities to 
ensure the long-term survival of implanted or regenerated beta cells. One of the main 
disadvantages of studying the disease in humans is the non-accessibility to the diseased 
organ, the pancreas. Hence the disease is intensively researched in animal models in 
which the diseased pancreas can be obtained upon sacrificing the animals. Even then, it is 
hard to follow the course of the disease and this challenge has given way to the search for 
non-invasive imaging techniques for analyses of pancreatic beta cell mass. This would 
allow the estimation of beta cell mass and autoreactive destruction in the same animal 
over the course of the disease. This strategy might be able to provide vital clues regarding 
the dynamics of beta cell mass during various stages of the disease. This in turn could 
facilitate the development of a successful cure or therapy option.  
 
A number of studies have tried several beta cell imaging modalities PET, CAT, 
bioimaging etc. Jirák et al.252 labeled beta cells with super paramagnetic iron oxide 
particles (SPIOs) and they found that the labeled islets could be detected and followed in 
vivo in a rodent model using MRI. Specific radiolabeled tracer molecules have been used 
to image transplanted islets by PET and SPECT253. But all these techniques have their 
own advantages and disadvantages. We chose luciferase bioimaging due to several 
reasons. It is non-toxic to the cells making it ideal for long-term studies. Using luciferase 
imaging to follow beta cell death during diabetes is more desirable than using fluorescent 
reporters like GFP. This is because the luciferase reaction requires ATP, which can be 
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 present only in living cells and hence the signal better represents the living beta cell mass. 
On the other hand, GFP signal could be observed even after the cells are dead and hence 
the total signal would represent the whole beta cell mass including the dead cells. Hence 
using luciferase imaging to assess and follow beta cell mass presents a valuable research 
tool.  
 
Luciferase imaging has already been used to assess beta cell mass in mouse models. Lu Y 
et al.254 successfully used bioluminescent imaging to monitor islet graft survival over 
time. Several research groups have already generated transgenic mice expressing 
luciferase in the beta cells and these studies show a clear correlation between the signal 
intensity and the beta cell mass255- 257. Park et al.256 generated transgenic mice expressing 
firefly luciferase under the control of mouse insulin 1 promoter in the CD1 background. 
They found that the mice had normal islet architecture and that the luciferase expressing 
beta cells could be readily imaged even after transplantation into NOD-SCID mice. These 
studies suggest that luciferase expression via viral transduction of reporter genes has no 
deleterious effect on beta cell development and maintenance. We felt that it would be 
quite useful to generate beta cell reporter mice in the context of a spontaneous diabetes 
model like the NOD mouse. These reporter mice would enable us to follow beta cell mass 
changes over the course of diabetes development. We also generated luciferase reporter 
mice in the NOD-SCID background for use in adoptive immune cell transfer 
experiments.  
 
We decided to use the RIP promoter as it has been better validated than the mouse insulin 
promoter. We found the RIP-hluc construct to be specific and used this to generate the 
reporter mice. We found our mice to express luciferase, though this expression was 
dispersed around the abdominal area. We found an additional signal in the thymus, which 
could be explained owing to insulin expression in the thymus262. When we took out 
organs from the luciferin injected mice, we observed a signal albeit slight, from the 
spleen in addition to pancreas. The luciferase signal from the spleen was quite puzzling, 
as rat insulin promoter should restrict the expression of hluc to insulin expressing cells. 
We observed this disperse signal pattern in most of our pRLM mice even at the lowest 
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 signal intensities and shortest exposure times. The pRLM+ mice exhibited no gross 
defects and behaved similar to wt mice under both normal and experimental conditions. 
 
The first indication that despite its disperse nature, the signal could be specific to beta 
cells came when we imaged severely diabetic pRLM+ mice. Luciferase signals were 
barely detectable in the diabetic mice indicating that the signal was beta cell specific. To 
further clarify the origin of the signal, we used 2 different models of induced diabetes. 
We injected mice with STZ or CY and found that in both cases, mice lost their luciferase 
signal upon developing diabetes. Hence despite the strong abdominal signal before the 
induction of diabetes, the signal was significantly reduced / lost upon the loss of beta 
cells. These data strongly supported the beta cell specific expression pattern of luciferase. 
We could detect significant levels of luciferase mRNA only in the pancreas of the 
pRLM+ mice. Smaller luciferase levels were detected in the thymus while no expression 
was observed in any of the other organs tested. This further proved that luciferase 
expression was pancreas specific. In light of all the data, we believe that in our mice, 
luciferase expression is limited to insulin producing cells in the pancreas and the thymus. 
We believe that the broad abdominal signal we observe is due to a really strong luciferase 
expression. This strong signal even at the lowest signal intensity setting and shortest 
exposure means our imaging machine is severely limited.  
 
Recently, Yong et al.258 reported the generation of MIP-TF transgenic mice in the 
C57BL/6 background that have a MIP driving the expression a trifusion (TF) protein of 
three imaging reporters including a luciferase. They were able to observe a progressive 
reduction in bioluminescence preceding hyperglycemia, upon low dose STZ treatment. In 
their discussion, they reported that they are currently breeding the TF gene into the NOD 
mouse background.  This approach is less ideal compared to our approach as crossing 
back a gene from the C57BL/6 background into the NOD background would always 
introduce linkage associated genes in addition to the desired gene from the C57BL/6 
background into the NOD background. Hence we feel that our mice are better suited as a 
reporter model of spontaneous diabetes. As part of the project, we also generated a NOD-
SCID pRLM mouse line. Towards this purpose, we crossed a NOD pRLM+ mouse with 
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 NOD-SCID wt mice. We then mated the heterozygous pups to obtain NOD-SCID 
homozygous pRLM+ mice. We then selectively mated the homozygous pRLM+ mice 
back into NOD-SCID background to obtain and maintain the NOD-SCID pRLM line. We 
believe these mice could prove useful in the field of adoptive transfer research studies.  
 
Originally we had planned to generate menin KD mice in the pRLM background. Menin 
is a tumour suppressor, the inactivation of which has been described to cause 
insulinomas. Hence a pRLM-menin knockdown mouse line would be an ideal model to 
study beta cell modulation using bioimaging. We aimed to generate a pRLM construct 
carrying an efficient menin shRNA and use the construct to generate a transgenic mouse 
line. Towards this purpose, we decided to validate the shRNA sequences in vitro in 
insulinoma cell lines first before proceeding to transgenic mice generation. We cloned in 
a total of 9 different shRNAs, most of them active against both rat and mouse menin. 
This was done intentionally as the in vitro experiments were done in both rat and mouse 
cell lines. During the early days of the project, we didn’t have the mouse cell line NIT-1 
and hence had to choose shRNA sequences which could knockdown menin in the rat 
insulinoma cell line INS-1 and which could also knockdown menin in the NOD mouse 
line, should we generate one.  
 
All the shRNAs showed considerable knockdown efficiency in a luciferase reporter 
assay. These constructs were then used to infect insulinoma cells and the infected cells 
were subjected to western blot to analyze the knockdown of menin. This was a difficult 
premise as menin expression is markedly reduced in insulinoma cells221. However we 
were able to detect a band at around 70KDa, the reported size of menin. To our surprise, 
none of the first 8 shRNAs tested could knockdown menin in vitro. None of the cells 
infected with these shRNAs showed a reduction in menin levels. This was quite 
surprising as most of them showed very good knockdown efficiencies in the luciferase 
assay. Karges et al.203 have reported the existence of 2 different isoforms of menin; the 
long λ transcript (2.4 kb product) and the short σ transcript (2.0 kb product). One of the 
possible reasons for the contradiction we observed might be that the shRNA sequences 
could have led to the degradation of only one of the isoforms and the other one might 
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 have compensated for the loss. Still it does not fully explain how 8 different sequences 
could not knockdown menin sufficiently.  
 
We tested #2079, our 9th sequence as Yokoyama et al.259 found it effective in knocking 
down menin. Though our design algorithms had recommended this sequence before, we 
hadn’t tested it, as it is not active against rat menin. As all the shRNA sequences tested, it 
showed good knockdown efficiency in the luciferase assay and was used to infect mouse 
insulinoma cells. #2760 infected cells showed a considerable reduction in menin protein 
expression in western blot. We isolated RNA from the infected cells and analyzed men1 
mRNA levels by qPCR. We were amazed to see that #2760 infected cells had almost 
double the amount of men1 mRNA compared to control cells. This could be explained 
when the shRNA causes translational repression, not mRNA degradation and when the 
target protein is regulated by a feedback loop. In this scenario, the protein at sufficient 
levels prevents translation and transcription of its gene and when the shRNA prevents 
translation of the gene product, the feedback loop leads to increased gene transcription to 
compensate for reduced protein levels and leads to enhanced mRNA levels of the gene. 
Menin has already been reported to be regulated via a feedback loop260 and hence fits the 
system perfectly.  
 
We then looked at the proliferation and apoptosis levels in the menin knockdown cells. 
We couldn’t pick up any difference in the proliferation levels using eFluor 670 staining. 
When we stained for cell cycle using propidium iodide, there was no significant 
difference between menin KD cells and control cells in any of the time points studied. 
However once we started with equal cell numbers, we could see an increased number of 
cells in the menin knockdown sample compared to the control sample, after few days in 
culture. Though we analyzed proliferation rates using 3 different techniques the results 
were contradictory. We believe that this might be due to the limited suitability of the 
techniques in the context of our experiment. Menin knockdown is found to cause 
insulinomas in mice but only over a very long period of time and hence the enhancement 
of proliferation is slight and cumulative over time. The experimental techniques we used 
might not be sensitive enough to pick up minor differences. The outcome is also 
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 complicated by the fact that the knockdown cells were analyzed over a maximum period 
of 15 days, which might not be long enough for the differences to be apparent. However 
the difference in cell numbers we observed gives us the indication that there is a trend for 
increased cell numbers upon menin knockdown.  
 
We analyzed the apoptosis levels in the knockdown cells using annexin/ PI double 
staining. Annexin would be able to pick up the early apoptotic cells while PI identifies 
late apoptotic cells. We couldn’t see any difference between the samples when we stained 
them. We then decided to use serum starved cells for further experiments as we felt that 
the increased apoptosis in serum starved cells might better magnify slight differences 
difficult to be noticed. Contrary to previous studies, we observed an increased level of 
apoptosis in our menin knockdown cells. Overexpression of menin in insulinoma cells 
has been reported to lead to an increased rate of apoptosis189. Hence logically, 
knockdown of menin should lead to a decreased rate of apoptosis. However, we observed 
an enhanced apoptosis in menin knockdown cells that were serum starved and this effect 
was not noticeable in cells grown in serum containing media. Similar to proliferation, the 
cells were grown over a period of 12 days and analyzed at regular intervals.  
 
Sayo et al.189 were able to observe significant enhancement of apoptosis and reduction of 
proliferation in insulinoma cells transfected with menin overexpression constructs. 
However the transfection of cells with menin constructs would lead to a stronger effect 
compared to infection with virus containing menin constructs. Transfection of cells 
usually results in the uptake of several constructs by the same cell leading to a magnified 
effect. During infection of cells with virus containing the construct, each cell is infected 
with a single virus and hence a single construct, thereby eliminating the possibility of a 
magnified effect.  This inherent contraction in the methods applied could to some extent 
explain the lack of or minor effects we observed in contrast to Sayo et al.189 The other 
contributing factor as mentioned before could be the lack of sensitivity of the 
experiments employed as well as the inability to pick up minor changes, which could 
have a cumulative effect over time.  
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 To summarize, we generated two beta cell reporter mouse lines; one in the NOD 
background and the other in the NOD- SCID background. We believe that these would be 
extremely useful in T1D research.  These mouse lines would allow the beta cell specific 
knockdown of target beta cell modulators and bioimaging would enable the follow- up of 
disease in the transgenic mice in a non- invasive manner.  We also identified an shRNA 
that could knockdown the beta cell modulator menin and hope to generate a menin 
knockdown mouse line in the pRLM background to study the effects of beta cell 
modulation in the development of spontaneous diabetes.  
 
In conclusion, type 1 diabetes affects around 0.5% of the population in developed 
countries and the incidence rates have been going up over the years. The destruction of 
beta cells is irreversible and the current therapy available to patients only manages the 
symptoms and does not prevent the associated pathological manifestations. The patients 
need lifelong therapy and intensive research is being carried out to identify ways to 
eliminate autoimmune responses directed against pancreatic beta cells and to replace or 
regenerate beta cells. Our work aimed at analyzing the role of a pro-inflammatory 
cytokine IL-17A in type 1 diabetes development and also in generating a beta cell 
reporter mouse line in the NOD background. We generated IL-17A KD mice in the NOD 
background using RNAi and lentiviral transgenesis. We analyzed diabetes incidence in 
the IL-17A deficient mice and found that the loss of IL-17A did not protect the transgenic 
mice from diabetes. Based on our observations, we believe that Th17 cells might not play 
a critical role in type 1 diabetes through the IL-17A pathway, though they might still be 
involved in the disease process through alternate pathways.  We also generated NOD and 
NOD-SCID mice, which exhibit beta cell specific luciferase expression combined with 
the ability to knockdown specific genes in beta cells. We used a single construct, which 
combined a luciferase sequence and an shRNA expression cassette under the beta cell 
specific RIP promoter and used lentiviral transgenesis to generate the transgenic mice. 
These mice will be of use in studying beta cell phenotype resulting from the knockdown 
of target genes, non- invasively using bioimaging. We characterized an shRNA active 
against men1 as a model for beta cell regeneration in the context of type 1 diabetes and 
hope to generate and characterize a menin KD mouse line in the pRLM background. We 
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 believe our work has contributed to diabetes research in generating two reporter mouse 
lines for diabetes studies and also in demonstrating the lack of a crucial role for IL-17A 
in type 1 diabetes.  
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